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ABSTRACT
Pulmonary fibrosis is the end stage of a heterogeneous group of disorders, characterised 
by the excessive deposition of extracellular matrix proteins within the pulmonary 
interstitium. Current evidence suggests that the differentiation of fibroblasts into highly 
synthetic and contractile myofibroblasts plays a central role in the pathogenesis of 
pulmonary fibrosis. Uncontrolled coagulation activity with extravascular expression of 
tissue factor (TF) leading to the activation of coagulation zymogens, including FVII, FX and 
prothrombin, has been documented in the lungs of patients with pulmonary fibrosis. In 
addition to their role in blood clotting, coagulation proteinases induce multiple pro- 
inflammatory and pro-fibrotic cellular effects via the activation of their major signalling 
receptors the PARs, including PAR!. Until recently, coagulation zymogens were thought to 
be exclusively derived from the circulation and then locally activated in response to tissue 
injury. This thesis shows for the first time that FX is locally upregulated in human and 
murine fibrotic lung tissue and that the alveolar epithelium represents a prominent cellular 
source of this protein. This thesis further reports that FXa is a potent inducer of the 
myofibroblast differentiation programme via PAR! and the transcriptional upregulation of 
thrombospondin-1 leading to the activation of TGF-Pi. The work presented here further 
demonstrates that PAR!, TSP-1 and a-SMA co-localize to fibrotic foci in idiopathic 
pulmonary fibrosis and a direct causal link between FXa and the development of fibrosis 
was demonstrated by showing that a direct FXa inhibitor attenuated bleomycin-induced 
lung fibrosis. This thesis therefore identifies a novel pathogenic mechanism by which FXa, 
a central proteinase of the coagulation cascade, is locally upregulated and drives the 
fibrotic response to lung injury. These findings herald a paradigm shift in the current 
understanding of the tissue origin of excessive procoagulant activity and further place 
PARi central to the crosstalk between pro-coagulant signalling and tissue remodelling.
To my parents and my brother
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Chapter 1 Introduction
Chapter 1: Introduction
1.1. Pulmonary Fibrosis
Pulmonary fibrosis is a pathological condition that is classically characterised by 
excessive and disorganised deposition of extracellular matrix (ECM) within the 
pulmonary interstitium. The main areas affected include the alveolar walls (including 
the epithelium and capillary endothelium), septae and the perivascular, perilymphatic 
and peribronchiolar connective tissue. It is generally held that this condition occurs as 
an aberrant wound healing response to acute or chronic lung injury. It profoundly 
compromises alveolar gas exchange and hence often leads to premature death. 
Varying degrees of pulmonary fibrosis in conjunction with inflammation are the hallmark 
of all interstitial lung diseases (ILDs), which are a heterogeneous group of over 200 
different disorders.
Although many of the ILDs share similar clinical, radiographic and sometimes even 
pathological features, the mechanisms of disease, treatment, prognosis and outcome 
are often very different. Until recently, classification of this group of diseases has 
therefore proven to be problematic. Some of the ILDs have known aetiologies including 
occupational factors (e.g. asbestosis, silicosis), systemic disorders (systemic sclerosis, 
rheumatoid arthritis) or are drug-induced (bleomycin, nitrofuramide). These can 
therefore be grouped into similar clinical characteristics (Table 1.1.). In contrast, most 
cases of ILD have no known aetiology and are termed idiopathic interstitial pneumonias 
(IIPs). In 1969, Liebow and Carrington first proposed a classification of the IIPs into five 
distinct histopathological categories. However, in 1998 these were reclassified by 
Katzenstein and Myers into a unifying category. Therefore, patients that presented with 
interstitial lung disease of unknown cause were diagnosed as having cryptogenic 
fibrosing alveolitis (CFA) or idiopathic pulmonary fibrosis (IPF). This is no longer correct 
as more recently, an expert committee, reclassified these diseases into a new 
classification scheme, which was adopted, by consensus, by the European Respiratory 
Society and the American Thoracic Society (American Thoracic Society/ European 
Respiratory Society International multidisciplinary consensus classification of the 
idiopathic interstitial pneumonias, 2002. These classified the IIPs into seven distinct 
disease entities which can be distinguished on the basis of clinical, radiological and 
histological characteristics (Table 1.2.).
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Table 1.1. Clinical classification of ILDs (adapted from (Laurent and Shapiro, 2007))
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Table 1.2. Classification of the idiopathic interstitial pneumonias
(Table adapted from: American Thoracic Society/ European Respiratory Society International 
multidisciplinary consensus classification of the idiopathic interstitial pneumonias, 2002)
1.2. Idiopathic Pulmonary Fibrosis (IPF)
IPF is the most common form of all IIPs, accounting for more than 45% of all cases 
(American Thoracic Society, 2000). Although epidemiological data on this disease 
varies in the literature, the number of deaths related to IPF is estim ted as 14 times 
greater than those related to asbestosis with a reported prevalence of approximately 14 
to 42.7 cases per 100,000 (Noth and Martinez, 2007), depending on a narrow or wide 
case definition (Raghu, 2006). It is further estimated that in the U.K. alone, over 1500 
people die of this condition per year (Johnston et al, 1990). These numbers are 
expected to rise further as recorded incidences have increased annually by 11% 
between the years 1991 and 2003, suggesting that the number of cases is doubling 
every 8 years (Gribbin et al, 2006). It is more common in men and the elderly and the 
mean age of onset typically lies between the ages of 67 and 69 years (Coultas et al, 
1994). There is no geographical pattern of disease distribution and no racial or ethnic 
predisposition.
IPF is also the most severe form of all IIPs which always progresses to destruction of 
the lung parenchyma and thus has a very poor prognosis (Selman et al, 2001). From 
the onset of symptoms of cough and breathlessness, the medium survival is estimated
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as 2.9 years, although the clinical course is often variable with some patients remaining 
stable for longer periods of time, whilst others experience acute exacerbations leading 
to rapid progressive respiratory failure and eventual death (Martinez et al, 2005). In 
addition, IPF appears to be resistant to conventional anti-inflammatory therapies, which 
are the main line of therapy used in the treatment of all I IDs (reviewed in NHLBI 
Workshop, American Thoracic Society/ European Respiratory Society International 
multidisciplinary consensus classification of the idiopathic interstitial pneumonias, 
2002). It is therefore very important to distinguish IPF/CFA from other types of IIPs. IPF 
has a classical, well characterised histological pattern referred to as usual interstitial 
pneumonias (UIP). Histologically, significant distortion of the lung architecture with 
fibrosis, honeycombing (enlarged and distorted airspaces resulting from the destruction 
of normal lung architecture), fibrotic foci (dense areas of proliferating fibroblasts) and 
mild to moderate inflammation are present (Figure 1.1.)- Classically, IPF affects both 
halves of the lung, however the distribution of lesions is very heterogeneous and 
patchy opacities can be observed on chest x-ray particularly associated with the lower 
lobes and around subpleural areas. Despite these distinct histological patterns, 
diagnosing IPF is still proving to be difficult. Normally, IPF lungs have regions of normal 
lung parenchyma interspersed with regions with a UIP pattern. However, in some 
cases, a UIP pattern may be seen in one surgical specimen, whilst specimens taken 
from other lung lobes have an entirely different histological pattern, although the clinical 
course is characteristic of IPF (Flaherty et al, 2001).
A. Normal lung B. IPF lung
Figure 1.1. Photomicrographs of histological sections taken from normal human lung (A) 
and IPF lung (B), stained with Martius Scarlet Blue In the IPF lung alveolar architecture 
appears distorted due to excessive collagen deposition (shown here in blue) within the alveolar 
interstitium (Images kindly provided by Dr Robin McAnulty, University College London).
22
Chapter 1 Introduction
Although the aetiology for IPF is unknown, several risk factors have been proposed. 
Some theories suggest that damaging environmental agents and occupational factors 
such as farming, hairdressing and stone-cutting may play a role, although no clear link 
has yet been established (Baumgartner et al, 2000;lwai et al, 1994). Cigarette smoking 
is a risk factor for IPF, however in patients with established IPF, smoking appears to 
improve disease prognosis (Baumgartner et al, 1997). Viral infections, such as those 
caused by Epstein-Barr virus and cytomegalovirus, have also been proposed to cause 
IPF, although no conclusive evidence has yet been provided (Tang et al, 2003). 
Medication such as anti-depressants may also play a role (Hubbard et al, 1998). Three 
percent of IPF patients may have familial causes suggesting that genetic factors are 
involved. Thus, gene polymorphisms in surfactant protein C (Lawson et al, 2004), 
transforming growth factor beta-1 (TGF-Pi), tumour necrosis factor alpha (TNF-a), 
interleukin-1-receptor antagonist (IL-1R), interleukin-6 (IL-6) and in genes with major 
histocompatibility complex loci have been identified. Nevertheless, only a small 
proportion of those exposed to known risk factors develop actual disease, suggesting 
that IPF is multi-factorial and that varying degrees of susceptibility exist (Verleden et al, 
2001).
1.3. Pathogenesis of Pulmonary Fibrosis
The pathogenesis of pulmonary fibrosis is complicated, and although important 
advances have been made in the past decade, the specific molecular and cellular 
mechanisms that lead to disease progression are still unknown. Most of our 
understanding of the underlying cell-and molecular pathways leading to fibrosis has 
come from studies in animal models of pulmonary fibrosis, the commonest of which is 
that induced by a single administration of the anti-neoplastic drug bleomycin to rodents 
(both mice and rats). Administration of this agent by intratracheal (Laurent and 
McAnulty, 1983), intraperitoneal (Adamson and Bowden, 1974), subcutaneous 
(Adamson and Bowden, 1974) intravenous (Adamson and Bowden, 1974), aerosolised 
(Gunther et al, 2003) and more recently by oropharyngeal route (Lakatos et al, 2006) 
all result in the development of an acute inflammatory response followed by the 
development of extensive fibrotic lesions which usually subside three weeks post­
injury. Interestingly, similar to the human disease, the extent and the severity of fibrosis 
following bleomycin injury in experimental animals is dependent on the genetic 
background of the particular strain. Whilst some mouse strains show progressive 
fibrosis (e.g. C57/BI6), others (e.g. Balb/c) appear to be resistant to this process 
(Bonniaud et al, 2004). Although this model has been much criticised due to its known
23
Chapter 1 Introduction
aetiology, its resolving nature and the lack of restrictive physiology as observed in 
patients with pulmonary fibrosis it has nevertheless helped the discovery of numerous 
basic mechanisms that are likely to be important in the pathogenesis of human 
pulmonary fibrosis.
It is generally held that one of the first events that occur in the development of 
pulmonary fibrosis is injury to the epithelium and endothelium, from the, as yet, 
unidentified stimuli. Evidence for this was provided by ultrastructural analysis of IPF 
lung tissues which demonstrated severe loss of type II alveolar epithelial cells, 
denudation of basement membranes as well as degeneration of the basement 
membrane of the capillary endothelium (Corrin et al, 1985).
In a normal healing response tissue injury triggers an acute inflammatory response 
which mediates the migration, proliferation and activation of mesenchymal cells, 
ensuring limited deposition of ECM into the wound space. Subsequently, myofibroblast 
contraction ensures wound closure after which these cells undergo apoptosis. Finally, 
epithelial cell proliferation promotes repopulation of the basement membrane. In 
pulmonary fibrosis it is hypothesised that extensive, multiple or persistent insults over 
time result in an abnormal response to tissue injury, where wound healing is grossly 
disregulated (reviewed in (Keane et al, 2006)). Continuous loss of basement 
membrane integrity results in inflammation and the inability of the alveolus to re- 
epithelialise. In addition, hyperplastic and proliferating type II alveolar epithelial cells 
that attempt to repair the disrupted basement membrane (Kasper and Haroske, 1996) 
produce a number of mediators that drive exaggerated proliferation, activation and 
migration of underlying fibroblasts into the provisional matrix. This results in the 
formation of fibrotic foci, consisting of fibroblasts that appear to be resistant to 
apoptosis, which continuously occupy alveolar airspaces and promote the excessive 
deposition of ECM leading to irreversible loss of lung function. Interestingly, recent 
evidence by Cool et al demonstrates that fibrotic foci are interconnected, forming a 
continuous fibrotic reticulum which suggests that individual foci may not arise from 
discrete sites of lung injury (Cool et al, 2006).
As already eluded to, a host of mediators including growth factors, chemokine, 
coagulation proteinases, proteinase inhibitors and cytokines have been shown to 
influence fibroblast function in the fibrotic lung, some of which are now being pursued 
in clinical trials (reviewed in (Scotton C.J. and Chambers, 2007); The major mediators 
are summarised in Table 1.3.).
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Mediators References
Chemokines
CXCL12 (Phillips et al, 2004;Agostini and Gurrieri, 2006)
CCL2/MCP-1 (Gharaee-Kermani et al, 1996)
Cytokines
IL-1 p (Postlethwaite et al, 1984;Singh et al,
1988;Elias et al, 1990)
IL-4 (Wallace et al, 1995;Gillery et al, 1992)
IL-13 (Kolodsick et al, 2004)
TNF-a (Vilcek et al, 1986;Elias et al, 1990)
ET-1 (Cambrey et al, 1994;Dawes et al, 1996)
IFN"Y (Gurujeyalakshmi and Giri, 1995;Hunninghake
et al, 1986;Elias et al, 1990)
PGE2 (Saltzman et al, 1982)
Growth factors
TGF-p, (Raghow et al, 1987;Willis et al, 2005)
CTGF (Frazier et al, 1996)
PDGF (Butt et al, 1995;Bonner, 2004)
IGF-1 (Phillips et al, 1987;Goldstein et al, 1989)
Coagulation proteinases
Thrombin (Chan et al, 1998;Chambers et al, 1998;
Factor Xa Blanc-Brude et al, 2005)
Table 1.3. Mediators of fibroblast function implicated in lung fibrosis
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These pro-inflammatory and pro-fibrotic mediators act via autocrine and paracrine 
mechanisms and are released from a variety of cell types including fibroblasts, 
inflammatory cells, endothelial cells, smooth muscle cells and platelets, although 
activated alveolar epithelial cells are thought to be a major source of these mediators in 
the fibrotic lung (Kasper and Haroske, 1996). Pro-fibrotic mediators which promote the 
pathogenesis of pulmonary fibrosis, include factors such as TGF-p, TNF-a and IL-13. 
Various anti-fibrotic mediators which are thought to counteract fibrotic processes have 
also been described, including IFN-y, PGE2 and the antioxidant glutathione and may be 
deficient in the IPF lung leading to an imbalance in pro-fibrotic and anti-fibrotic factors.
1.3.1. The role of inflammation in the pathogenesis of IPF
The question as to what role inflammation plays in the process of pulmonary fibrosis, 
particularly in the context of IPF, is highly controversial and subject of much debate. On 
the basis of historical studies of IPF biopsy material, inflammation was implicated as 
the major pathogenic mechanism involved (Selman et al, 2001;Ward and 
Hunninghake, 1998). This was based on the idea that persistent inflammation of the 
epithelial and vascular compartments leads to the loss of alveolar wall integrity and 
thus fibrotic changes. IPF was therefore regarded as a chronic inflammatory disorder 
and therapy was aimed at targeting inflammatory pathways (Ward and Hunninghake, 
1998). Unfortunately, none of the commonly used anti-inflammatory or 
immunosuppressive drugs such as prednisolone, azathioprine or cyclophosphamide, 
have shown any beneficial effect in slowing-down the progression of this disease. 
However, there are currently no effective therapies so that these drugs are still being 
prescribed as main line therapy for this condition (Raghu, 2006).
More recently, an alternative hypothesis has thus been proposed suggesting that IPF is 
the result of an aberrant interaction between the epithelium and mesenchyme, with little 
or no involvement of an inflammatory component (Selman et al, 2001). This theory is 
supported by the observation that fibroblast foci in IPF form in areas directly 
underneath the damaged epithelium, representing the ‘leading edge’ of the fibrogenic 
processes. The observation that similar degrees of inflammation exist both in the early 
as well as in the late stages of disease further supports this concept (Gauldie, 2002). In 
addition, over-expression of the potent pro-fibrotic mediator TGF-p, leads to 
progressive fibrosis and remodelling in mice, without any significant inflammatory 
involvement (Kolb et al, 2001). Similarly, mice deficient in the avp6 integrin are unable 
to effectively activate TGF-p and thus develop marked inflammation post bleomycin- 
induced lung injury but this response fails to progress to fibrosis (Munger et al, 1999).
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This theory has been at the centre of an active debate. Opponents argue that this 
theory only provides a ‘snapshot’ view of the disease and does not look at the natural 
history of IPF and disregards the common observation that tissue injury is always 
followed by an inflammatory response (Strieter, 2002). In addition, adenoviral 
expression studies such as those performed with TGF-p may be criticisable, as this 
cytokine is overexpressed at unphysiological concentrations (Strieter, 2002). Whilst 
anti-inflammatory therapy may not help for end-stage disease pathology, it is argued 
that a beneficial effect can not be ruled out at early stages of IPF where inflammation 
may play a role. Evidence for this has come from studies examining the 
histopathological variability of surgical tissue sections of patients with IIP (Flaherty et 
al, 2001). Whilst chronic inflammation is a major feature of inflammatory non-specific 
interstitial pneumonia (NSIP) this is not the case for IPF. However in 26% of patients 
both states co-existed in the same biopsy specimens, raising the possibility that the 
natural history of UIP may begin with the development of NSIP, which when left 
untreated, leads to progressive UIP in the later stages. Further strong evidence for an 
involvement of the inflammatory system has come from studies using microarray 
analysis to compare gene expression patterns of lung tissues taken from patients with 
IPF versus normal donor lungs (Zuo et al, 2002). The authors found four categories of 
genes highly expressed in patients with IPF, amongst which were genes encoding pro- 
inflammatory cytokines, chemokines and antioxidants, but also genes encoding 
amyloid, which are all associated with chronic inflammatory disorders (Strieter, 2005). 
Furthermore, no difference was observed in the gene expression profiles obtained for 
patients with IPF compared to that obtained from patients with NSIP (Rosas and 
Kaminski, 2007) suggesting that inflammation might well be a major part of IPF.
A unifying hypothesis has been suggested that combines both of the above theories. 
This theory proposes that acute inflammation precedes the chronic fibrotic process, 
however inflammation is necessary but not sufficient for fibrogenesis to occur 
(Sheppard, 2001b). Evidence for this has been provided by a study performed by Kolb 
and colleagues where transient overexpression of IL-1 (3 lead to an acute inflammatory 
response that evolved into pulmonary fibrosis (Kolb et al, 2001). One potential 
interpretation of this result is that in this system IL-1(3-mediated inflammation induces 
the defective cross-talk between mesenchymal cells and epithelial cells leading to 
failure of normal re-epithelialization and re-endothelialization. Subsequent fibrosis is 
then driven by TGF-|3, persistent expression of which occurs in the context of IL-1 p- 
induced inflammation.
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Other theories suggest that multiple injuries lead to an imbalance in Th-1/Th-2-type 
cytokines. Analysis of lung tissue and bronchoalveolar lavage fluid (BALF) samples 
taken from patients with IPF revealed an inflammatory pattern characteristic of a TH-2 
immune response, as demonstrated by an increase in eosinophils, mast cells and 
cytokines such as IL-4, IL-5, IL-10 and IL-13 (Rottoli et al, 2005). It was therefore 
suggested that a local imbalance in TH-1/TH-2-type cytokines favours a Th-2 profile 
(Antoniou et al, 2007;Strieter, 2002) which directly contributes to the fibrogenic process 
(Figure 1.2.)- A link between a TH-2 type profile and fibrosis has now been well 
established in animal models of pulmonary fibrosis, although a functional link in human 
IPF is still lacking (Thannickal et al, 2004). IFN-y, which is one of the major cytokines 
implicated in the modulation of TH-1/TH-2 imbalance, has thus been proposed as a 
promising target in IPF. However, recent clinical trials assessing the therapeutic 
potential of IFN-y in IPF, were largely disappointing but showed a glimpse of hope 
(reviewed in (Scotton C.J. and Chambers, 2007)).
TH-1 Cytokines
IL-2,IL-12,IL-18,IFN-y
TH-2 Cytokines 
IL-4,IL-5,IL-10JL-13
Cell mediated immunity Chronic fibroproliferative 
lung disease
Cytokine balance
Figure 1.2. TH-1/TH-2 Cytokine balance in pulmonary fibrosis
Lung fibrosis involves a shift in the local balance of TH-1/TH-2-type cytokines in favour of a TH- 
2 profile. TH-2 cytokines such as IL-4 and IL-13 promote fibrosis by stimulating fibroblast 
collagen synthesis whilst TH-1 cytokines such as IFN-y may inhibit fibroblast function and 
collagen synthesis and are thus anti-fibrotic.
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1.4. Extracellular matrix deposition in the fibrotic lung
As discussed in the previous section, a number of mechanisms may lead to the 
development of pulmonary fibrosis. However, the excessive deposition of collagen and 
other ECM components within the pulmonary interstitium remain the hallmarks of this 
disorder. The next section will focus on the distribution and metabolism of collagen in 
the normal and fibrotic lung.
1.4.1. Collagen structure
The collagens are a family of 28 closely related extracellular matrix proteins, each 
comprising a characteristic triple helix consisting of three polypeptide chains of unique 
but homologous amino acid sequence (Pace et al, 2003)). At least 11 different collagen 
subtypes are known to be present in the lung (reviewed in (Chambers, 1997)). 
Collagen subtypes can be classified into homotrimers composed of three identical a- 
chains, (e.g. collagen III) or heterotrimers consisting of two or three different a-chains 
(e.g. collagen I or collagen VI respectively). Each a-chain contains a high proportion of 
glycine residues, which occur in a regularly repeating triplet, Gly-X-Y, where 
approximately every third X is proline and every third Y is hydroxyproline (Miller, 1985). 
Each individual a-chains forms a left handed polyproline helix and further assembles 
into a right handed triple helix with the remaining two other a-chains. This structure is 
stabilised by interchain hydrogen bonding resulting in a triple helix with a coiled-coil 
confirmation. This structure renders collagen highly resistant to proteolysis as each 
glycine and peptide bond is buried within or alongside the axis of the helical structure.
Collagens I, II, III, V and XI are classically referred to as fibril-forming interstitial 
collagens, which form large bundles of collagen fibres, several pm in diameter. The 
major role of fibrillar collagen is to provide tensile strength. 90% of the total lung 
collagen is made up of collagen types I and III in a ratio of 2:1 (Kirk et al, 1984). These 
collagens are widely distributed throughout the pulmonary interstitium and are believed 
to be crucial in providing structural integrity in an organ which contains intricate and 
extensive networks of airspaces and capillaries. Fibroblasts are thought to be a major 
source of these types of collagen. However, other cell types, including alveolar 
epithelial cells, endothelial cells and smooth muscle cells have also been shown to 
produce these collagen types. The major non-fibrillar collagen found in the lung is 
collagen type IV which serves as an important structural component of the alveolar and 
capillary basement membrane.
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Other important collagen types present in the lung include collagen type V which is 
mainly found in the basement membrane and pulmonary interstitium, type VI which 
forms fine filaments with collagens type I and III and collagen type II which is only 
present in cartilage and is therefore particularly abundant in the large airways. Collagen 
Types IX and XI are similarly distributed with Type II collagen in the trachea and large 
airways (reviewed in (Chambers, 1997)).
1.4.2. Collagen deposition in a normal and fibrotic lung
In the normal lung collagen exists in a dynamic equilibrium where synthesis and 
degradation are highly regulated. Early studies in our laboratory revealed that as much 
as one tenth of the total collagen in the lung of a young adult mammal is synthesised 
and degraded per day (McAnulty and Laurent, 1987). It is generally held that in fibrotic 
lung disease this balance is disturbed thus leading to increased deposition of collagen 
(McAnulty and Laurent, 1987). This excessive and disorganised deposition of collagen 
results in gross thickening of the normally thin alveolar interstitium leading to the 
destruction and remodelling of the lung architecture and progressive loss of alveolar 
function.
In early fibrosis, several reports have observed an imbalance in the ratio of type III to 
type I collagen, whereby the former is thought to increase disproportionately (Kirk et al, 
1984). In contrast, once fibrosis is established higher levels of collagen I versus III are 
observed. However, it is generally held that excessive collagen production rather than 
a change in the ratio of different types of collagen is important in fibrotic lung disease. 
For example, increased procollagen I gene expression as measured by in situ 
hybridisation has been documented in patients with IPF (Broekelmann et al, 1991). In 
addition, elevated levels of procollagen peptides (collagen cleavage products) have 
also been measured in BALF taken from patients with pulmonary fibrosis (Harrison et 
al, 1991). Similarly, in animal models of pulmonary fibrosis, such as that induced by 
bleomycin, increases in expression of the procollagen genes COL1A1, COL1A2 and 
COL3A1 have been reported (Zhang et al, 1994b;Shahzeidi et al, 1994). In contrast, a 
decrease in collagen degradation in the fibrotic lung has also been documented. For 
example, decreased collagenolytic activity has been reported in the lungs of IPF 
patients (Selman et al, 1986). Further evidence for a non-degradative state in the 
fibrotic lung has come from studies examining the expression of matrix 
metalloproteinases (MMPs), important in the degradation of matrix proteins and their 
endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). These
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studies have shown that TIMPs are upregulated to a greater extent than MMPs in the 
fibrotic lung aiding persistent matrix deposition (Selman et al, 2000).
Excess collagen is deposited in fibrotic foci and the presence and persistence of fibrotic 
foci is a key element in the histopathologic diagnosis of IPF and correlates with disease 
progression and decreased survival of affected individuals (King, Jr. et al, 2001). Thus 
mechanisms that regulate the deposition of collagen by fibroblasts are the main 
determinants of disease progression. These include mechanisms that regulate collagen 
synthesis rates in fibroblasts at a per cell basis by influencing procollagen gene 
transcription, translation and posttranslational modification. Similarly, collagen 
degradation in a fibroblast can be modulated by regulating the rate of procollagen 
mRNA degradation. Additional mechanisms that lead to an increase in the fibroblast 
cell population in the lung including chemotactic attraction to the site of injury and 
mitogenesis of fibroblasts. Finally, fibroblasts may undergo phenotypic modulation and 
change into a myofibroblast phenotype that promotes excessive collagen deposition 
and thus favours fibrogenesis. The work in this thesis has particularly focused on the 
role of the myofibroblast in pulmonary fibrosis and the next section will describe this 
cell phenotype in more detail.
1.5. The myofibroblast and pulmonary fibrosis
1.5.1. Discovery and origin of the myofibroblast
The myofibroblast was first described 30 years ago as a major cell type involved in the 
wound healing process. Studies performed by Gabbiani and Majno examined an 
experimental wound healing model by electron microscopy and observed the transient 
appearance and disappearance of the myofibroblast within granulation tissue (reviewed 
in (Desmouliere et al, 2005)). This particular cell phenotype exhibited smooth muscle 
cell-like features, including bundles of microfilaments, an abundance of rough 
endoplasmic reticulum and irregular shaped nuclei and it was therefore proposed that 
the myofibroblast may be responsible for the force generation resulting in wound 
contraction and connective tissue retraction that is observed during wound healing 
(Gabbiani et al, 1972). The term myofibroblast was therefore proposed for this plastic 
and contractile fibroblast phenotype. Extensive work later showed that the 
myofibroblast was important in a number of biological processes and was not only 
present in normal tissues, where force generation was needed but also in pathological 
conditions associated with aberrant wound healing, excessive contraction and 
extracellular matrix deposition, such as hypertrophic scars, scleroderma, Dupuytren’s
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disease (Hinz, 2007) as well as fibrotic conditions of the heart (Brown et al, 2005) liver, 
kidney (Desmouliere et al, 2003) and lung (Adler et al, 1989). This led to the concept 
that following tissue injury, differentiation of fibroblasts into the myofibroblast phenotype 
contributes to tissue repair and regeneration, but in pathological states it promotes the 
severe impairment of organ function through excessive contraction and extracellular 
matrix deposition.
The differentiation of fibroblasts into the myofibroblast phenotype is a complex process 
that follows a highly regulated chain of events (Hinz et al, 2007). In normal non- 
pathological environments fibroblasts express little actin-dependent cell-cell and cell— 
matrix contacts and their synthetic rate in ECM components is low (Tomasek et al, 
2002). Following tissue injury, locally produced cytokines promote the migration of 
fibroblasts into the wound space and increase their production of ECM components. 
Mechanical tension arising from disruption of normal tissue integrity further induces the 
assembly of contractile stress fibres containing cytoplasmic actins. This intermediate 
fibroblast phenotype is termed the protomyofibroblast (Desmouliere et al, 2005). The 
acquisition of stress fibres enables this cell type to connect to ECM components 
through integrin-containing cell matrix junctions and to other cells via cell-cell adherens 
junctions (Hinz et al, 2004). This cell type also upregulates the production of cellular 
fibronectin, a variant of fibronectin usually present during development and absent in 
normal adult connective tissue (Serini et al, 1998). Protomyofibroblasts are particularly 
observed in tissue culture where rigid plastic substrate generates the necessary 
tension for the induction of this cell phenotype (Hinz, 2006). In vivo, this intermediate 
phenotype proceeds to differentiate into the myofibroblast which is characterised by the 
de novo expression of the mechanosensitive protein alpha smooth muscle actin (a- 
SMA) which is recruited to stress fibres under influence of high tension (Goffin et al,
2006). a-SMA is therefore considered to be the most significant marker of 
myofibroblastic cells, although other proteins such as smooth muscle myosin heavy 
chain, desmin, intermediate filament proteins and caldesmon are also expressed (Hinz 
et al, 2001;Cogan et al, 2002;Sappino et al, 1990;Chambers et al, 2003). 
Myofibroblasts are highly synthetic for collagen and other ECM components and the 
expression of a-SMA correlates with increased contractility of this cell phenotype (Hinz 
et al, 2001). The exact mechanism of how increased contractility is achieved is still 
unknown although the N-terminal region of a-SMA, Ac-EEED, which is specific to this 
isoform of actin has been implicated. Evidence for this was provided by studies where 
micro-injection of synthetic Ac-EEED peptide into myofibroblastic cells caused the 
disappearance of a-SMA protein as detected by immunolocalisation and further
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reduced the ability of myofibroblasts to contract in vitro as well as in vivo (Hinz et al, 
2002).
1.5.2. The role of myofibroblast in pulmonary fibrosis
The presence of myofibroblasts in tissues taken from patients with pulmonary fibrosis, 
as well as in animal models of the disease, has been documented for some time (Adler 
et al, 1989;Mitchell et al, 1989;Kuhn, III et al, 1989;Pache et al, 1998). It was 
hypothesised that this distinct fibroblast phenotype may contribute to the development 
and progression of fibrosis. Studies showing increased collagen synthetic capacity of 
granulation tissue myofibroblasts and their localisation to fibroblastic foci during active 
matrix deposition strongly favoured such a role (Kuhn and McDonald, 1991). This was 
further supported by the finding that myofibroblasts were able to synthesise other 
extracellular matrix components such as vitronectin, fibronectin and laminin, the 
deposition of which is also an important feature of active disease (Kuhn and McDonald, 
1991). The first direct evidence for the myofibroblast as a key source of collagen 
production in the fibrotic lung came from in situ hybridisation studies that confirmed 
colocalisation of collagen type I mRNA with a-SMA immunostaining in fibrotic foci of 
tissue sections taken from the pulmonary fibrosis model induced by bleomycin (Zhang 
et al, 1994b). This finding was supported by the observation that the appearance and 
disappearance of myofibroblasts in fibrotic foci correlated with the development and 
subsequent resolution of active fibrosis in experimental pulmonary fibrosis and that in 
human disease myofibroblast persistence associated with progression of fibrosis 
(Zhang et al, 1994b;Kuhn and McDonald, 1991).
The mechanisms leading to an increased ECM synthetic capacity of myofibroblasts are 
however less well understood. One theory suggests that the myofibroblast undergoes 
phenotypic changes that permanently ‘reprogram’ this cell to promote fibrogenesis. 
Evidence for this has come from studies analysing phenotypic differences between 
fibroblasts isolated from normal lungs and fibroblasts/myofibroblasts isolated from 
fibrotic lungs. These studies showed that fibroblasts/myofibroblasts isolated from IPF 
lungs exhibited an increased synthetic capacity for collagen and other ECM proteins in 
response to pro-fibrotic mediator stimulation compared to fibroblast isolated from 
healthy lungs (Hetzel et al, 2005). These fibroblasts/ myofibroblasts also exhibit an 
enhanced migratory phenotype (Suganuma et al, 1995), increased production of pro- 
fibrotic mediators (Moodley et al, 2003), and increased contractility of collagen matrices 
(Miki et al, 2000) and appear to be more resistant to apoptosis (Ramos et al, 
2001;Moodley et al, 2004). Similarly, they have been reported to produce less
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antifibrotic factors, such as cyclooxygenase-2-derived PGE2 (Keerthisingam et al, 
2001;Wilborn et al, 1995) and are less responsive to the inhibitory effects of PGE2 on 
fibroblast proliferation (Mio et al, 1992). However, these studies are not conclusive 
primarily because they have produced conflicting results. For example, fibroblasts 
isolated from fibrotic lungs have been shown to have higher proliferative capacities 
when compared to those isolated from normal donor lung, however, in more advanced 
stages of the disease these fibroblasts appear to proliferate at lower rates (Raghu et al, 
1988;Hetzel et al, 2005). It is also argued that isolated cells may not provide a true 
representation of pathology as they may undergo phenotypic modulation when grown 
in in vitro culture systems where the cellular microenvironment is very different to the in 
vivo situation.
Whilst there is no dispute that myofibroblasts display an increased synthetic capacity, it 
is less well established whether the contractile properties of myofibroblasts, which have 
convincingly been shown in experimental wound healing models, contribute 
significantly to the pathophysiology of fibrosis. Increased contractility of collagen gels in 
vitro by fibroblasts/myofibroblasts isolated from rat lungs following bleomycin-challenge 
correlates with an increase in a-SMA expression (Zhang et al, 1996). Indirect evidence 
for a role of myofibroblasts in contraction and connective tissue remodelling in vivo is 
reflected in the pathological stiffness of lungs of patients with pulmonary fibrosis 
(reviewed in (King, Jr. et al, 2001)). However, no direct link has yet been established 
between increased contractility and decreased lung compliance observed in the fibrotic 
lung and the expression of a-SMA positive myofibroblasts in vivo.
It has also been suggested that myofibroblasts play a role in the inflammatory process 
that may accompany fibrotic lung disease and thus potentiate its progression (reviewed 
in (Phan et al, 1999)). Myofibroblasts represent a significant source of growth factors 
(Finlay et al, 2000), cytokines (Phan et al, 1999), chemokines (Zhang et al, 1994a) and 
also reactive oxygen species (Thannickal et al, 1998) and express markers typical of 
immune cells such as CD40 (Brouty-Boye et al, 2000). In addition, they express 
adhesion molecules such as intracellular adhesion molecule -1 (ICAM-1) and vascular 
cell adhesion molecule (VCAM) which enable the docking of inflammatory cells to their 
cell surface (Burns et al, 1996;Crowston et al, 1997). This has lent credence to the 
theory that myofibroblasts may modulate the environment of acute resolving 
inflammation and drive the change to a chronic, persistent inflammation implicated in 
IPF (Buckley et al, 2001).
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Finally, myofibroblast differentiation is thought to play a part in alveolar epithelial cell 
apoptosis, denudation of basement membrane and retardation of epithelial 
regeneration (Waghray et al, 2005) thought to contribute to the pathogenesis of 
pulmonary fibrosis (see Section 1.3.). Thus the myofibroblast is not only important in 
ECM deposition but also promotes inflammation and contributes to the aberrant wound 
healing process implicated in the pathogenesis of pulmonary fibrosis.
1.5.3. Origin of myofibroblasts
Current opinion suggests that lung myofibroblasts have at least three possible origins 
although the relative contribution of each of these pathways in pulmonary fibrosis is 
currently unknown. Based on cytoskeletal phenotype, tissue localization and in vitro 
studies, it is traditionally believed that myofibroblasts are solely derived from resident 
mesenchymal cells, particularly from peribronchial and perivascular adventitial 
fibroblasts as well as pericytes and smooth muscle cells (Zhang et al, 1994c;Chamley 
et al, 1977), the population of which expands in response to stimuli secreted by 
inflammatory and epithelial cells during the fibrogenic process. In support of this theory, 
in vitro studies have provided biochemical and morphological evidence for a fibroblastic 
origin (Oda et al, 1988) including the ability of isolated fibroblast to differentiate into the 
myofibroblast phenotype in response to cytokine stimulation in vitro (Serini and 
Gabbiani, 1999). More recently, although controversial, new studies have suggested 
additional sources of myofibroblasts derived from transdifferentiation of adjacent 
epithelial cells (Willis et al, 2005) as well as from circulating fibrocytes and other bone 
marrow derived progenitor cells ((Abe et al, 2001 .’Phillips et al, 2004), Figure 1.3.).
Fibrocytes were originally identified by Bucala et al in 1994 as Collagen 
I7CD347CD45R0+ cells which are likely derived from haematopoietic stem cells 
(Bucala et al, 1994). While initially these cells were only described in the context of 
wound healing they have since been found to participate in granuloma formation, 
antigen presentation and various fibrosing disorders (reviewed in (Gomperts and 
Strieter, 2007)). Recent studies using bone marrow chimeric mice where bone marrow- 
derived cells were tracked through their expression of specific marker proteins, have 
provided evidence that these cells may represent an additional source of fibroblasts in 
the lung (Hashimoto et al, 2004;Brocker et al, 2006). Evidence for a pathogenic role for 
fibrocytes in pulmonary fibrosis has recently been provided by studies demonstrating 
that blockade of fibrocyte recruitment is protective in experimentally-induced pulmonary 
fibrosis (Moore et al, 2005;Phillips et al, 2004). However, it remains to be determined if
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these cells contribute to the excessive collagen deposition seen in IPF or if they have 
alternative roles such as serving as mediators of a pro-fibrotic milieu.
A potential third cellular source are epithelial cells that undergo transdifferentiation to 
form fibroblasts and hence myofibroblasts by a process termed epithelial-mesenchymal 
transition (EMT). The concept of EMT has been recognized for more than twenty years 
and has been a major focus of research in the field of kidney fibrosis. It is a 
fundamental process, whereby epithelial cells are thought to lose their characteristic 
markers, such as E-cadherin and zona occludens (ZO)-1, and acquire mesenchymal 
markers such as fibroblast specific protein (FSP)-1 and a-SMA (reviewed in (Willis et 
al, 2006). Increasing evidence has now emerged supporting a role for EMT in IPF both 
in vitro and in vivo (Willis et al, 2005;Kim et al, 2006), However, the relative contribution 
of this cell type to the fibrotic process needs further investigation.
Figure 1.3. Potential origins of myofibroblasts in fibrotic lung disease
Myofibroblasts are key effector cells in IPF which are highly synthetic in collagen and are 
characterised by the de novo expression of a-SMA. Myofibroblasts are thought to arise from 
proliferation and differentiation of resident fibroblasts, recruitment of circulating fibrocytes and 
from epithelial-mesenchymal transition (EMT).
Fibroblast
Fibrocyte Myofibroblast
recruitment from
bone marrow
Highly synthetic for collagen 
a-SMA positiveEpithelial cell
m
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1.5.4. Regulation of myofibroblast differentiation
At least three major events in granulation tissue formation have been described that 
drive the myofibroblast differentiation programme which include mechanical stress 
(Tomasek et al, 2002), the cytokine TGF-p (Desmouliere et al, 1993) and components 
of the ECM such as the ED-A splice variant of cellular fibronectin (Serini et al, 1998). 
This thesis has particularly worked on the role of TGF-p in myofibroblast differentiation 
in the context of pulmonary fibrosis. A more extensive description of TGF-p, its 
signalling pathways and its effect on myofibroblast differentiation will thus be discussed 
here in more detail.
1.6. Role of TGF-p in myofibroblast differentiation and pulmonary fibrosis
1.6.1. TGF-p function and signalling
TGF-p belongs to a superfamily of more then 42 structurally related polypeptides, 
which are divided into two subfamilies, the TGF-p/activin/nodal subfamily and the BMP 
(Bone Morphogenic Protein)/GDF (Growth and Differentiation Factor)/MIS (Muellerian 
Inhibiting Substance) subfamily. These subfamilies are defined by similarities in 
sequences and activation of specific signalling pathways (Table 1.3.). In humans, there 
are three distinct TGF-p isoforms TGF-p!, TGF-p2, and TGF-p3. They display 
overlapping as well as distinct functions, which are dependent on the cell type. TGF-P! 
is the most widely studied isoform in the context of experimentally lung fibrosis 
(Eickelberg et al, 1999) and is generally accepted as one of the key pro-fibrotic 
mediators in the bleomycin model (Khalil et al, 1989), as well as in patients with fibrotic 
lung disease (Khalil et al, 1996;Khalil et al, 1991).This isoform will thus be the focus of 
this section. The major source of TGF-p! are haematopoietic cells (Zhang et al, 1995) 
although fibroblasts and epithelial cells also secrete substantial amounts. TGF-Pi 
regulates a number of normal physiological processes such as cellular proliferation, 
differentiation, angiogenesis, metastasis and tissue repair (Border and Noble, 1995). 
Importantly, mice deficient in TGF-pi display widespread lethal tissue inflammation and 
autoimmunity suggesting that TGF-Pi plays an important role in regulating innate and 
acquired immunity (Kulkarni et al, 1993). Appropriate levels of TGF-Pi are therefore 
necessary for homeostasis and hence bioavailability of this pluripotent cytokine is 
highly regulated (see Section 1.6.2.).
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Table 1.3. TGF-p superfamily and their signalling receptors
BMP= bone morphogenic protein, GDF= growth and differentiation factor, MIS= muellerian 
inhibiting substance (table adapted from (Massague and Gomis, 2006))
TGF-pi signals by interacting with three classes of receptors, type I (TGFpiR or ALK5), 
type II receptors (TGFpllR) and type III receptor (TGFpillR, or betaglycan) (Table 1.3., 
(Rubtsov and Rudensky, 2007)). The characteristic features of TGF-p receptors include 
a toxin fold in the extracellular ligand-binding domain, a single transmem rane domain 
and an intracellular serine/ threonine kinase domain, whereas TGFpilR only has a 
short intracellular domain. TGFpillR acts as an accessory receptor which binds TGF-Pi 
and recruits TGF-p! to TGFpilR. Once TGF-Pi has bound to the TGFpilR, hetero­
oligomerization with TGFpiR occurs, allowing the constitutively active kinase domain of 
TGFpilR to phosphorylate the TGFpiR kinase domain (see Diagram 1.4.). This 
induces a conformational change of the type I receptor and initiates downstream 
signalling through the recruitment and phosphorylation of the Smad proteins, 
specifically Smad2 and Smad3 (receptor associated Smads (R-Smads)). Recruitment 
of R-Smads to the type I receptor can be facilitated by auxiliary proteins such as Smad 
Anchor for Receptor Activation (SARA)(Tsukazaki et al, 1998). The phosporylated 
Smad 2/3 then associates with Smad4 (co-mediator Smad (co-Smad 4)), the complex 
translocates to the nucleus where it binds directly to DNA and modulates transcription 
of a large number of genes ((Rubtsov and Rudensky, 2007)). In contrast, the inhibitory 
Smad (l-Smad-7) negatively regulates TGF-Pi signalling by competing with the R- 
Smads (Nakao et al, 1999). In addition, cell signalling by activated Smad proteins is
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terminated by protein phosphatases and ubiquitin ligases. Thus under continuous TGF- 
stimulation Smads undergo constant receptor-mediated phosphorylation and protein 
phosphotase-mediated dephosphorylation, shuttling in and out of the nucleus (Inman et 
al, 2002b).
TGF-0! triggers various Smad-independent pathways including ERK1/2, c-Jun NH2- 
terminal kinase (JNK), p38MAPK, PI3K and Akt and Rho-like GTPases (Derynck and 
Zhang, 2003) and there is complex cross-talk between these pathways and the Smad 
pathway. However, TGF-p! signalling via the Smad pathway has been widely 
implicated in the pathogenesis of pulmonary fibrosis (Hu et al, 2003). In endothelial 
cells TGF-Pi may signal via the additional ALK1 (Smad 1/5) pathway. This alternative 
pathway appears to have opposing effects to the classical ALK5 (Smad2/3) pathway 
which inhibits endothelial cell proliferation and migration (Lebrin et al, 2004). Signalling 
via the ALK1 (Smad1/5) pathway is facilitated by endoglin, thus cells lacking endoglin 
have decreased ALK1-and increased ALK5 signalling and thus do not proliferate 
(Lebrin et al, 2004).
1.6.2. The latent TGF-pi complex
TGF-p! activity is controlled on a number of levels, namely transcription, mRNA, 
stability and translation, storage of latent TGF-Pi, activation of latent TGF-Pi and TGF- 
p receptor expression. Although numerous mediators that induce TGF-Pi gene 
expression have been described (see Figure 1.4.), activation of this cytokine appears 
to be a major rate limiting step in the regulation of its bioavailability (Sheppard, 
2001a;Sheppard, 2006). TGF-Pi is initially synthesised in its precursor form known as 
pro-TGF-Pi and is subsequently processed intracellularly to yield the mature form of 
the protein. Cleavage of pro-TGF-Pi results in the formation of an inactive complex 
consisting of TGF-Pi which is noncovalently associated to an endogenous inhibitor, the 
latency associated peptide, LAP (Hyytiainen et al, 2004) It is the association of LAP 
with TGF-Pi that renders this cytokine inactive and unable to interact with its receptor 
and to induce most of its cellular effects. In almost all cells, including fibroblasts, this 
complex is further bound by disulphide linkage of LAP to another protein family, called 
latent TGF-Pi binding protein (LTBP) (Todorovic et al, 2005). This binding protein 
directly cross-links the complex to fibronectin, so that high concentrations of the latent 
form of this cytokine are bound to the extracellular matrix (Sheppard, 2001a).
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Figure 1.4. TGF-pi SMAD signalling pathway
TGF-p, signals via the Smad pathway. TGF-p, binds to the TGFpillR which facilitates TGF-p, 
binding to TGFpllR. This leads to recruitment of the type I receptor and hetero-oligomerization 
of TGFpllR with TGFpiR occurs, allowing the constitutively active kinase domain of TGFpil to 
phosphorylate the TGFpiR kinase domain, which propagates the signal downstream through 
phosphorylation of Smad2 and Smad3. Smad2 and Smad3 then form a complex with Smad4. 
The complex translocates to the nucleus, where it activates target genes. The inhibitory Smad 
(Smad7) negatively regulates TGF-p, signalling by competing with the Smads2 and 3. (Image 
taken from Cambridge University Press, Expert reviews, 2003)
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Mediator Cell type Reference
IL-1 p Aortic smooth muscle (Yue et al, 1994;Phan et al,
cells, Endothelial cells 1992)
CCL2/MCP-1 Fibroblasts (Gharaee-Kermani et al, 1996)
PDGF Chondrocytes (Villiger and Lotz, 1992)
bFGF Pituitary cells (Qian et al, 1996)
Angiotensin II Cardiac fibroblasts and (Campbell and Katwa, 1997)
myofibroblast
IL-13 in Macrophages (Fichtner-Feigl et al, 2006)
combination with
TNF-a
TNF-a Endothelial cells (Phan et al, 1992)
Table 1.4. Mediators of TGF-p gene induction
In order for TGF-p! to activate its receptor and induce cell signalling, the cytokine 
needs to be converted to its active state. This process requires degradation of LAP or 
alteration of the interaction of LAP with TGF-Pi. In vitro, numerous stimuli that induce 
mild protein denaturation have been shown to activate TGF-Pi, including extremes of 
temperature or pH as well as exposure to oxidants and ionizing radiation (Munger et al,
1997). However, the relative significance of these mechanisms in vivo remains 
unknown. In vivo, several possible TGF-Pi activation mechanisms have been 
described. Evidence from smooth muscle-cell and endothelial cell co-culture systems 
suggests that proteolysis by plasmin represents a potential mechanism of activation for 
TGF-Pi. Plasmin is thought to induce TGF-Pi activation by directly cleaving LAP from 
the mature TGF-p! or by releasing active TGF-pi bound to the extracellular matrix (Sato 
and Rifkin, 1989). Similarly, the matrix-metalloproteinases 2 and 9 (MMP-2 and MMP- 
9) are thought to proteolytically cleave and activate TGF-Pi (Yu and Stamenkovic, 
2000). The integrin avp6, an epithelial-cell membrane protein, can activate TGF-Pi by 
binding to the RGD sequence in LAP resulting in a conformational change in LAP 
(Munger et al, 1999). Consistent with a role for this mechanism in vivo, animals 
deficient in the avp6 integrin develop exaggerated inflammation of the skin and lungs 
(Huang et al, 1998). However, as expression of the avp6 integrin is restricted to 
epithelial cells, this mechanism of activation appears to be specific to the epithelium. 
Interestingly, the integrin avp8 can present latent TGF-Pi to the transmembrane 
protease MMP-14 which causes the release of free TGF-Pi (Mu et al, 2002). Current 
evidence suggests that activation of TGF-Pi by the matrix protein thrombospondin-1
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(TSP-1) is a major activation mechanisms of TGF-p! during post-natal development 
(Crawford et al, 1998). Mice deficient in TSP-1 show similarities in tissue pathology to 
TGF-Pi knock out mice and this phenotype can be reversed by treatment with a 
synthetic TSP-1 peptide that activates TGF-pi (Crawford et al, 1998). This thesis has 
examined the activation of TGF-p! by TSP-1 in fibroblasts and this mechanism will thus 
be discussed here in more detail.
1.6.3. Activation of TGF-pi by TSP-1
TSPs are a family of five disulphide linked homotrimeric extracellular matrix proteins of 
which TSP-1 is the most widely characterised isoform (reviewed in (Murphy-Ullrich and 
Poczatek, 2000)). TSP-1 exists both in a secreted, soluble and also in an insoluble 
matrix bound state and is expressed by a variety of cells including platelets, endothelial 
cells and mesangial cells (Reed et al, 1995;Hugo et al, 1995). TSP-1 is involved in 
platelet aggregation, angiogenesis, cell proliferation, cell adhesion and migration and 
as previously mentioned it induces the activation of latent TGF-P! (reviewed in 
(Murphy-Ullrich and Poczatek, 2000)). TSP-1 bound to the cell matrix supports weak 
cell attachment whereas soluble TSP-1 has anti-adhesive properties and promotes 
cytoskeletal reorganisation by regulating focal adhesions (Murphy-Ullrich and Hook, 
1989). TSP-1 expression in vitro can be induced by TGF-pi itself as well as PDGF and 
fibroblast growth factor-2 (FGF-2) and is particularly found at sites of inflammation and 
wound healing in vivo (Bornstein, 1995). In addition, during the course of this PhD a 
study revealed that thrombin induces the expression of TSP-1 in endothelial cells 
(McLaughlin et al, 2005a).
TSP-1 was first shown to be an important activator of TGF-Pi by Murphy-Ullrich et al 
who observed that the inhibitory effects of TSP-1 on platelet growth were partially TGF- 
Pi dependent (Murphy-Ullrich and Poczatek, 2000). Subsequently, a role for TSP-1 
mediated activation of TGF-pi was confirmed in both cell culture and cell free systems 
(Schultz-Cherry et al, 1994). TSP-1 activates TGF-Pi by interacting both with the LAP 
and with TGF-Pi itself, thus forming a trimolecular complex, assembly of which is not 
dependent on the interaction with LTBP (Figure 1.5.). The interaction of TSP-1 with 
TGF-Pi requires the binding of the hextapeptide WxxW (WSHW, WSPW or WGPW) 
from the type 1 repeat of TSP-1 to the active TGF-p! domain (Tsukazaki et al, 
1998;Schultz-Cherry et al, 1995).
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Figure 1.5. Activation of TGF-pi by TSP-1
TSP-1 activates TGF-p! by directly binding to the LAP and TGF-Pi forming an active ternary 
LAP-TSP-1- TGF-p! complex. This interaction requires the binding of the WxxW (WSHW, 
WSPW or WGPW) from the type 1 repeats of TSP-1 to the active TGF-p! domain, enabling the 
binding of the second TSP-1 motif (KRFK) to the N-terminal sequence of the LAP. This 
interaction induces a conformational change in the LAP in such a way that LAP is unable to 
confer latency to TGF-pi resulting in the generation of active TGF-pi (Figure adapted from 
(Hugo, 2003)).
43
Chapter 1 Introduction
This enables the interaction of a second TSP-1 motif, the KRFK amino acid sequence 
with the N-terminal LSKL sequence of the LAP (Schultz-Cherry et al, 1994;Schultz- 
Cherry et al, 1995)), a region of LAP which is implicated in conferring latency to TGF-Pi 
(Sha et al, 1991). Interaction of TSP-1 with the LSKL region is thought to induce a 
conformational change in the LAP thus leading to the generation of active TGF-Pi that 
is still assembled in the ternary complex (Schultz-Cherry and Murphy-Ullrich, 1993).
The TSP-1-TGF-Pi mechanism may be particularly relevant in the activation of TGF-Pi 
in the context of the lung. Thus, TSP-1 null mice develop spontaneous lung 
inflammation which closely resembles that of mice deficient in TGF-Pi (Crawford et al, 
1998). Furthermore, in vivo TSP-1 inhibition in wild type pups, induced by the 
intraperitoneal administration of an LSKL peptide, which specifically blocks activation of 
TGF-Pi by TSP-1, has been shown to induce similar pathology (Lawler et al, 1998). 
Similarly, TSP-1 null mice are protected from spontaneous lung pathology when 
treated with the TGF-p! activating peptide KRFK (Lawler et al, 1998). Recent evidence 
suggests that this mechanism may play a role in the bleomycin model of lung injury and 
fibrosis (Khalil et al, 1989). Activation of macrophage-derived TGF-P! is mediated by 
the interaction of plasmin with TSP-1 and its receptor CD36 in vitro. Treatment of mice 
with a synthetic CD36 peptide blocked activation of TGF- p! and subsequent fibrosis 
following bleomycin injury (Yehualaeshet et al, 1999).
1.6.4. TGF-(31 and fibrosis
TGF-P! is generally held as the most important mediator of pulmonary fibrosis both in 
experimental animal models (Khalil et al, 1989) and in human fibrotic lung disease 
(Khalil et al, 1996). TGF-Pi levels as well as most of the TGF-pt -inducible genes 
(Kaminski et al, 2000) are elevated in the lungs of animals with experimentally-induced 
lung fibrosis (Coker et al,. 1997). Overexpression of TGF-Pi leads to the development 
of progressive fibrosis, whilst inhibition this cytokine using either blocking antibodies or 
inhibitors targeting TGF-Pi signalling pathways affords protection in bleomycin-induced 
lung injury and fibrosis (Giri et al, 1993). Similarly, TGF-P! levels are increased in BALF 
of patients with fibrotic lung disease (Ludwicka et al, 1995).
TGF-P! is an important mediator of fibroblast to myofibroblast differentiation via the 
transcriptional upregulation of a-SMA and SMAD dependent signalling (Cogan et al, 
2002;Subramanian et al, 2004;Chambers et al, 2003). Recent evidence suggests that 
TGF-Pi also plays a role in the differentiation of myofibroblasts from alveolar epithelial 
cells (Willis et al, 2005). One of the mechanisms implicated in the transcriptional
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upregulation of a-SMA by TGF-pi in fibroblasts is regulation of the cold shock domain 
protein YB-1, which is a known repressor of a-SMA transcription (Zhang et al, 2005).
TGF-Pi also induces myofibroblast differentiation in granulation tissue in vivo 
(Desmouliere et al, 1993). Administration of TGF-Pi to animals before dermal wounding 
enhances subsequent healing, whilst administration of neutralising antibodies to TGFpi 
results in a reduced inflammatory response and delayed wound healing. Importantly, 
overexpression of TGF-Pi in rat lungs results in the development of progressive 
interstitital and pleural fibrosis which is preceded by the appearance of myofibroblasts 
(Sime et al, 1997). The ED-A domain (EIIIA) of fibronectin has been implicated as a 
crucial candidate for the induction of a-SMA expression by TGF-pi. Tissue injury gives 
rise to this form of fibronectin and is necessary for TGF-Pi to trigger a-SMA expression 
and collagen secretion by myofibroblasts although TGF-p! itself has been shown to 
induce the expression of ED-A fibronectin both in vivo and in vitro (Serini et al, 1998).
Following wound repair and tissue regeneration myofibroblasts are thought to 
disappear from sites of injury via the process of apoptosis (Darby et al, 1990). Due to 
its self limiting nature the disappearance of myofibroblasts also occurs in the bleomycin 
model of lung injury and fibrosis however in IPF the persistence of the myofibroblast 
phenotype is thought to contribute to the progressiveness of this disease (Zhang et al, 
1994c). TGF-p! is thought to play a major role in inhibiting this process. In vitro studies 
have shown that TGF-Pi stimulation may prolong myofibroblast survival (Zhang and 
Phan, 1999). This may also be a potential mechanism in vivo as myofibroblast 
disappearance in bleomycin-induced lung injury and fibrosis correlates with the decline 
of TGF-P! (Zhang et al, 1995). One of the cytokines that has been shown to induce 
myofibroblast apoptosis in vitro is IL-1 p, which is a known inducer of nitric oxide (NO) 
(Zhang et al, 1997). This led to the suggestion that NO may be mediating myofibroblast 
apoptosis in vivo (Zhang et al, 1997). TGF-Pi has been shown to inhibit this process by 
at least two mechanisms; the suppression of inducible NO synthase and the prevention 
of a decline in B cell leukaemia 2 (Bcl-2), which is involved in inhibiting apoptosis 
(Zhang et al, 1997).
TGF-Pi is also the most potent inducer of collagen characterized to date and influences 
its deposition by a number of mechanisms important in collagen synthesis and 
degradation. For example, TGF-pi induces procollagen gene transcription (Raghow et 
al, 1987;lgnotz et al, 1987), increase mRNA stability (Raghow et al, 1987), decreases 
intracellular degradation of procollagen (McAnulty et al, 1991) and decreases
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extracellular degradation of collagen by inhibiting MMP and promoting TIMP production 
(Overall et al, 1989;Edwards et al, 1987).
Finally, TGF-Pi is able to induce the expression of other pro-fibrotic factors in 
fibroblasts, most notably CTGF (Igarashi et al, 1993).
1.7. The role of the coagulation cascade in fibrosis
Compelling evidence has arisen suggesting that activation of the coagulation cascade 
with the resultant activation of coagulation proteinases may also play an important role 
in pulmonary fibrosis (reviewed in (Chambers, 2003)). A recent, non-blinded, 
randomized small trial in IPF of prednisolone alone or prednisolone plus 
anticoagulation (oral warfarin for outpatients or low molecular weight heparin for 
hospitalized patients) (Kubo et al, 2005) reported a significant increase in survival in 
the anticoagulant group, by reducing mortality associated with acute exacerbation. 
Despite some methodological caveats, this remains one of the most significant 
beneficial outcomes on survival in an IPF clinical study to date. This thesis has 
specifically focused on the role of the coagulation cascade in pulmonary fibrosis and 
this section will therefore describe the coagulation cascade in more detail.
1.7.1. The coagulation cascade
One of the earliest events following tissue injury is the activation of the coagulation 
cascade. The primary role of the coagulation cascades is to ensure the formation of 
stable haemostatic clots to prevent blood loss in response to damage to the extensive 
lung capillary and microcapillary vasculature. Following tissue injury, successive steps 
of coagulation proteinase activation via the intrinsic and extrinsic pathways of the 
coagulation cascade result in the generation of thrombin and fibrin (reviewed in (Mann 
et al, 2003a)). This process will be reviewed in the following section and a diagram 
representing the coagulation cascade is represented below (Figure 1.6.).
The activation of the coagulation cascade and the eventual formation of fibrin is a 
highly regulated process (reviewed in (Mann et al, 2003b)). The events occur most 
efficiently when restricted to a phospholipid membrane found on activated platelets, 
damaged extravascular cells and procoagulant phospholipids (microparticles) which 
allows high concentration of the proteinases to accumulate locally and thus increase 
enzymatic reactions by several orders of magnitude. In addition, non-lipid components 
expressed on cell surfaces such as protein binding sites may be influencing the
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generating capacity of active proteinases (Monroe et al, 2002). These processes are 
highly dependent on the presence of calcium ions, which enable proteinase binding to 
phospholipid membranes and further enhance proteinase activation. Further regulation 
by circulating and endogenous anticoagulants ensures that clot formation is localised to 
the site of initial injury and thus prevents disregulated activation at non-involved sites 
(please see also Section 1.7.2.).
Coagulation proteinases circulate in the blood as inactive zymogens and are activated 
by limited proteolysis (reviewed in (Riewald and Ruf, 2002)). The major activator of the 
coagulation cascade in vivo is the extrinsic pathway. It is initiated when injury to the 
vessel wall causes blood components to come into contact with the glycoprotein 
receptor tissue factor (TF). This receptor is usually expressed at very low levels and 
exclusively on extravascular cells such as smooth muscle cells, fibroblasts and 
endothelial cells, as well as platelets (Mann et al, 2003a). This ensures that blood 
components are physically separated from TF under normal circumstances. At sites of 
vascular endothelial damage, upregulation of TF expression on extravascular cells 
allows blood components such as FVII to come into contact with TF which 
subsequently activates and thus converts FVII to FVIIa. The resulting vitamin K- 
dependent TF/FVIIa complex binds to FX to form the so called extrinsic tenase 
complex (TF/FVIIa/FX) which catalyses the conversion of FX to FXa and also induces 
the conversion of limited amounts FIX to FIXa. The resulting ternary complex 
(TF/FVIIa/FXa) is thought to be transient as a small amount of FXa dissociates and 
forms the prothrombinase complex (FVa, FXa, phospholipids, calcium) which converts 
prothrombin to thrombin. The activation of thrombin is a two stage process, involving 
the formation of an intermediate thrombin molecule, termed meizothrombin, which 
however stays bound to the complex in a proteolytically active form until secondary 
cleavage produces the mature thrombin molecule. Thrombin in turn converts fibrinogen 
to fibrin, activates FV, FVIII, FXI and FXII and platelets which cross link the provisional 
fibrin clot and thus from a stable haemostatic plug. However, the generation of 
thrombin via the extrinsic coagulation pathway is thought to only generate limited 
amounts of thrombin. Continuous activation of the coagulation cascade is achieved by 
the activation of factors FXI, FIX, FVIII by the TF/FVIIa/FXa ternary complex. This 
initiates the activation of the intrinsic pathway which plays an important role in 
mediating sustained generation of thrombin. Thus following vascular injury initial 
activation of the extrinsic pathway generates trace amount of thrombin and FXa. These 
feed back into the intrinsic pathway, which serves as an amplification step leading to 
the continuous activation of thrombin and thus sustained coagulation activity.
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Figure 1.6. The coagulation cascade.
The catalytic activity of most coagulation proteinases is regulated by their binding to cell surface 
phospholipids and the presence of calcium ions (Ca2+). In addition, FIXa and FXa only gain 
their full activity when complexed with their respective cofactors, FVIIIa and FVa. Finally, 
thrombin activates the intrinsic pathway via positive feedback mechanisms. Please note that 
only the procoagulant events and positive feedback mechanisms are illustrated for clarity.
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1.7.2. Regulation of the coagulation cascade
The coagulation cascade is tightly regulated by a number of positive and negative 
feedback mechanisms, co-factor expression as well as endogenous anticoagulants 
(reviewed in (Laurent and Shapiro, 2007)). Positive feedback mechanisms mainly 
constitute amplification routes initiated by thrombin activation, as described in the 
previous section, although FXa also mediates a number of feedback loops. The 
expression of co-factors, which are all required by factors FVIIa, FIXa and FXa for 
downstream zymogen activation, is another important control; thus procoagulant 
activity is highly dependent on the availability of these cofactors. FVIIa cannot activate 
FX in the absence of TF and similarly FXa is highly dependent on binding to FV for the 
assembly of the prothrombinase complex.
The most important control feature of the coagulation cascade however, is the 
regulation of coagulation proteinases activity by physiological anticoagulants including 
antithrombin, heparin cofactor II, a2-macroglobulin, -protease inhibitor, protein Z- 
dependent protease inhibitor and tissue factor pathway inhibitor (TFPI) (reviewed in 
(Rau et al, 2007)). The extrinsic pathway is mainly regulated by TFPI which is the 
major plasma inhibitor of FVII (Monroe and Key, 2007). TFPI contains three Kunitz type 
serine protease domains, the first of which mainly reacts with TF/FVII whilst the second 
domain inhibits FXa activity by forming an inactive binary complex with this proteinase 
(reviewed in (Lwaleed and Bass, 2006)). The role of the third domain is currently 
unknown. TFPI is a unique inhibitor in its ability to strongly bind both TF/FVIIa and FXa 
to form a quaternary complex, but leaving low levels of FVIIa active. This is due to its 
inability to bind free FVIIa which results in a highly sophisticated inhibitory mechanism 
that allows the coagulation cascade to be triggered when necessary but induces the 
rapid shut-down of the initiation complex, preventing any ongoing activation. TFPI is by 
far the most potent inhibitor of the coagulation cascade, and mice deficient in the first 
Kunitz domain die in utero, suggesting that a deficiency in this inhibitor is not 
compatible with life (Huang et al, 1997).
The main endogenous inhibitor of the intrinsic pathway is antithrombin, which is a 
single-chain glycoprotein that belongs to the serpin family and that is not dependent on 
the presence of vitamin K. Antithrombin irreversibly neutralises thrombin and also 
inhibits FXI la, FXIa, FIXa and FXa (reviewed in (Rau et al, 2007)). The presence of 
heparin is required for these processes to occur efficiently, although extremely high 
levels of heparin are needed for antithrombin-mediated inhibition of FVIIa thus 
questioning the physiological relevance of this process. Deficiency in antithrombin
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leads to widespread venous thrombosis indicating the importance of this inhibitor in 
regulating coagulation activity. In addition to their inhibitory role during blood 
coagulation, antithrombin and TFPI also play a role in the catabolism of the inhibited 
proteinase. Within minutes of their inhibition, the antiproteinase-proteinase complexes 
are cleared from the blood and targeted to the liver where they are finally degraded 
(Narita et al, 1998;Ho et al, 1996).
Finally, the coagulation cascade is controlled when low concentrations of thrombin bind 
to thrombomodulin, an integral membrane protein expressed on the surface of 
endothelial cells (reviewed in (Mann et al, 2003b)). Binding of thrombin to 
thrombomodulin induces a conformational change in the proteinase thereby changing 
thrombin’s substrate specificity and essentially converting it from a procoagulant into an 
anticoagulant factor. In contrast to its role during coagulation, thrombin in this 
conformation preferentially cleaves the inactive zymogen protein C thus converting it to 
its active form, activated protein C (APC). This reaction is highly dependent on the 
zymogen protein C binding to the endothelial protein C receptor (EPCR) and activated 
protein S which acts as its cofactor. APC controls coagulation by influencing the activity 
of the FIXa/FVIIIa and FXa/FVa complexes through proteolytic inactivation of their 
cofactors FVa and FVIIIa. This mechanism also prevents further feedback generation 
of thrombin as these factors are then unable to form the prothrombinase and intrinsic 
tenase complexes.
1.7.3. Evidence for the role of the coagulation cascade in pulmonary fibrosis
It is increasingly recognised that the coagulation cascade is activated in fibrotic lung 
disease and may contribute to the pathophysiology of pulmonary fibrosis. Extravascular 
intra-alveolar accumulation of fibrin has been described for patients with pulmonary 
fibrosis (Chapman et al, 1986;lkeda et al, 1989;Kotani et al, 1995), organising 
pneumonia (Peyrol et al, 1990), acute lung injury (ALI) and the acute respiratory 
distress syndrome (ARDS) (Bachofen and Weibel, 1982;ldell et al, 1987;ldell et al, 
1989). Extensive research into the role of the coagulation cascade in the past years 
has emphasised the importance of the TF-dependent extrinsic pathway in the 
extravascular space and it is now generally held that this pathway is activated in fibrotic 
lung disease. Evidence for this has been provided by studies reporting strong 
immunoreactivity for TF, the main initiator of the extrinsic pathway, on type II 
pneumocytes as well as on macrophages that are closely associated with fibrin 
deposits in patients with idiopathic pulmonary fibrosis, as well as with systemic 
sclerosis (Imokawa et al, 1997). Increased TF expression can be mediated by TNF-a
50
Chapter 1 Introduction
and TGF-P! stimulation in cultured epithelial cells (Idell et al, 1994). In addition, TF 
expression is also upreguated in epithelial cells, macrophages and fibroblasts in the 
bleomycin model of lung injury and fibrosis (Wygrecka et al, 2007b;ldell, 2003).
The persistent activation of the coagulation cascade is thought to arise from an 
imbalance between pro- and anti-coagulant factors. For example, increased levels of 
the coagulation proteinase thrombin have been measured in the BALF of patients with 
pulmonary fibrosis associated with systemic sclerosis (Hernandez Rodriguez et al, 
1995;Ohba et al, 1994), in pulmonary fibrosis associated with chronic lung disease of 
prematurity (Dik et al, 2003b) and in experimental animal models of pulmonary fibrosis 
such as those induced by radiation-pneumonitis (Huang et al, 2001) or by 
administration of bleomycin (Tani et al, 1991;Howell et al, 2001). Increased levels of 
other coagulation proteinases including, fibrinogen and Factors FVII and FX have also 
been described in patients with intra-alveolar fibrosis associated with BOOP/COP 
(Peyrol et al, 1990). Similarly, levels of endogenous anticoagulants such as 
antithrombin in patients with ARDS (a condition associated with fibroproliferative 
changes in 40% of cases, reviewed in (Ware et al, 2006)) and lower levels of APC 
have been measured in patients with interstitial lung diseases respectively (Yasui et al, 
2000).
1.7.4. Fibrinolysis in the fibrotic lung
Current evidence suggests that fibrinolysis, which is involved in the clearance of 
deposited fibrin, is disregulated in fibrotic lung disease (Swaisgood et al, 2000;Bertozzi 
et al, 1990). The process of fibrinolysis is initiated by the proteolytic conversion of 
plasminogen leading to the generation of plasmin by the proteinases, urokinase type 
plasminogen activator (u-PA) and tissue type plasminogen activator (t-PA) 8 (reviewed 
in (Kucharewicz et al, 2003)). The major role of plasmin is the cleavage of fibrin into 
several fibrin degradation products (FDP). t-PA is the main converter of plasminogen in 
plasma, whilst u-PA controls the fibrinolytic system primarily in the extravascular space. 
Similarly to the coagulation system, the activity of the fibrinolytic system is regulated by 
several endogenous inhibitors, including the plasma glycoprotein, thrombin-activatable 
fibrinolysis inhibitor (TAFI), protein C inhibitor (PCI) and plasminogen activator inhibitor- 
1 (PAI-1). TAFI promotes fibrin persistence by cleaving specific C-terminal lysine 
residues which are exposed on fibrin molecules during fibrinolysis. PAI-1 is the main 
regulator of plasminogen cleavage by either u-PA or t-PA and PCI suppresses 
plasminogen activation and further inhibits the activity of APC. Increased levels of all 
these inhibitors have been reported in patients with ILDs and in experimental animal
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models of pulmonary fibrosis (Fujimoto et al, 2003). The resulting decrease in alveolar 
fibrinolytic activity thus leads to reduced degradation of extracellular matrix and 
promotes fibrin persistence in the fibrotic lung (Swaisgood et al, 2000).
1.7.5. Targeting the coagulation cascade
A number of studies have provided compelling evidence that targeting the coagulation 
cascade is protective in experimental animal models of pulmonary fibrosis. For 
example, previous work in our laboratory has shown that direct thrombin inhibition 
leads to a significant reduction in lung collagen accumulation in the bleomycin model of 
lung injury and fibrosis in rats (Howell et al, 2001). Similarly, intratracheal instillation of 
the endogenous anticoagulant APC is protective in mice following bleomycin injury 
(Yasui et al, 2001) although it is currently unclear from this study weather APC exerts 
its inhibitory effects via its anticoagulant or anti-inflammatory properties. Administration 
of nebulised heparin in rabbits, which binds to antithrombin and increases its ability to 
inhibit thrombin, FIXa, and FXa, has also been shown to reduce bleomycin-induced 
lung injury and fibrosis (Gunther et al, 2003). Finally, intratracheal gene transfer of 
TFPI has been shown to exert profound protective effects on bleomycin-induced lung 
injury and fibrosis in mice by reducing both thrombin activity, as well as lung collagen 
accumulation (Kijiyama et al, 2006).
1.7.6. Mechanisms by which the coagulation cascade exerts its pro-fibrotic 
effects
The role of fibrin deposition in the pathogenesis of pulmonary fibrosis has recently 
been questioned and remains controversial (Hattori et al, 2000). Fibrin is thought to 
influence fibrogenesis in a number of ways. First excessive deposition of fibrin is 
thought to adversely influence alveolar surfactant function thus leading to alveolar 
collapse or atelectasis. Second, in vitro studies have demonstrated that fibrinogen can 
induce the expression and release of a host of pro-inflammatory mediators from 
neutrophils (Walzog et al, 1999), macrophages (Smiley et al, 2001), endothelial cells 
(Qi et al, 1997) and fibroblasts (Liu and Piela-Smith, 2000) which may be directly 
influencing fibroblast recruitment and differentiation and thus collagen deposition. 
Third, fibrin serves as a reservoir of fibrogenic growth factors and cytokines which are 
released during fibrinolysis (Grainger et al, 1995). Studies directly altering the activity of 
the fibrinolytic system by either promoting or inhibiting its activity support a role of fibrin 
in the pathogenesis of pulmonary fibrosis (Eitzman et al, 1996;Gunther et al, 
2003;Fujimoto et al, 2003). However, a recent study reporting the finding that 
fibrinogen knock-out mice are not protected from bleomycin-induced lung injury and
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fibrosis has suggested that fibrin deposition is necessary but not sufficient for the 
progression of fibrosis, at least in this model (Hattori et al, 2000).
There is increasing evidence that the coagulation cascade may promote fibrogenesis 
through the ability of coagulation proteinases of the extrinsic pathway to directly induce 
cellular effects which may be important in influencing inflammatory and tissue repair 
responses (Chambers, 2003;Kijiyama et al, 2006). In particular, the pro-fibrotic effects 
of thrombin have received considerable attention, although recent work has suggested 
that coagulation proteinases upstream of thrombin in the coagulation cascade, 
including FXa may also play an important role. The work presented in this thesis has 
specifically focussed on the role of FXa. Despite the traditional view that FXa is 
exclusively synthesised in the liver (Hung and High, 1996), a recent exciting 
transcriptional profiling study performed in our laboratory revealed that FX was 
expressed in the lung (Figure 1.7.)- As part of a wider microarray global expression 
study Drs Scotton and Lee compared gene expression profiles of mice treated with 
saline or bleomycin and identified numerous genes that were differentially regulated 
between the groups. Amongst the most highly regulated genes was the zymogen FX. 
This led to the hypothesis that FX is synthesised locally in the lung and may play a role 
in the bleomycin model of lung injury and fibrosis. This hypothesis forms a major part of 
this PhD work and the next section will thus discuss the structure and synthesis of this 
proteinase in detail.
1.8 Coagulation Factor X
1.8.1. Structure
FX is a glycoprotein that is synthesised in the liver and circulates in plasma as a 
precursor to the active coagulation proteinase FXa (reviewed in (Laurent and Shapiro,
2007)). The gene for FX is located in chromosome 13 at position q32-qter. It is 27 kb 
long and contains eight exons and seven introns, resulting in the transcriptional 
generation of a 1.5 kb mRNA molecule. 1475 nucleotides of the mRNA code for the 
pre-pro-leader sequence of 40 amino acids, a light chain of 139 amino acids and a 
connecting peptide of 303 amino acids that makes up the heavy chain. The protein is 
synthesised in the liver by hepatocytes, as a single-chain 70 kDa precursor, the pre­
proprotein, of 488 amino acids with 24 half cystines. This FX precursor undergoes a 
number of posttranslational modification steps before it circulates in the plasma as the 
mature two chain zymogen (Figure 1.8.).
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Figure 1.7. Transcriptional profiling of bleomycin-induced lung injury and fibrosis
Heat map showing hierarchical clustering of the top 100 genes differentially regulated 14 days 
following bleomycin instillation in mice. Colour represents mRNA expression levels from low 
(green) to high (red). FX was one of the most highly upregulated genes (data provided by Dr 
Chris Scotton, UCL).
These include translocation of the newly formed precursor protein to the endoplasmic 
reticulum where the pre-peptide signal is cleaved off by a signal peptidase (Wallin and 
Turner, 1990). The remaining pro-peptide directs the subsequent y-carboxylation by 
the vitamin K dependant y-carboxylase which converts 10-12 glutamic acid residues in 
the N-terminal part of the protein into y-carboxyglutamic acid (Gla) residues, an 
essential modification to ensure optimal activation of the zymogen once secreted (Furie 
and Furie, 1988). Following cleavage of the propeptide by a processing protease, the 
FX precursor undergoes (S-hydroxylation of Asp63 in the first EGF-like domain and a 
high degree of N-linked glycosylation close to the side of the activation peptide region, 
which increases the relative mass of FX from 58.2 kDa to 58.9 kDa.
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Figure 1.8. Processing and activation of FX
(A) FX polypeptide before processing. FX protein is synthesised in the liver by hepatocytes as a 
single-chain 70kDa precursor, containing the pre-propeptides, y-carboxyglutamic acid (Gla) 
domain, EGF-like repeats, activation peptide and protease domain. y= Gla residues, (3=|3- 
hydoxylated Asp63 (B) Processed FX protein. During post-translational modification, the 
prepeptide signal sequence is cleaved off by a signal peptidase while the propeptide directs y- 
carboylation of the first 11 Glu residues of the N-terminus (Gla domain). After further 
intracellular processing, FX is secreted into the blood as a glycosylated, two-chain, disulphide- 
linked inactive zymogen. (C) Activated FX, FXa. FX is activated via hydrolysis of a peptide bond 
at a single site (Arg194) in the heavy chain to release a small 52 amino acid activation peptide, 
catalyzed by either TF/FVIIa or FIXa/FVIIa (Image taken from (Laurent and Shapiro, 2007)).
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The final processing step results in the cleavage of FX into a light and heavy chain, 
which occurs by an unknown mechanism but involves the release of the basio 
tripeptide Arg140-Lys-Arg142 from the centre of the molecule. The 16-2 kDa Il9ht chain 
contains the Gla and EGF-like domains whilst the activation peptide and the latent 
serine protease domain are situated on the 42 kDa heavy chain. The two chains are* 
additionally linked together by a disulphide bond between Cys132 and Cys302. K is these 
two chains that make up the mature form of FX and both are required for FX exhibit 
its procoagulant and cellular effects once activated. Although this structure shares high 
homology to the trypsin family, FXa confers specificity for its substrates and 'hhibitora 
through the insertion of various sized peptide sequences, called insertion loops onto 
the external surface of the molecule.
1.8.2. FX activation
FX is activated by hydrolysis of a peptide bond at a single site (Argi94) fronrj the jsj- 
terminus of the heavy chain to release a small 52 amino acid activation peptide 
(Mr=8000), providing a potentially measurable maker of FXa activation ((Di Sc*pio et al. 
1977), Diagram 1.8.)- As already eluded to in previous sections FX. cleavage con be 
catalysed by either FIXa/FVIIIa complex or by the TF/FVIIa complex and both factions 
generate the identical FXa product. Activation of FX by the FIXa/FVlHa complex plays a 
central role in the intravascular space as FIXa-deficient mice are completely Protected 
from thrombus formation in vascular injury models (Gui et al, 20o7). In contrast, it is 
generally believed that the TF/FVIIa complex plays a major role in the activation °f FX 
in environments of high TF expression, such as those generated in the extravascular 
space post tissue injury (Chambers and Laurent, 2002). However, fX  can bo actuated 
by alternative mechanisms independently of either intrinsic or extrinsic coagulation 
pathway activity. Thus in inflammatory environments, FX may bind to Cp1lb/CC)l8 
(MAC-1) expressing monocytic cells, which subsequently mediate FX cleavaQe via th© 
secretion of the proteinase cathepsin G (Plescia and Altieri, 1996). FXa acth^tion rnay 
also be mediated by invading organisms during infectious states. Viruses sgch as 
cytomegalovirus, herpes simplex virus types 1 and 2 all display the appropriate 
phospholipids to promote FXa generation in a FVII-dependent but TF- ind^penqent 
manner (Sutherland et al, 1997). In addition, certain bacterial proteinases* such as 
gingipain-Rs from Porphyromonas gingivalis, can cleave and directly activate fX  and 
thereby initiate the activation of the coagulation cascade (Imamura et al, 1997).
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1.8.3 Biological functions of FXa
FXa exerts several cellular effects which may directly influence inflammatory 
responses. For example, FXa induces the secretion of various pro-inflammatory 
cytokines, including IL-1 by fibroblasts (Jones and Geczy, 1990), IL-2 by lymphocytes 
(Altieri and Stamnes, 1994) as well as IL-6 and IL-8 by endothelial cells (Senden et al,
1998). Some of these effects appear to be mediated via the initial release of NO, which 
additionally affects the inflammatory reaction and vascular tone. FXa also induces 
oedema formation when injected subcutaneously in a rat paw inflammation model, via 
the local recruitment of mast cells (Cirino et al, 1997). Furthermore, FXa mediates the 
expression of adhesion molecules on monocytes (Senden et al, 1998) and induces NK- 
kB and Cyr61 gene expression in HeLa cells (Riewald et al, 2001).
FXa is a potent mitogen for a variety of cell types. In smooth muscle cells, FXa 
stimulates DNA synthesis and mitogenesis via the autocrine stimulation of PDGF 
(Herbert et al, 1998;Gasic et al, 1992) or epiregulin (Koo and Kim, 2003). Similarly, 
FXa stimulates endothelial cell proliferation via autrocrine production of PDGF 
(Gajdusek et al, 1986). FXa is also mitogenic to mesangial cells (Tanaka et al, 
2005;Tanaka et al, 2005) and to lymphocytes and the mitogenic effect on lymphocytes 
is thought to be mediated via the release of IL-2 (Altieri and Stamnes, 1994). FXa is 
further known to modulate tumour cell growth, invasion and metastasis (Sampson and 
Kakkar, 2002).
The contribution of FXa’s cellular effects to pathophysiological processes has only just 
begun to unfold. Recent evidence from our laboratory has implicated a role for FXa in 
stimulating fibroblast responses which may contribute to the pathogenesis of fibrotic 
lung disease (Blanc-Brude et al, 2005). At the same time, evidence was provided that 
similar to thrombin, FXa exerted its effects on certain cell types via its ability to activate 
members of the novel family of seven transmembrane G-protein coupled receptors 
called proteinase activated receptors (PARs). This evidence will now be discussed in 
greater detail.
1.9. Proteinase Activated Receptors (PARs)
The quandary as to how coagulation proteinases, such as FXa and thrombin, influence 
cellular responses was elucidated by the discovery of the PARs in the early 1990s 
(Ossovskaya and Bunnett, 2004). The PARs are a novel family of ubiquitously 
expressed seven transmembrane domain G-coupled protein receptors. As their name
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suggests, the receptors are activated by a unique mechanism involving limited 
proteolysis of a specific sequence at the N-terminus by the proteinase, leading to the 
unmasking of a ligand which is tethered to the receptor. This tethered ligand binds to 
the second extracellular loop, which induces a conformational shape change in the 
receptor, allowing it to interact with heterotrimeric G-proteins and thus initiate 
downstream signalling (Figure 1.9.).
Proteinase
Tethered Ligand
111 
Cell signalling
Figure 1.9. Activation of proteinase-activated receptors
Following proteolytic cleavage of PARs, the newly generated tethered ligand binds to the 
second extracellular loop of the receptor. This induces a conformational change in the receptor, 
allowing it to interact with heterotrimeric G-proteins and initiate downstream signalling 
responses.
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Currently, the PAR family comprises four members, PAR! to PAR4. All four PAR genes 
share a homologous structure. They contain two exons of which exon 1 encodes a 
signal peptide and exon 2 the mature receptor protein (Kahn et al, 1998). The genes 
for PARi-3 are all located on the same chromosome locus (5q13), whilst PAR4 is 
located on 19p12 (Xu et al, 1998). Collectively, the proteinases of the coagulation 
cascade can activate all four members of the PAR family. Thrombin is considered the 
major activator of PARi, PAR3 and PAR4, whereas FXa activates PAR! and PAR2. 
However, there is increasing evidence that PARs can also be activated by non­
coagulation proteinases. For example, trypsin and tryptase are major activators of 
PAR2 and a recent report has suggested that PARi can also be activated by the matrix 
metalloproteinase, MMP1 (Boire et al, 2005). To dissect the different PARs in terms of 
function, synthetic peptides which mimic the tethered ligands of PARi, PAR2, and PAR4 
are capable of eliciting a number of cellular responses by functioning as PAR agonists 
which can activate the receptors independent of proteolysis (Coughlin, 1999). For 
example, PARi can be activated by SFLLR-NH2 or TFLLR-NH2 peptides. However, 
these receptor-activating peptides are generally less efficient than the in vivo 
physiological activators of the PARs because they do not enable certain specific 
interactions to occur between receptor and proteinase which are important to facilitate 
their binding. The agonists for each receptor, together with tissue localization of the 
receptors, and their potential physiological roles are shown in Table 1.5. This thesis 
has particularly focused on the role of PARi in mediating FXa cellular effects, thus the 
forthcoming section will particularly concentrate on the physiological consequences of 
PARi activation in normal physiology and disease.
1.9.1. P A ^
As already alluded to, PARi is the major cellular receptor for thrombin, although it can 
also be activated by FXa, the ternary complexes (TF/FVIIa /FXa) (Riewald et al, 2001), 
activated protein C (Riewald et al, 2002), and plasmin (Mandal et al, 2005). Thrombin 
is a very efficient activator of PARi which is facilitated by a hirudin-like binding domain 
situated at N-terminus of PARi. The attraction between this domain and thrombin’s 
anion binding exosite enables thrombin to effectively complex with PARi and thus 
initiate cleavage of the receptor. In contrast, FXa lacks this binding side but efficient 
activation of PARi by this proteinase is facilitated by FXa complexing with TF and FVIIa 
at the site of its generation, so that the proteinase is localised to the cell membrane. In 
this constellation FXa is five times more potent at activating this receptor compared to 
FXa alone (Riewald et al, 2001). Similarly, APC utilizes the cell surface receptor EPCR 
as a cofactor to facilitate its activation of PARi (Riewald et al, 2002).
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Table 1.5. Proteinase-activated receptors (PARs)
A summary of PAR activating proteases, disabling proteases, activating peptides, localization 
and phenotypes of PAR deficient mice. Updated from (Ossovskaya and Bunnett, 2004)
1.9.2. PARi signalling pathways
PAR, exerts its multiple cellular effects via interaction with downstream G-proteins. G 
proteins are heterotrimeric guanine nucleotide binding proteins which consist of a, p 
and y subunits. Ga is in its inactive form when bound to GDP. Following cleavage of 
the receptor by the proteinase, a conformational change in the receptor initiates the 
phosphorylation and thus conversion of GDP to GTP. This induces the dissociation of 
the a subunit from the (3y subunits and thus initiates cell signalling. Three main classes 
of G proteins can be distinguished according to the primary sequence of the a subunit
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and PARt is able to couple to Gah Gaqand Ga12/i3 (reviewed in (Coughlin, 1999)). The 
type of G protein to which PARi is coupled to dictates the nature of the cellular 
response (reviewed in (Hollenberg and Compton, 2002)). In addition, it is increasingly 
recognized that in the same cell type, responses to different agonists may vary greatly. 
For example, thrombin and activated protein C (APC) which both signal via PAR, in 
TNF- a perturbed endothelial cells have been reported to mediate distinct biological 
effects (Riewald and Ruf, 2005). This observation may be explained by the 
phenomenon of functional selectivity whereby different agonists of PARi selectively 
activate different G-protein pathways by their ability to alter receptor/G protein binding 
(McLaughlin et al, 2005b). Thus, thrombin and the PAR agonist peptide, TFLLR, both 
activate PAR! on endothelial cells to influence barrier permeability and calcium 
mobilization. However activation by thrombin is associated with more efficient receptor 
coupling to Ga12/13 and a greater effect on barrier permeability, whereas activation by 
TFLLR is associated with more efficient receptor coupling to Gaq and a greater effect 
on calcium mobilization (McLaughlin et al, 2005b).
PARi impacts on a substantial network of signalling pathways, as shown in Figure 
1.10. The cell signalling pathways involve multiple interactions at a number of levels, 
and are very cell-specific.
PARrGa, pathway
PARi coupling to various G-protein a subunits is mediated by the presence of different 
binding sites on the receptor. For example, the third intracellular loop of PAR! is 
involved in PARi coupling to the pertussis-toxin sensitive Gaj. Coupling to the Gaj 
subunit leads to downstream inhibition of adenyl cyclase and reduces the generation of 
cyclic adenosine monophosphate (cAMP) and potentiates calcium ion mobilisation in 
response to thrombin-mediated activation (Hung et al, 1992b). PARi- Gaj coupling also 
activates Src tyrosine kinase, which triggers the Ras, Raf and mitogen-activated 
protein kinase (MAP kinase) pathway. This pathway is necessary for thrombin-and 
FXa-induced fibroblast proliferation (Blanc-Brude et al, 2005;Trejo et al, 1996). Recent 
studies have also shown that PARi- Gaj coupling is responsible for the increased 
expression of thrombospondin-1 (TSP-1) induced by thrombin in vascular endothelial 
cells (Riewald and Ruf, 2005). Binding of PARi to Gaj is also necessary for thrombin- 
induced changes in endothelial barrier permeability (Riewald and Ruf, 2005).
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Figure 1.10. Major PAR1 G-protein coupled signalling pathways
PARt exhibits the ability to couple to multiple G-protein family subunits, including Gas, Goq or 
Gfli2/13 within the same cell type. In general, the Gaj pathway inhibits adenyl cyclase and the 
generation of cyclic adenosine monophosphate (cAMP); the Goq pathway involves 
phospholipase C-0 (PLC-0) activation and concomitant calcium mobilization and PKC 
activation; whereas the Ga12/13 pathway activates Rho kinase and regulates actin remodelling. 
(Figure modified from (Coughlin, 2000;0ssovskaya and Bunnett, 2004))
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PARr Gaq-pathway
A major PAR! signalling pathway is through coupling to Gaq (Hung et al, 1992a).The c- 
terminal tail of PARi is required for the interaction with Gaq. Gaq activates the 
phospholipase-p (PLC-(3) pathway (Babich et al, 1990) which subsequently triggers 
phosphoinositide hydrolysis (PIP2) to generate inositol triphosphate (IP3) and 
diacylglycerol (DAG). This in turn mobilises calcium from intracellular stores, increasing 
the intracellular calcium concentration from approximately 10'7M to 10'3M and also 
causes the activation of protein kinase C (PKC) (Berridge, 1993). Calcium, as a second 
messenger, activates calcium-dependent kinases and phosphatases such as CaM 
kinases, Ras guanine-nucleotide exchange factors (GEFs) and MAP kinases. PKC is a 
key enzyme in ERK (one of the MAP kinases) signalling and Raf is the primary target 
of PKC (Kolch, 2000). The Gaq pathway is involved in thrombin-induced fibroblast 
proliferation and differentiation, platelet aggregation and granule secretion 
(Bogatkevich et al, 2001;Benka et al, 1995;Baffy et al, 1994). Gaq -mediated PARi 
responses on platelets may be particularly relevant in vivo since Gaq -deficient mice 
exhibit reduced thrombin-induced aggregation and degranulation (Offermanns et al,
1997). PARr  Gaq is responsible for NFkB activation and ICAM-1 transcription in 
endothelial cells following activation by thrombin (Rahman and MacNee, 1998).
PARr Ga12/i3 pathway
Ga12/13 has been mainly implicated in the regulation of cytoskeletal structure, cell shape 
and migration. Following interaction of PARi with Ga12/13, guanine-nucleotide exchange 
factor binding results in the activation of small G-proteins such as Rho GTPases. Rho 
GTPases belong to the RAS superfamily (which consists of Rho, Rac and Cdc42). 
These are involved in the control of cell growth and organisation of the actin 
cytoskeleton (Wennerberg et al, 2005) and mediate the downstream activation of 
RhoA. PARi is known to couple to Ga12/13 in platelets, endothelial cells and 
astrocytoma cells (Aragay et al, 1995;Offermanns et al, 1994;Vouret-Craviari et al,
1998). Thus thrombin mediates platelet shape and cytoskeletal organisation in 
endothelial cells via the via the Gai2/13 pathway (Vouret-Craviari et al, 1998;Klages et 
al, 1999). Apart from RhoA, PARi coupling to Ga12/13 activates the Jun-N-terminal 
kinase pathway, which together with the activation of Gaq has been suggested to play 
role in thrombin-mediated fibroblast transformation (Marinissen et al, 2003). Finally, the 
PAR! Gai^a pathway is responsible for thrombin-stimulated DNA synthesis and cell 
migration in smooth muscle cells (Seasholtz et al, 1999).
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1.9.3. Regulation of PARi signalling
Activation of PARi by proteinases such as thrombin is an irreversible process as 
cleavage of the N-terminus by the proteinase results in the permanent attachment of 
the tethered ligand to the receptor thus enabling continuous activation. A number of 
mechanisms contribute to the cessation of PARi signalling (reviewed in (Ossovskaya 
and Bunnett, 2004;Dery et al, 1998)).
First, the PARt receptor undergoes rapid intracellular desensitisation leading to the 
uncoupling of PARi from its downstream signalling cascades and internalisation of the 
receptor (Ishii et al, 1993). In this process, receptor phosphorylation effectively disrupts 
the ability of the receptor to interact with G proteins and thus terminates signal 
transduction. This process is mediated via two classes of protein kinases. Homologous 
receptor desensitization involves agonist-dependent phosphorylation of specific C- 
terminal residues of the receptor by G protein receptor kinases, which utilise proteins 
known as p-arrestins as cofactors. Heterologous receptor desensitization involves 
agonist-independent activation of a separate receptor C-terminal phosphorylation by 
other intracellular protein kinases such as PKC and PKA (Yan et al, 1998).
Second, following activation, PAR! is recruited into clathrin-coated pits and internalised 
by endocytosis to be degraded intracellularly (Hoxie et al, 1993). Over 85% PARi is 
internalised within 1 min in erythroleukemic and megakaryoblastic cell lines (Hoxie et 
al, 1993) and trafficked to lysosomes for degradation (Brass et al, 1994). This process 
requires lysosomal sorting which is dependent on the c-terminus of PAR! (Brass et al, 
1994) and the membrane associated protein, sorting nexin-1 (SN-1) (Wang et al, 2002) 
A portion of cleaved PARi avoid degradation and traffic back to the cell surface but 
remain unresponsive to further proteolytic activation (Brass et al, 1994). Receptor 
endocytosis also occurs independently of receptor activation, and thus PARi is known 
to cycle constitutively between the plasma membrane and intracellular stores (Shapiro 
et al, 1996).
The ability of a cell to replenish PAR at the cell surface is dependent on both the 
mobilization of intracellular receptor stores and the synthesis of new receptors. 
Abundant intracellular stores of PARs have been reported in endothelial cells (Horvat 
and Palade, 1995), fibroblasts (Hein et al, 1994) and epithelial cells; although in all 
cells, receptor replenishment after prolonged exposure to activating proteinases is 
dependent on the synthesis of new receptors. Platelets lack the ability to synthesize
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new receptors and have limited intracellular receptor pools. Thus they are unable to 
regain responsiveness following their activation by thrombin (Coughlin, 1999).
PARi may also be subject to extracellular inactivation by proteinases such as 
neutrophil elastase, cathepsin G and proteinase 3. These proteinases have been 
shown to remove the tethered ligand from PAR! by limited proteolysis thus rendering 
PAR! unable to further activation by proteinases (Renesto et al, 1997).
1.10. Role of PARi in fibrosis
Since the generation of PAR! knock-out mice by Connolly et al in 1996 (Connolly et al, 
1997) our understanding of PARi biology has seen rapid advances. The phenotype of 
the PARi 7' mouse shows 50% intraembryonic lethality due to a defect in vascular 
development, however those that survive are grossly normal (Griffin et al, 2001). By far 
the most significant role of PARi post-development is in mediating platelet aggregation 
by thrombin. However PARi exerts a variety of different cellular effects that may play 
an important role in tissue inflammation and repair and may thus contribute to the 
process of fibrosis (reviewed in (Chambers, 2003)). These will now be discussed in 
detail.
1.10.1. PARi and inflammation
Activation of PARi by thrombin plays a major role in inducing the release of potent pro- 
inflammatory cytokines and chemokines from a variety of different cell types including 
fibroblasts, epithelial cells, monocytes/macrophages and vascular endothelial cells 
(summarised in Table 1.6., also reviewed in (Bunnett, 2006;Coughlin and Camerer, 
2003). These are also released following FXa and TF/FVIIa/FXa complex-mediated 
activation of PARi. Similarly, a number of different pro-inflammatory mediators may 
induce tissue factor expression on epithelial cells, macrophages and fibroblasts (Idell et 
al, 1994), so that it has been proposed that PARi acts as a cellular sensor of tissue 
injury mediating the cross talk between inflammation and coagulation (Chambers, 
2003). Thrombin is a known inducer of endothelial cell adhesion molecule expression, 
including P-selectin and ICAM-1 in vitro (Sugama et al, 1992) and may therefore 
facilitate the recruitment of inflammatory cells via both chemokine production and 
adhesion molecule expression.
PARi is highly expressed on endothelial cells and activation of the receptor by thrombin 
induces endothelial cell permeability and contraction in vitro (Bogatcheva et al, 2002). 
This mechanism may be directly relevant in vivo as intravenous infusion of thrombin
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increases pulmonary vascular permeability in experimental animal models (reviewed in 
(Siflinger-Birnboim and Johnson, 2003)). Thus PAR! mediated signalling events post 
lung injury may be a major mechanism by which vascular permeability is increased, 
allowing the leakage of coagulation proteinases and fibrin into the extravascular space 
(reviewed in (Idell, 2003)).
Interestingly, recent studies have shown that APC can have barrier protective effects 
on an endothelial cell monolayer (Feistritzer and Riewald, 2005;Finigan et al, 2005), 
which at least in vitro is thought to be mediated by PARi-dependent transactivation of 
sphingosine-1 phosphate signalling (Feistritzer and Riewald, 2005). Thus, activation of 
PARi by either thrombin or APC can mediate both barrier disruption and barrier 
protection, respectively. However, very low concentrations of thrombin had similar 
barrier protective effects to APC and very high concentrations of APC were barrier 
disruptive (Feistritzer and Riewald, 2005), suggesting that the rate of PARi activation 
determines downstream cellular effects of different PARi activators. Similarly to APC, 
FXa has now been shown to mediate barrier protection via PAR! and also via a PAR2-  
dependent mechanisms (Feistritzer et al, 2005).
1.10.2. PARi exerts potent pro-fibrotic effects in vitro
Research performed over the last ten years in our laboratory and by others has 
provided compelling evidence that PARi is the main receptor involved in mediating the 
pro-fibrotic effects of thrombin, including its effects on fibroblast chemotaxis (Dawes et 
al, 1993), proliferation (Dawes et al, 1993), extracellular matrix production (Chambers 
et al, 1998) and fibroblast to myofibroblast differentiation (Bogatkevich et al, 2001). 
More recently, our laboratory has also shown that the stimulatory effects of FXa on 
fibroblast proliferation and procollagen production are mediated via the activation of 
PARi rather then PAR2 (Blanc-Brude et al, 2005). Furthermore, thrombin has also been 
shown to be a major fibroblast mitogen in BALF fluid from patients with pulmonary 
fibrosis (Hernandez Rodriguez et al, 1995) (Ohba et al, 1994). In contrast to fibroblast 
biology, PARi activation on epithelial cells has been implicated in alveolar epithelial cell 
apoptosis in vitro (Suzuki et al, 2005).
The majority of PARi-mediated cellular effects are mediated via the induction and 
release of a host of secondary mediators. These include several pro-inflammatory and 
pro-fibrotic mediators, many of which have been implicated in the pathogenesis of 
pulmonary fibrosis. An extensive list of all mediators released following PARi activation 
is provided in Table 1.6. For example, PARi has been shown to be a potent inducer of
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PDGF-AA and also upregulates the expression of the receptor PDGF a-receptor in 
fibroblasts. There is good evidence that this is a major mechanism by which PAR! 
mediates its potent mitogenic effects in these cells (Blanc-Brude et al, 2001 ;Ohba et al, 
1994). In addition blocking PDGF is associated with significant protection from 
experimentally-induced pulmonary fibrosis (Rice et al, 1999;Yoshida et al, 1999). PARi 
activation leads to the rapid and potent induction of CTGF by cultured lung fibroblasts 
(Chambers et al, 2000), as well as epithelial cells (Riewald et al, 2001). Interestingly, 
this growth factor has been shown to mediate both myofibroblast differentiation and 
collagen deposition via its N-terminal domain and fibroblast proliferation via the C- 
terminal domain (Grotendorst and Duncan, 2005). There is good evidence that CTGF 
exerts its effects on these processes depending on the relative presence of the growth 
factors IGF (promotes CTGF mediated proliferation) and EGF (promotes CTGF- 
mediated collagen deposition) (Grotendorst and Duncan, 2005).
During the course of the work performed in this thesis, another mechanism by which 
activation of PARt may promote fibrosis was uncovered by Jenkins et al working in 
collaboration with our laboratory. The observation was made that PAR! ligation can 
lead to the activation of latent TGF-fr in alveolar epithelial cells (Jenkins et al, 2006). 
This mechanism is thought to occur in an avp6 integrin-dependent manner and it has 
been further proposed that this mechanism may contribute to latent TGF-p! activation 
following bleomycin-induced lung injury (Jenkins et al, 2006). Interestingly, previous 
studies in our laboratory revealed that in PARi knock out mice, TGF-p 
immunoreactivity, particularly in fibrotic foci following bleomycin-injury, was decreased. 
This raised the possibility that PARi may also be important in TGF-pi 
production/activation in fibroblasts. The work presented in this thesis has examined this 
hypothesis in the context of FXa signalling.
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Pro-inflammatory Cellular source
mediators
RANTES Synovial fibroblasts (Hirano et al, 2002)
CCL2 Monocytes/macrophages (Colotta et al, 1994)
Endothelial cells (Colotta et al, 1994;Riewald et al, 2002) 
Dermal fibroblasts (Bachli et al, 2003)
Hepatic stellate cells (Fiorucci et al, 2004)
HUVEC (Marin et al, 2001)
TNF-a Monocytes/macrophages (Naldini et al, 1998) 
Microglia (Suo et al, 2002)
IL-1p Monocytes/macrophages (Naldini et al, 2002)
IL-6 Endothelial cells (Johnson et al, 1998) 
Monocytes (Naldini et al, 2000)
Lung epithelial cells (Asokananthan et al, 2002) 
Lung fibroblasts (Sower et al, 1995)
Smooth muscle cells (Kranzhofer et al, 1996)
IL-8 HUVEC (Marin et al, 2001)
Lung epithelial cells (Asokananthan et al, 2002) 
Dermal fibroblasts (Bachli et al, 2003)
Lung fibroblasts (Ludwicka-Bradley et al, 2000) 
Monocytes (Naldini et al, 2000)
p g e 2 HUVEC (Houliston et al, 2002)
Colonic fibroblasts (Seymour et al, 2003) 
Epithelial cells (Asokananthan et al, 2002)
Pro-fibrotic
mediators
Cellular source
PDGF Alveolar macrophages (Tani et al, 1997)
HUVEC (Shankar et al, 1994)
Lung fibroblasts (Blanc-Brude et al, 2005)
Vascular smooth muscle cells (Stouffer et al, 1993) 
Lung epithelial cells (Shimizu et al, 2000)
CTGF Lung fibroblasts (Chambers et al, 2000) 
Epithelial cells (Riewald et al, 2001)
TGF-p1 Vascular smooth muscle cells (Stouffer and Runge, 1998) 
Platelets (Soslau et al, 1997)
Epithelial cells (Jenkins et al, 2006)
bFGF Vascular smooth muscle cells (Stouffer and Runge, 1998)
Endothelin-1 Endothelial cells (Marsen et al, 1995)
Vascular smooth muscle cells (Lepailleur-Enouf et al, 2000) 
Monocytes (Srivastava and Magazine, 1998)
TSP-1 Endothelial cells (McLaughlin et al, 2005a)
IGF Vascular smooth muscle cells (Du et al, 2001)
Table 1.6. Pro-inflammatory and pro-fibrotic mediators induced in response to PARi
activation
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1.10.3. PARi exerts potent pro-fibrotic effect in vivo
In support of a role of PARi in mediating the fibrotic response to lung injury, our 
laboratory has shown that the immunoreactivity for PAR! is highly increased in the 
bleomycin model of lung injury and fibrosis and is mainly associated with inflammatory 
and fibrotic foci (Howell et al, 2001). Furthermore PARi immunoreactivity in the human 
fibrotic lung mirrors that of the bleomycin animal model, as PAR! immunoreactivity is 
very low in normal human lung but highly increased in fibrotic lung samples where it 
localises to macrophages and fibroblasts within active fibrotic lesions (Howell et al,
2005). More recently, our laboratory has further shown that mice deficient in the PAR! 
receptor are protected from inflammatory cell recruitment, microvascular leak, lung 
oedema and fibrosis in response to bleomycin injury (Howell et al, 2005). This is 
associated with a reduction in key pro-inflammatory and pro-fibrotic cytokines, including 
CCL2/MCP-1 and CTGF which are known to be induced following PARi activation in 
vitro (see Table 1.6.). The reduction in the growth factor CTGF is particularly important 
given the previous observation that protection from bleomycin-induced lung fibrosis by 
direct thrombin inhibition is also associated with a decrease in CTGF protein 
expression (Howell et al, 2001). CTGF has been highly implicated in the pathogenesis 
of pulmonary fibrosis, although the mechanism by which CTGF contributes to the 
development of pulmonary fibrosis is not well understood. For example, direct 
adenoviral gene transfer of CTGF into mice lungs only resulted in a transient fibrotic 
response suggesting that CTGF is not a direct pro-fibrotic mediator in this organ 
(Bonniaud et al, 2003). However, in vitro studies clearly demonstrated pro-fibrotic roles 
for this growth factor (Grotendorst and Duncan, 2005) and co-administration of CTGF 
and bleomycin in mice resistant to fibrosis induced a progressive pro-fibrotic response 
(Bonniaud et al, 2004). In addition, increased amounts of CTGF have been measured 
in patients with fibrotic lung disease compared with normal patients (Allen et al, 1999). 
The observation that CCL2/MCP-1 expression is reduced following bleomycin injury in 
PARi knock-out mice is also of particular interest since CCL2/MCP-1 blockade has 
been shown to be protective in both bleomycin-and FITC-induced models of pulmonary 
fibrosis (Gharaee-Kermani et al, 2003;Moore et al, 2001). This may thus represent 
another potential mechanism by which PARi exerts its pro-fibrotic effects in vivo.
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1.11. Summary and hypothesis
Pulmonary fibrosis is the end stage of a heterogeneous group of disorders, 
characterised by the excessive deposition of extracellular matrix proteins within the 
pulmonary interstitium. Current evidence suggests that the differentiation of fibroblasts 
into highly synthetic and contractile myofibroblasts is central to the pathogenesis of 
pulmonary fibrosis.
In this chapter, the role of the coagulation cascade and in particular the coagulation 
proteinase FX in lung pathobiology has been reviewed. Uncontrolled coagulation 
activity has been documented in the lungs of patients with pulmonary fibrosis, with 
increased procoagulant activity in the BALF obtained from these patients. FXa has 
been shown to exert a number of cellular effects and these are mediated via the 
activation of its major signalling receptors, PARi and PAR2.
It is generally held that coagulation zymogens are principally synthesized in the liver 
and released into the circulation as inactive precursors which are only activated as a 
consequence of the initiation of the tissue factor (TF)-dependent coagulation pathway 
at sites of injury. However, recent global expression profiling studies performed in our 
laboratory revealed that the FXa precursor, zymogen Factor X (FX), is locally 
upregulated in response to bleomycin-induced fibrosis in the murine lung (Scotton et al, 
unpublished observation).
This thesis will therefore address the following hypothesis:
FX/FXa is locally expressed in the fibrotic lung and contributes to the 
development of pulmonary fibrosis by influencing fibroblast function.
The specific aims of this thesis are to:
(i) Confirm the local upregulation of FX in the fibrotic lung by assessing FX mRNA 
and protein levels in the bleomycin model of lung injury and fibrosis and in 
human IPF samples.
(ii) Determine if FXa influences fibroblast to myofibroblast differentiation and 
identify the signalling receptor involved and the potential role of TGF-fr in 
mediating this effect.
(iii) Evaluate the role of FXa in the development of pulmonary fibrosis in vivo, by 
assessing the effect of the potent and selective direct FXa inhibitor, ZK 807834 
on lung collagen accumulation in the bleomycin model of lung injury and 
fibrosis.
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Chapter 2: Materials & Methods 
Materials
2.1. Chemicals, solvents and tissue culture materials
All chemicals were of analytical grade or above and obtained from Sigma Aldrich (UK) 
unless stated otherwise. All water used for the preparation of buffers was distilled and 
deionised using a Millipore Water Purification system (Millipore R010 followed by Milli- 
Q Plus; Millipore Ltd., UK). Solvents used for the preparation of high pressure liquid 
chromatography (HPLC) buffers and solutions were of HPLC grade and obtained from 
BDH-Merck Ltd. {UK). Sterile tissue culture flasks and plates, polypropylene centrifuge 
tubes and pipettes were all obtained from Nunc (Denmark). All sterile tissue culture 
media, sterile tissue culture grade trypsin/EDTA and antibiotics were obtained from 
Invitrogen (UK). Foetal calf serum (FCS) was purchased from Invitrogen (UK).
2.2. Coagulation factors, cytokines, growth factors and peptides
Purified human FXa was purchased from Enzyme Research Labs Ltd. (UK)] human cx- 
thrombin was obtained from Sigma-Aldrich (UK)] human TGF-fr and TNF-a were 
purchased from R&D Systems (UK) Bleomycin was purchased from Kyowa-Hakka 
(USA). The specific PAR! agonist peptide TFLLR-NH2 and the corresponding control 
peptide FTLLR-NH2 were synthesized and provided by Professor R. Mecham 
(University of Washington, MO, USA). The PAR2 agonist peptide, SLIGKV-NH2 was 
purchased from Auspep (Australia). All preparations were dissolved in DMEM culture 
medium, aliquotted and stored at -80 °C.
2.3. Inhibitors and Antibodies
The specific thrombin inhibitor, recombinant leech hirudin (rHir), was purchased from 
Sigma-Aldrich (UK). The selective PAR, antagonist RWJ-58259 was a kind gift from Dr 
Claudia Derian (Johnson and Johnson Pharmaceutical Research and Development, 
USA). The specific FXa inhibitor, antistasin core peptide D-Arg32-Pro38, was 
purchased from Bachem (UK). Pertussis toxin was obtained from Merck Chemicals 
(UK). The Q94 compound was a kind gift from Annette Gilchrist, (Caden Biosciences, 
Wl, USA). The TGF-0! type I receptor kinase (ALK5) inhibitor, SB431542, was 
purchased from Sigma-Aldrich (UK). The ALK5 inhibitor SD-208 was a kind gift from 
Dr. Linda Higgins (Scios, CA, USA). The thrombospondin-1 (TSP-1) inhibitory peptide 
LSKL and the scrambled control peptide SLLK were a kind gift from Professor Murphy- 
Ullrich {University of Alabama, AL, USA).
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The small molecule inhibitor of FXa activity, ZK 807834, was a kind gift from Dr John 
Morser (Berlex Inc., CA, USA).
The antibodies used for Western blotting were as follows. A mouse polyclonal anti-a- 
SMA (clone 1A4) was purchased from Sigma-Aldrich (UK){Skalli et al, 1986). Mouse 
monoclonal anti-TGF-p (clone 1D11) was from R&D Systems (UK){Dasch et al, 1989). 
The rabbit polyclonal anti-FX antibody was obtained from Santa Cruz Biotechnology 
(Germany) (Lenzerini et al, 1981)- this antibody recognizes the heavy chain of FX and 
showed crossreactivity with FXa on western blotting. The mouse polyclonal anti-TSP-1 
antibody was purchased from Neomarkers (USA) (Dixit et al, 1986) - this antibody only 
recognises the reduced form of TSP-1. The rabbit polyclonal anti- 
phosphoSmad2/3(Heldin et al, 1997) and anti-Smad2 (Heldin et al, 1997) total were 
purchased from Cell Sigaling Technology (USA). The goat polyclonal anti-ERK2 
antibody was purchased from Santa Cruz Biotechnology (Germany) (Boulton et al, 
1991). ERK2 was used as a loading control to ensure equal protein loading on SDS- 
PAGE; it was chosen above traditional loading controls such as (3-actin or total actin 
since the level of these proteins changed upon FXa stimulation of fibroblasts.
Antibodies used for immunohistochemical localization studies were as follows. Rabbit 
polyclonal anti-FX (Lenzerini et al, 1981) was purchased from Santa Cruz 
Biotechnology {Germany). The goat polyclonal anti-TSP-1 (Riewald and Ruf, 2005) 
was purchased from Santa Cruz Biotechnology (Germany). The rabbit polyclonal anti- 
a-SMA was purchased from Lab Vision (Fremont, California). The rabbit polyclonal 
anti-TRED PAR! antibody was a generous gift from Professor Eleanor Mackie 
(University of Melbourne Australia).
2.4. Alveolar and bronchial epithelial cells, fibroblasts and tMLEC
A human type II alveolar epithelial cell line (A549), human bronchial epithelial cell line 
(BEAS-2B) and human foetal lung fibroblast cell line (HFL-1) were obtained from the 
American Type Culture Collection (ATCC) and were used at no more than passage 20. 
Although the A549 cell line was originally obtained through explant culture of lung 
carcinoma tissue it is nevertheless widely used as a model of alveolar epithelial cell 
behaviour as it expresses all the characteristic markers of this cell type (Lieber et al, 
1976).
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Primary cultures of human adult lung fibroblasts (pHALFs) were a kind gift from Dr. 
Robin McAnulty in our laboratory, and previously showed high responsiveness to 
stimulation by coagulation proteinases (Chambers et al, 2000). Primary fibroblasts 
were grown from 1mm3 explants dissected from normal human lung tissue. The 
explants were cultured in DMEM supplemented with 10% FCS. The culture medium 
was replaced with fresh medium one day after isolation and every three days thereafter 
for three weeks. Eventually, fibroblasts were collected by trypsinisation and then 
characterised morphologically and by differential immunocytochemical staining for a 
selection of smooth muscle cell, endothelial and fibroblast markers such as a-SMA, von 
Willebrand factor, vimentin and myosin. Primary cells were discarded after 5 to 10 
passages.
Wild-type mouse lung fibroblasts and PAR!-deficient mouse lung fibroblasts were a 
kind gift from Dr P. Andrade-Gordon (R.W. Johnson Pharmaceutical Research Institute 
Spring House, PA, USA). These fibroblasts were immortalised through SV40 
transformation and used between passage 20 and 35 without any noticeable alteration 
in phenotype.
Transformed mink lung epithelial reporter cells (tMLEC) stably expressing firefly 
luciferase under the control of a TGF-p-sensitive portion of the plasminogen activator 
inhibitor-1 promoter were a gift from Dr Dan Rifkin (Department of Cell Biology, New 
York University School of Medicine, NY, USA) and have been previously described 
(Abe et al, 1994).
Fibroblasts deficient in GOq/n were isolated from Gaq/11-deficient mouse embryos at 
embryonic day 10.5 and were a kind gift from Professor Stefan Offermanns 
(Pharmakologisches Institut, University of Heidelberg, Germany) and have been 
previously described (Zywietz et al, 2001).
Methods
2.5. Animals
Male C57BI/6J mice (Harlan UK Ltd., UK) were kept at the Central Biological Services 
Unit, University College London. Animals were housed in a specific pathogen-free 
facility in individually-ventilated cages, with free access to food and water (12h 
light/dark cycle, normal sodium dry fishmeal diet, temperature 18-20 °C). All 
procedures were performed on mice between 8 and 10 weeks of age, in accordance
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with the UK Home Office Animals Scientific Procedures Act. Animals were weighed 
prior to investigation and then daily for the duration of the experiment.
2.6. Animal Model of Pulmonary Fibrosis
2.6.1. Oropharyngeal instillation of bleomycin
Bleomycin (1 or 2mg/kg body weight in 50pl of saline) or saline was administered by 
oropharyngeal installation as described previously by Lakatos et al (Lakatos et al,
2006). Following light halothane-induced anaesthesia, mice were hung from an elastic 
band by their teeth, the nose was pinched shut, and the tongue was held (to prevent 
the swallow reflex) - forcing the mouse to breathe through its mouth. Consequently, 
saline/bleomycin introduced to the back of the animal’s mouth was aspirated. Mice 
were later sacrificed by intraperitoneal injection of pentobarbitone, and severing of the 
abdominal inferior vena cava.
For measurement of total lung collagen, real time RT-PCR and immunoblotting, lungs 
were removed, blotted dry and the trachea and major airways were excised before the 
separated lobes were immediately snap frozen in liquid nitrogen, weighed and 
pulverized under liquid nitrogen. For histological and immunohistochemical analysis, 
the trachea was cannulated and lungs were insufflated with 4% paraformaldehyde in 
PBS at a pressure of 25cm H20, followed by removal of the heart and inflated lungs en 
bloc and immergence for 4 hours in fresh fixative. Subsequently, lungs were 
transferred to 15% sucrose in PBS and left overnight at 4°C before transfer to 70% 
ethanol. For BALF analysis, the trachea was cannulated and normal saline was instilled 
in 0.5ml aliquots over 15 seconds, left in situ for 30 seconds, and withdrawn over 15 
seconds and stored in polypropylene tubes on ice. The procedure was repeated five 
times and greater than 90% of the total instillate was recovered. Lung tissue 
homogenates were prepared based on a method described by (Keane et al, 1999). 
Frozen lung powder was mixed with 0.5ml PBS with added protease inhibitors 
(Complete Mini, Roche Diagnostics, UK) in polypropylene tubes. Samples were 
homogenised (3 x 20 seconds on ice) with a Polytron PT1035 mechanical homogeniser 
(Kinematica GmbH, Switzerland), filtered through a 1.2pm filter (Sartorius, Germany) 
and aliquots were frozen at -80eC until use.
2.6.2. Aerosolized instillation of bleomycin
This bleomycin model was performed by Dr Konigshoff in Professor Eickelberg’s 
laboratory in Giessen, Germany. The obtained lung material was then subsequently
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provided for analysis. Six to eight week-old pathogen-free female C57BL/6N mice 
(Charles River, Germany) were used throughout this study. All experiments were 
performed in accordance with the guidelines of the Ethic's Committee of University of 
Giessen School of Medicine and approved by the local authorities. Mice had access to 
water and rodent laboratory chow ad libitum. Bleomycin sulphate (Almirall 
Prodesfarma, S.A.) was dissolved in sterile saline solution and applied by microspray 
as a single dose of 0.08mg/mouse in a total volume of 200pl. Control mice received 
200|il saline. The lungs from mice sacrificed after 7, 14, or 21 days of bleomycin 
exposure were harvested and immediately snap-frozen in liquid nitrogen.
2.7. BALF FXa activity
BALF samples were obtained using the method described in Section 2.6.1. and 
centrifuged at 300g for 10 minutes at 4fiC. FXa activity was measured using a 
commercially-available spectrophotometric assay for FXa (American Diagnostica, 
USA). A standard curve was generated by diluting stock FXa (1U/ml; certified value 
800pg/100U) in PBS. A 25pl aliquot of each dilution or undiluted BALF sample was 
pipetted into a 96-well plate and 25pl of chromophore S222 (1mM, Methoxycarbonyl-D- 
cyclohexylglycyl-arginine-para-nitoanilide acetate, Spectrozyme® FXa, American 
Diagnostica Inc., USA) was added to each sample and incubated at 3 7 ^ . FXa 
converts this chromophore into the chromogen, p-nitroaniline (pNA). The enzymatic 
activity of FXa was thus detected by measuring the increase in absorbance of the free 
chromophore p-nitroaniline (pNA) generated per unit time at A 405 nm •
Serial measurements were read on a kinetic recording spectrophotometer, every 
minute for three hours. Absorbance for each FXa dilution was plotted graphically 
against time. The rate of change in absorbance was then calculated over the initial 
linear part of the curve. FXa concentrations in each sample were then calculated by 
extrapolating values from the standard curve.
2.8. FXa inhibition in vivo using ZK 807834
The in vivo contribution of FXa to lung collagen accumulation was investigated using 
the direct FXa inhibitor ZK 807834 in the bleomycin model of fibrosis induced by 
oropharyngeal instillation of bleomycin (described in Section 2.6.1.). Twenty-four hours 
post-bleomycin, administration of ZK 807834 (50mg/kg in acidified saline) or vehicle 
was started, by intraperitoneal injection twice a day in the first week and once a day in
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the second week until the end of the experiment (14 days). This regime was chosen 
because this dosing gave a circulating concentration of ZK 807834 above 2pM, which 
is sufficient to double the prothrombin time in C57BI/6J mice (data provided by Berlex). 
Mice were subsequently sacrificed and total lung collagen was determined by 
measuring hydroxyproline content in aliquots of pulverized lung (described in Section
2.9.). During the course of the ZK 807834 experiment, three mice in the saline/ZK 
807834 group (originally n=6) and three mice in the bleomycin/ZK 807834 group 
(originally n=9) were sacrificed due to intraperitoneal haemorrhage arising from the 
multiple intraperitoneal injections. In addition, one mouse in the bleomycin/vehicle 
group (originally n=8) was excluded from the HPLC analysis as an outlier, because it 
did not display the characteristic loss of body weight following bleomycin instillation or 
any increase in lung weight.
2.9. Determination of total lung collagen
Total lung collagen was determined by measuring hydroxyproline (Hyp) content in 
aliquots of pulverised lung as described previously (Campa et al, 1990;Chambers et al, 
1994), and assuming that lung collagen contains 12.2% w/w hydroxyproline (Laurent et 
al, 1981). Hydroxyproline was quantified by reverse-phase high performance liquid 
chromatography (HPLC) of 7-chloro-4-nitrobenzo-oxa-1,3-diazole (NBD-CI)-derivatised 
acid hydrolysates. Secondary amino acids such as hydroxyproline react with NBD-CI to 
generate a chromophore with maximum light absorbance at 495nm. NBD-CI also 
reacts with primary amino acids but these amino acids only have limited absorbance at 
these wavelengths. In addition the reactions with Hyp and proline occurs one order of 
magnitude faster than with primary amino acids (Ahnoff et al, 1981). Interference from 
primary amino acids is therefore minimised by keeping the derivatisation time to 20 
min, a timepoint at which the extent of Hyp derivatisation with NBD-CI at 37 °C was 
previously shown to be maximal for up to 20nmol Hyp (Campa et al, 1990).
2.9.1. Pre-Column Derivatisation
For each sample, approximately 20mg of lung powder was accurately weighed, and 
hydrolysed in 2ml 6M HCI for 16hours at HO^C in a pyrex tube. Hydrolysates were 
decolourised with activated charcoal, filtered through a 0.65pm filter (Millipore Ltd., 
UK), and diluted 1 in 100. 200pl aliquots of each hydrolysate were transferred to a 
microfuge tube and evaporated to dryness under vacuum on a Speedvac (Thermo 
Electron Corporation, UK). The resulting residue was re-dissolved in 100pl HPLC- 
grade water, buffered with 1 OOjllI of 0.4M potassium tetraborate (pH 9.5) and reacted
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with 10Ofxl 36mM NBD-CI (in methanol) to a final concentration of 12mM NBD-CI. The 
samples were then incubated in a hot block at 37°C for 20 minutes. The reaction was 
stopped by the addition of 50pl 1.5M HCI. At this point 150pl of 3.33x Buffer A was also 
added (Buffer A is described in Table 2.1.). Samples were then filtered through an 
HPLC low dead-volume filter (pore size 0.22pm, type GV; Millipore Ltd, UK) into a 
polypropylene insert within an Amber Snap Seal vial (Laboratory Sales Ltd., UK). 
These vials were then loaded onto the HPLC apparatus and the samples were 
sequentially injected onto the HPLC column and eluted with an acetonitrile gradient as 
described below.
2.9.2. Instrumentation and chromatography conditions
The HPLC apparatus employed for these measurements was a Beckman System Gold 
HPLC (Beckman Coulter, UK) with a reverse-phase cartridge column (LiChroCART 
LiCrospher, 250mm length x 4mm diameter, 5pm particle size, 100 RP-18; BDH/Merck, 
UK) protected by a directly coupled pre-column (LiChrosorb, 4mm x 4mm, 5pm, 100 
RP-18; BDH/Merck). Columns were continuously maintained at 40°C in a heated 
column oven. At the beginning of each experiment, the running buffers were degassed 
with helium (BOC Ltd, UK) and the HPLC system equilibrated in running buffer A for 40 
minutes. The first two samples derivatised were Hyp standard solutions (equivalent to 
50 pmol/L Hyp, Sigma) which were then used for calibration. NBD-CI derivatives in 
samples and standards were eluted with an acetonitrile gradient, which was achieved 
by changing the relative proportions of running buffers A and B over time. 
Chromatographic conditions and buffers employed in this process are summarised in 
Table 2.1.
Post-column detection was achieved by monitoring absorbance at 495nm using a flow­
through variable wavelength monitor. Hyp elutes as a discrete peak between five and 
seven minutes following its injection onto the column, between glutamine (3.5 minutes) 
and serine (seven to nine minutes) and just prior to the mobile phase becoming 
predominantly organic. Remaining amino acid derivatives in the sample were eluted as 
the hydrophobicity of the acetonitrile organic buffer was increased. The column running 
and regeneration time was 25 minutes.
Quantification of the hydroxyproline content in each 100 pi sample injected into the 
column was determined by comparing peak areas of chromatograms obtained for each 
sample to those generated from the standard solutions derivatised and separated
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under identical conditions at the beginning of each experiment. Total lung collagen was 
expressed as mg/lung and derived from the equation:
Total lung collagen = HPLC peak area x 10 x 100 x 5 x 1/1000 x 100/12.2 x 
131/1000000 x lung weight/powder weight
Column 
Mobile phase
LiChrosopher, 100 RP-18,250 x 4mm, 5pm 
Buffer A - aqueous acetonitrile (8% v/v) 
50mM sodium acetate, pH 6.4
Buffer B - aqueous acetonitrile (75% v/v)
Column flow rate 
Column temperature 
Detection wavelength 
Elution gradient
1.0 ml/min 
40 °C 
495nm 
Time (min) 
0
5
6 
12 
12.5 
25
% Buffer B 
0 
5 
80 
80 
0 
0
Table 2.1. Conditions and buffers for the separation of hydroxyproline by reverse-phase 
HPLC
2.10. RT-PCR and real-time RT-PCR analysis
2.10.1. Precautions taken to prevent RNA degradation
For all experiments involving RNA isolation, deionised water was pre-treated with 0.1% 
(v/v) diethyl pyrocarbonate (DEPC) overnight at room temperature; the treated water 
was then autoclaved to inactivate the DEPC. All subsequent reagents were made from 
molecular biology grade chemicals DEPC-treated deionised water. All equipment was 
cleaned thoroughly using RNaseZap (Sigma Aldrich, UK), and nuclease-free pipette 
tips (Continental Lab products, UK) were used throughout the extraction process.
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2.10.2. RNA extraction
Total RNA from frozen powdered lung tissue or cell cultures was isolated with TRIzol 
reagent as per the manufacturer’s protocol (Invitrogen, UK). TRIzol is a solution of 
phenol and guanidine isothiocyanate which disrupts cell membranes by dissolving cell 
components but maintaining the integrity of RNA. Briefly, 1ml of TRIzol was added to 
50-100 mg of lung tissue and this was further homogenised through a 25 gauge needle 
attached to a 1 ml syringe. For isolation from cell cultures, 1ml of TRIzol was added to 
each well of cells that were grown in a 6-well plate and the well was scraped with a 1 ml 
pipette tip and solution transferred to a 1.5ml eppendorf tube. Subsequently samples 
were left at room temperature for 5 minutes after which 200pl of chloroform was added 
to disrupt the cell suspension. Each tube was vortexed and left at room temperature for 
10 minutes to allow the solution to separate into an upper aqueous and a lower organic 
phase. Tubes were then centrifuged at 13,000 rpm for 15 minutes at 4<C in a microfuge 
and the upper aqueous phase containing the RNA was transferred to a fresh tube with 
0.5 ml isopropanol. Tubes were left at room temperature for 10 minutes to allow the 
RNA to precipitate and were then centrifuged at 13,000 rpm for 15 minutes at 4°C. The 
supernatants in each tube were discarded and 900 pi of 75 % ethanol (BDH VWR 
International, UK) were added to the pelleted RNA and centrifuged at 13,000 rpm for a 
further 15 minutes at 4°C. The supernatants in each tube were discarded and pellets 
were air dried and resuspended in an appropriate volume of nuclease-free water 
(Ambion, UK).
2.10.3. DNAse treatment
Total RNA was DNase-treated to remove contaminating genomic DNA, using an 
Ambion DNAfree kit. This kit comprised a 20 pi reaction in which total RNA, DNase I 
and RNase inhibitor were added and left to incubate at 37‘C for 20 minutes. The 
reaction was then stopped by adding “inactivating reagent”- a resin which binds the 
DNase. This was then removed by centrifugation.
RNA quality was subsequently analysed by running samples on an agarose gel: a 
mixture of 1 pi of total RNA and 11 pL DEPC-treated water was mixed with 3 pi of 
loading buffer (48 % deionised formamide [Gibco BRL, UK\, 6 % formaldehyde [BDH, 
UK\, 5 % glycerol, 20 mM MOPS, 5 mM sodium acetate and 1 mM EDTA pH 8.0 made 
up in DEPC-treated water). Each RNA sample was heated to 65 °C for 5 minutes and 
placed on ice prior to loading. The RNA was analysed by electrophoresis on a 1 % 
agarose-formaldehyde gel (6 % formaldehyde, 1 % agarose, 20 mM MOPS, 5 mM 
sodium acetate, 1 mM EDTA pH 8.0).
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Images of the RNA were captured with a Syngene Gene Genius Bio-imaging system 
(Synoptics, UK). A ratio of approximately 2:1 of the intensities of the 28S rRNA to the 
18S rRNA bands confirmed that the RNA was not significantly degraded. The RNA 
concentration and protein contamination in each sample was assessed on an Ultrospec 
3000 spectrophotometer (Amersham Biosciences, UK) by measuring the A26o, and the 
A26o/A28o ratio, respectively.
2.10.4. cDNA synthesis
cDNA was prepared by reverse transcription (RT) using a RT-PCR kit from Applied 
Biosystems, UK. Reactions were performed according to the manufacturer’s 
instructions. Briefly, a mix was prepared containing a maximum of 1 pg of total RNA, 
and incubated at room temperature for 10 minutes, 42 °C for 15 minutes, 99 °C for 5 
minutes and then 5 qC for 5 minutes:
a) 5 mM MgCI
b) 1 x PCR Buffer
c) 1 mM dNTP mix
d) 2.5 pM random hexamers
e) 1 pg RNA
f) 1 U/pl RNase Inhibitor
g) 2.5 U/1 pi reverse transcriptase
2.10.5. Primer design
The primers were designed with the help of Dr Chris Scotton and using internet based 
software. The Ensembl database (http://www.ensembl.oraA was used to locate 
accession numbers for the genomic DNA and RNA and then Spidey 
(http://www.ncbi.nlm.nih.aov/IEB/Research/Ostell/Spidev/) was used to align the 
genomic and RNA sequences in order to locate intron/exon boundaries. When 
possible, primers were designed to span introns, eliminating the possibility of 
amplifying genomic DNA. The mRNA sequence was copied into the primer-designing 
software, Primer3 (http://frodo.wi.mit.edu/cai-bin/primer3/primer3 www.cai). The 
program’s parameters were set at: product size 85-130 bp; primer size 18-22 
nucleotides long; primer melting temperature 58 °C to 62 °C with an optimum of 60 °C 
and a maximum temperature difference of 0.5 *C; primer GC % was 40 % to 60 % with 
an optimum of 50 %; maximum self-complimentarity was set at 6.0 and maximum 3’ 
self-complimentarity of 2.0 and finally, the maximum poly-X was set at 3 to avoid runs
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of nucleotides. The primers were then selected from the list and run in silico using 
FastPCR software. A BLAST search (http://www.ncbi.nlrn.nih.gov/BLAST) was also 
performed to check that the forward and reverse primers were specific for the intended 
sequence. The primers were manufactured by Invitrogen, UK. Primers can be seen in 
Table 2.2.
Gene Forward primer Reverse primer
h TGF-pi 5’-AAGGGCTACC ATGCC AACT-’3 5’-CCGGGTTAT GCTGGTT GTA-3’
m FX 5’-CAG CGGTT ACTT CCT GGGT A-3’ 5’-GCC AC AG ACCT CTT CCT ACG -3’
h FX 5’-GCCC ACT GT CT CT ACC AAGC-3’ 5’-CTTG AT G ACC ACCT CC ACCT-3’
hPARi 5’-CC AT CGTT GT GTT CAT CCT G-’3 5’-G ACCC AAACT GCC AAT CACT-‘3
h PAR2 5’-C ACC AT CC AAGG AACC AAT AG-3’ 5’-TGCAGAAAACTCATCCACAGA-3’
h a-SMA 5’-AT CCT G ACT G AGCGTGGCT ATT -3’ 5’-GGCCATCTCA I I I ICAAAGTCC-3’
m/h18s 5’-TT GACGGAAGGGC ACC ACC AG-3' 5’-GCACCACC ACCC ACGG AAT CG-3’
h TSP-1 5’-CAATGAACGGGACAACTGC-3’ 5’-AT CT CC AAT GCGGT CT G AGT -3’
h HPRT 5’-GGCTTTGTATTTTGCI I I ICCA-3’ 5’-AAGGACCCCACGAAGTGTTG-3’
Table 2.2. Primers used for real-time FIT- PCR
h=human, m=murine
2.10.6. RT-PCR
RT-PCR was performed using a tetrad (PTC-225, Peltier Thermal cycler, Global 
Medical Instrumentation, USA). For each primer pair, a master mix was prepared 
containing all reagents except the cDNA. The final volume of each PCR reaction was 
25 pi, containing cDNA, AmpliTaq DNA polymerase, buffer, dNTPs, magnesium 
chloride (all from Applied Biosystems, UK) and 0.25 pM of each primer. The following 
cycling conditions were used: 94 °C 5 minutes/ 35 cycles of 94 °C for 30 seconds/ 60 
°C for 30 seconds/ 72 <€ for 30 seconds/ 72 °C for 7 minutes and 25 °C for 30 
seconds.
20 pi of each PCR reaction was added to 5 pi of loading buffer (40 % w/v sucrose; 0.25 
% w/v bromophenol blue; 0.25 % w/v xylene cyanol, made up in distilled water) and 
electrophoresed through a 2 % agarose gel containing 0.5 pg/ml ethidium bromide and
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TBE (90 mM tris, 90 mM borate and 2 mM EDTA). Bands were visualised by UV 
transillumination. Their sizes were estimated using a co-migrated DNA size marker 
from Roche Diagnostics.
2.10.7. Real-time RT-PCR
Real time RT-PCR was conducted using the Platinum SYBR Green qPCR SuperMix 
UDG (Invitrogen, UK) with 1ng of cDNA and forward and reverse primers each at a 
final concentration of 500nM, on a LightCycler 1.5 Real-time Detection System {Roche, 
UK) and analysed using LightCycler Real-time PCR Detection System Software 
Version 3.5. Cycling conditions were as follows: one cycle of 50 'C (2 minutes), 95 °C 
(2 minutes); 45 cycles of 95 °C (5 seconds), 55 ‘C (5 seconds), 72 °C (15 seconds). 
For laser capture microdissected samples quantitative PCR was performed using an 
Applied Biosystems Sequence Detection System 7700 (PE Applied Biosystems, CA, 
USA).
The magnesium concentration for each primer set was then optimised. A number of 
real time RT-PCR reactions were performed in parallel, using template cDNA from a 
sample known to express the gene of interest but substituted with varying 
concentrations of Mg2+. Reactions with the steepest logarithmic amplification plot, and 
typically also the lowest cycle number at which detectable amplification occurred, 
indicated the optimal Mg2+ concentration for use with the given primer set.
The efficiency of each primer pair was also assessed by determining crossing point 
(Cp) values for RT-PCR reactions using a series of half logarithmic dilutions of 
template cDNA. Cp values were defined as the earliest point of the linear region of the 
logarithmic amplification plot reaching a threshold level of detection. Log 
concentrations of samples were plotted against Cp values, and the slope of the plot 
determined. Efficiency was then given by the equation: Efficiency = io ('1/slope). Primers 
were only used if the PCR efficiency was greater than 95%.
To examine the quantitative differences in the mRNAtarget gene expression in each 
sample, Cp values were determined from the linear region of the logarithmic 
amplification plot. Each sample was also tested for expression of an appropriate 
“housekeeping” gene, either 18S, HPRT or PDGB - the Cp value of which was used to 
normalise between samples. Fold change was subsequently calculated using the 
standard 2 AACp approach. The specificity of the products obtained by PCR was
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confirmed by melting curve analysis, demonstrating a single melting curve indicative of 
a single PCR product. Statistical analysis was performed using the ACp values.
2.11. Histological Analysis
2.11.1. Preparation of slides
Individual lobes of mouse lungs or human biopsy material were placed in processing 
cassettes, dehydrated through a serial alcohol gradient, and embedded in paraffin wax 
blocks. Before immunostaining, 5 pm-thick lung tissue sections were dewaxed in 
xylene, rehydrated through decreasing concentrations of ethanol, and washed in PBS.
2.11.2. Immunohistochemical localisation of FX, TSP-1, PARj and a-SMA
Antigens were unmasked by microwaving sections in 10mM citrate buffer, pH 6.0 (2 x 
10 mins) before washing in PBS and incubation with normal goat serum (DAKO, UK) 
for FX, PAR! and a-SMA or with normal rabbit serum for TSP-1. Antigens were 
localized by overnight incubation with rabbit anti-FX (1:100 dilution), goat anti-TSP-1 
(1:250), rabbit anti-PARi (1:1000) or rabbit anti-a-SMA (1:400) primary antibody. 
Sections were then washed in PBS, and incubated with a biotinylated goat anti-rabbit 
or rabbit anti-goat secondary antibody (1:200 dilution) for 1 hour, before washing again 
in PBS. Sections were incubated with a streptavidin/peroxidase complex (1:200 
dilution) for a further 30 minutes, followed by a solution of 600pg/ml of 3,3’- 
diaminobenzidine tetrahydrochloride {Vector Laboratories, UK) for colour development. 
Sections were washed and counterstained using Gill-2 haematoxylin (Thermo- 
Shandon, USA), dehydrated through a series of incubations in increasing 
concentrations of ethanol and then xylene, and mounted using a Sakura Coveraid 
automatic coverslipping machine and Tissue-Tek coverslipping film (Bayer Diagnostics, 
UK). Specificity of the signal obtained was confirmed by incubating control sections 
with an isotype-specific, nonimmune rabbit or goat IgG primary antibody {DAKO, UK). 
Sections were then visualized by microscopy (Leica DM5000B microscope, Leica 
Microsystems, Germany) and images were captured using a Qicam 12-bit colour fast 
camera using Q capture software version 2.81 (both from Qlmaging Corporation, 
Canada).
2.11.3. Demonstration of lung architecture
Two different staining methods were used to visualise the lung architecture. A modified 
trichrome staining method (Martius Scarlet Blue (MSB)) was used to highlight collagen 
deposition as a readout of lung fibrosis. This staining method is based on the use of
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differential permeability of tissues to dyes of differing molecular size. The large Chicago 
Sky Blue 6GX dye permeates collagen fibrils causing areas of fibrosis to appear blue. 
In order to enable appreciation of inflammatory cell infiltration, a heamatoxylin and 
eosin method was used. Automated staining of sections was performed using a Sakura 
DRS 601 Diversified Stainer (Bayer Diagnostics).
2.12. Patient samples
2.12.1. Giessen cohort
Lung tissue biopsies were obtained from ten patients with IPF (usual interstitial 
pneumonia (UIP) pattern; mean age 51.3 ± 11.4 years; 4 females, 6 males) and ten 
control subjects (organ donors, mean age 47.5 ± 13.9 years; 5 females, 5 males). The 
study protocol was approved by the Ethics Committee of the Justus-Liebig-University 
School of Medicine (AZ 31/93). Informed consent was obtained from each subject for 
the study protocol.
2.12.2. Brompton cohort
Lung biopsy specimens were obtained from 7 patients with IPF (6 male and 1 female, 
mean age 55.3±10.6; 5 specimens obtained at diagnostic surgical lung biopsy and 1 
from lung explanted at transplant) and 6 control patients (4 male and 2 female, mean 
age 65.3 ± 15.8; obtained from uninvolved tissue during cancer resection surgery). All 
biopsies in this study were classified using the diagnostic criteria of the American 
Thoracic Society/European Respiratory Society consensus (American Thoracic 
Society/ European Respiratory Society International multidisciplinary consensus 
classification of the idiopathic interstitial pneumonias, 2002) a pattern of “usual 
interstitial pneumonia (UIP)”. Approval for the use of material was obtained from the 
Royal Brompton, Harefield, NHLI and the UCL/UCLH ethics committee. Informed 
consent was obtained from each subject.
2.12.3. Pittsburgh cohort
Pittsburgh Tissue Microarrays (TMA) were provided by Dr Naftali Kaminski, University 
of Pittsburgh and were generated as previously described (Kajdacsy-Balla et al, 2007) 
from formalin-fixed paraffin embedded tissues, stored at the University of Pittsburgh 
Tissue Bank at the Tissue Array Core facility. The TMA included 12 samples with 
sarcoidosis, seven samples with hypersensitivity pneumonitis, 18 samples with UIP, as 
well as three samples from head and neck tumours. Use of stored de-identified tissues 
has been approved by the University of Pittsburgh Institutional Review Board.
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2.13. Laser-capture microdissection
Microdissection was performed by Dr Melanie Konigshoff in Professor Oliver 
Eickelberg’s laboratory, Giessen, Germany and was described previously (Fink et al, 
1998;Fink et al, 2000b). In brief, 10pm cryosections were mounted on glass slides, 
stained with hemalaun for 45 seconds, immersed in 70% and 96% ethanol, and stored 
in 100% ethanol until use. Alveolar septae were selected and microdissected with a 
sterile 30G needle under optical control using the Laser Microbeam System (P.A.L.M., 
Bernried, Germany). Microdissected tissues were then transferred into reaction tubes 
containing 200pl TRIzol and samples processed for RNA analysis, as described in 
Section 2.10.
2.14. Alveolar epithelial cell isolation
Primary alveolar type II epithelial (ATII) cells were isolated from saline- and bleomycin- 
treated mice by Dr Melanie Konigshoff. Lungs were lavaged with 2 x 1 ml sterile PBS, 
then the tissue was minced with scissors and digested with dispase (2 mg/ml for 60 
mins). The suspension were sequentially filtered through 100-, 20-, and 10-pm nylon 
meshes and centrifuged at 200c; for 10 min. The pellet was resuspended in DMEM and 
a negative selection for lymphocytes/macrophages was performed by incubation on 
CD16/32- and CD45-coated petri dishes for 30 min at 37°C. Negative selection for 
fibroblasts was performed by adherence (45 min) on cell culture dishes. Cell purity was 
routinely assessed by epithelial cell morphology and immunofluorescence analysis of 
panCK, pro-SPC (both positive), a-SMA, and CD45 (both negative). Freshly isolated 
ATII cells were used for further analysis.
2.15. Fibroblast isolation
Lungs from saline- or bleomycin-treated mice, or from tissue samples from IPF/donor 
lungs, were minced into small pieces and incubated in a solution of human dispase (2 
mg/ml) for 60 min. Pieces were plated out and outgrowing fibroblasts were purified by 
passaging and cultured for about 2 weeks. Identification of fibroblasts was based on 
the presence of vimentin, collagen and a-SMA staining. Cells were used between 
passages 2-4. Cells were maintained in DMEM supplemented with 10% FCS, in a 
humidified atmosphere containing 5% C02.
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2.16. Cell culture conditions
HFL-1, pHALFs, mouse lung fibroblasts (MLF), A549, BEAS-2Bs and HepG2s were 
maintained using standard cell culture techniques. HFL-1,pHALFs, MLF and HepG2s 
were grown in Dulbecco’s modified eagle’s medium (DMEM), supplemented with 
penicillin (200 units/ml), streptomycin (200 units/ml), glutamine (4 mM) and 10% (v/v) 
FCS. BEAS-2Bs were grown in Optimem supplemented with penicillin (200 units/ml), 
streptomycin (200 units/ml), glutamine (4 mM) and 10% (v/v) FCS. A549 were grown in 
F12 Kaign’s medium (F12K), supplemented with penicillin (200 units/ml), streptomycin 
(200 units/ml), glutamine (4 mM) and 10% (v/v) FCS. HFL-1, pHALFs, MLF and 
HepG2s were incubated in a humidified atmosphere containing 10% C02. A549 and 
BEAS-2Bs were maintained in a humidified atmosphere containing 5% C02. Cells were 
routinely tested for mycoplasma contamination using a commercially-available assay 
(MycoAlert; Cambrex, UK).
Upon reaching visual confluence (3-4 days), cells were sub-cultured (passaged) into 
new culture flasks. The medium was removed and the cell layer was washed twice with 
10 ml Ca2+/Mg2+-free phosphate buffered saline (PBS) to remove any remaining culture 
medium. Cells were brought into suspension by adding 1 ml of trypsin (0.05%, 
w/v)/EDTA (0.02%, w/v) solution and incubating the cells at 3 7 ^  until cell detachment 
occurred. Trypsin was neutralized by addition of 9 ml of the appropriate culture medium 
supplemented with 10% FCS. Cell suspensions were split at a ratio 1 to 6. Under these 
conditions cells remained viable for about 10 to 20 passages for HFL-1, A549, BEAS- 
2Bs and MLFs , and up to 6 to 10 passages for pHALFs.
2.17. Preparation of agonists and antagonists
FXa, thrombin, TGF-fh, TNF-a, TFLLR, FTLLR, and SLIGKV were reconstituted in 
DMEM, aliquoted and stored until use at -80'C at the following stock concentrations: 
FXa (1 pM), thrombin (2 pM), TFLLR, FTLLR and SLIGKV all at 10 mM, TGF-p1 (1 
ng/ml), and TNF-a (1 pg/ml). Prior to use an aliquot of the relevant agonist was 
defrosted and diluted in the appropriate serum-free medium.
rHir, and ASN were prepared in DMEM prior to aliquoting and freezing at -80°C. The 
LSKL and SLLK were provided in PBS solution due to their high hydrophilic nature 
which would have otherwise caused the powder to crystallise during transport. 
Pertussis toxin was dissolved in tissue culture-tested water. ZK 807834 was dissolved
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in acidified saline. All other antagonists and inhibitors were dissolved sterile tissue 
culture-tested DMSO (Invitrogen, UK).
Prior to use, in vitro inhibitors were evaluated individually over a range of dilutions in 
the relevant assay. The maximal working concentrations were determined to obtain 
optimal neutralisation at doses that do not interfere with basal cell functions, or 
experiments using rHir and ASN, FXa or thrombin were preincubated with inhibitors in 
molar excess in serum-free DMEM for 3 hours at 37 °C, with regular shaking, prior to 
the addition to cell cultures. Control media without inhibitors were incubated under the 
same conditions.
For experiments involving RWJ-58259 and Ro-31-8425, these compounds were pre­
incubated for 20 minutes with cells in fresh medium, and the concentration of DMSO 
vehicle was standardised amongst all samples. Subsequently thrombin or FXa of the 
required concentrations were spiked in.
ZK 807834 was preincubated with FXa in serum-free DMEM for 1 hour at 37 °C, with 
regular shaking, prior to the addition to cell cultures. Control media without inhibitors 
were incubated under the same conditions.
2.18. Cell preparation for experiments
A suspension of cells trypsinised from one tissue culture flask were placed in a 50 ml 
sterile polypropylene centrifuge tube. Cells were centrifuged at 1000 rpm for 10min at 
room temperature using a bench centrifuge (MSE Mistral 3000, UK). The supernatant 
was discarded and the cell pellet was brought into a single cell suspension with 10ml 
DMEM/10% FCS by gentle mixing. An aliquot of 10 pi of the suspension was removed 
with a sterile pipette and cells were counted using an improved Neubauer 
haemocytometer (BDH-Merck Ltd, UK). For each experiment, appropriate cell density 
of the cell suspension was then adjusted with DMEM/10% NCS (see relevant 
experimental section for cell concentrations).
2.19. Western blot analysis of a-SMA, pSMAD/SMAD, TSP-1 and ERK2
2.19.1. Cell culture conditions and sample collection
pHALFs were prepared as described in Section 2.18. and seeded in 12-well plates at a 
density of 150 x103 cells/well. Cells were allowed to adhere for 24 hours and
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subsequently starved in serum-free conditions for a further 24 hours. At the start of the 
experiment, the medium was removed and replaced with fresh serum-free medium with 
or without mediators and/or inhibitors as described in Section 2.17. After the treatment 
period, plates were placed on ice, and cells were washed twice with cold PBS. Cell 
were lysed in 100 pi RIPA buffer (1% PBS, 1% Igepal Ca-630, 0.5% Sodium 
deoxycholate, 0.1% sodium dodecyl sulphate) supplemented with complete protease 
inhibitor cocktail (Complete-mini; Roche, UK) and left to stand for 5 minutes. The cell 
layer was subsequently scraped with a yellow pipette tip and the lysate was transferred 
into a 1.5ml eppendorf tube. To remove any insoluble cell debris, lysates were spun 
down at 13,000 rpm for 5 min at 4 ‘C in a microfuge and the supernatant was 
transferred into a clean tube. DNA was sheered by passing the sample 15 times 
through a 25G needle on a 1 ml syringe. Prior to storing samples -80 qC, the protein 
concentration of each lysate was determined (see Section 2.19.2.)
2.19.2. BCA protein assay
Protein concentration of cell or tissue lysates was assessed using the bicinchoninic 
acid (BCA) protein assay (Pierce, USA), as per the manufacturers' protocols, The BCA 
assay works by the biuret reaction whereby protein reduces Cu2+ to Cu1+ in an alkaline 
medium. Each Cu1+ ion then complexes with 2 molecules of bicinchoninic acid (BCA) to 
form a water-soluble purple-coloured reaction product that exhibits a strong 
absorbance at 562nm which is linear with increasing protein concentration over a broad 
working range from 20 pg/ml to 2000 pg/ml. The amount of protein in samples can be 
derived by comparison a bovine serum albumin standard curve. The assay was 
performed by adding 200 pi of freshly prepared BCA working reagent to 20 pi of each 
sample or standard (assayed in duplicate) in a 96-well plate. The plate was agitated on 
a plate shaker for 30 seconds, and then incubated at 37 °C for 30 min prior to reading 
the absorbance at 550nm on a Titertek Multiscan MCC/340 plate reader (Labsystems, 
Finland).
2.19.3. Western blotting procedures
Samples were adjusted with RIPA buffer to standardise their total protein 
concentration. An aliquot of each sample (equivalent to 5 pg of protein for the detection 
of a-SMA, 30 pg for detection of pSMAD and TSP-1) was mixed with 5x Laemmli 
Buffer (3.125 mM TRIS HCL pH 6.8, 10% SDS, 20% Glycerol, 50nM DTT, 
bromophenol blue (added as required), 4.375 ml H20), boiled for 10 min at 100 °C, 
then placed on ice prior to loading. Either 30pJ of sample or 5p.l of SeeBlue® Plus 2 
protein ladder (Invitrogen) was then added to each well of a 10% SDS-polyacrylamide
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gel (made using buffers from National Diagnostics, UK, in a Novex mini-gel system, 
Invitrogen, UK), and run at 100V in Tris/Glycine/SDS running buffer (0.25M TRIS base,
1.92 M Glycine, 1%SDS).
Following separation, the gel was removed from the cassette and proteins were 
transferred onto a Hybond-ECL nitrocellulose membrane (Amersham, UK), using a 
horizontal semi-dry transfer method (Multiphor II; Pharmacia LKB, Sweden) according 
to the manufacturer’s instructions (transfer buffer was 25 mM Tris-HCI, 0.2 M glycine, 
20% methanol), at a current of 1mA per cm2 of gel, for 1 hour). The quality of protein 
transfer was assessed by briefly staining the membrane with 2% Ponceau Red solution 
(Sigma) which was destained by a quick wash in double distilled water followed by one 
wash in tris-buffered saline (50 mM Tris, 150 mM NaCI, pH 7.4;TBS) containing 0.1% 
Tween20 (TBST). Blots were stored submerged in TBST at 4 °C before enhanced 
chemiluminescent detection.
2.19.4 Protein Detection
Blots were incubated with blocking buffer containing 5% nonfat dry milk in TBST (50 
mM Tris, 150 mM NaCI, 0.1% Tween-20, pH 7.4) for 1 hour. Blots were then incubated 
with anti-a-SMA, anti-phosphoSMAD (pSMAD) or anti-TSP1 antibodies at 1:1000 
dilution in 5% skimmed milk in TBST overnight at 4 ^ .  All blots were then washed 3 x 5  
mins in TBST and incubated for 1 hour at room temperature with HRP-conjugated 
secondary antibody. After further washing in TBST, excess wash solution was drained 
off, and 2ml of ECL reagent (Amersham, UK) was applied to the membrane and 
incubated for 1 minute. Excess reagent was drained off and immunoreactive bands 
were visualized by exposing the membrane to autoradiography film (Kodak, UK), for 
between 30 seconds and 10 minutes.
For examination of total ERK2 and Smad2 levels, the blots were washed in TBST and 
incubated with stripping buffer (62.5 mM 1MTris-HCI (pH 6.8), 2% SDS, 0.1 M p- 
Mecaptoethanol) for 40min at 60 °C. Immunoblotting using anti-total ERK2 or anti-total 
SMAD2 antibodies was then performed as described above.
2.19.5. Quantification of western blot
Semi-quantitative analysis of western blots was performed using densitometry. Briefly, 
blots underwent transmissive greyscale scanning at 300dpi on a standard flatbed 
scanner (Epson, UK). The scanned images were transferred to the public domain NIH 
Image 1.61 program (developed at the U.S. National Institutes of Health and available
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on the Internet at http://rsb.info.nih.gov/nih-imaae/) and the optical density of each 
protein band was calculated with reference to a calibration curve (specifically 
generated by scanning a Kodak Photographic Step Tablet (Kodak, UK) with known 
optical density gradient, using the same settings as described above). The optical 
density of the band for the target gene was then normalised against the optical density 
for the housekeeping gene (ERK2 or SMAD2, as appropriate), allowing correction for 
protein loading and therefore meaningful comparison between samples.
2.20. Immunocytochemical visualisation of actin fibres
pHALFs were seeded in 8-well chamber slides (Permanox, Nunclon, Fisher Scientific, 
UK), and left overnight to adhere in a humidified atmosphere with 5% C 02 at 37°C. The 
medium was then removed, and replaced with serum-free medium for a further 24 
hours. This medium was then aspirated, and cells were exposed to FXa (10nM) in 
200pl serum-free DMEM for various time points. Cells were then washed three times in 
PBS, and then fixed and permeabilised in ice cold methanol for 45 seconds, before 
being washed again in PBS at 4'C.
Fixed cells were incubated for 5 minutes at room temperature with normal goat serum 
(Dako, UK) at a dilution of 1:20 in 200pl PBS, to block non-specific binding sites, then 
were washed three times with PBS before incubation with mouse anti-human a-SMA 
antibody, at a dilution of 1:100 in 200pl PBS at for 60 minutes. After a further PBS 
wash, cells were incubated for 30 minutes with a 1:50 dilution of goat anti-mouse-FITC 
conjugated antibody (Dako, UK) in PBS at room temp in the dark. This solution was 
then aspirated, and the side-walls of the chambers were carefully removed. Cells were 
washed a further 3 times in PBS. Coverslips were mounted onto each slide using 3 
drops of vectorshield mounting medium (Vector Laboratories, UK) containing 4’6- 
Diamidino-2-phenylindole (DAPI) which is a highly sensitive nucleic acid stain. Images 
were captured using an inverted fluorescence microscope (Zeiss Axioskop 2) with an 
attached camera (Olympus C-35DA-2).
2.21. Measurement of TGF-p activity with the tMLEC assay
2.21.1. Principles of assay
TGF- p activity in cell culture supernatants, or in co-culture, was measured using a 
mink lung epithelial cell bioassay. This assay was originally set up by Abe et al (Abe et 
al, 1994) in 1994, and utilizes the ability of TGF-p to specifically induce PAI-1
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expression. Mink lung epithelial cells were stably transfected with an expression 
construct containing a truncated PAI-1 promoter fused to the firefly luciferase reporter 
gene. Exposure of these cells to TGF-p results in a dose-dependent increase in 
luciferase activity in cell lysates. Importantly, this promoter fragment was shown to be 
only minimally influenced by other known inducers of PAI-1 expression such as bFGF, 
PDGF-BB, rIL-ip, and EGF (Abe et al, 1994). Hence the assay is highly specific for 
TGF-p activity.
2.21.2. Co-cultures
pHALF and tMLEC cells were harvested by trypsinization and mixed at a ratio of 1:1 
and seeded at 40x103 cells/ml in DMEM/10% FCS in 48-well plates and allowed 24 
hours incubation for adhesion and cell spreading. This medium was then changed to 
serum-free DMEM overnight and medium containing TFLLR or FTLLR (200 pM each) 
supplemented with either 1D11 (concentration), LSKL or SLLK (10pM) was added. The 
co-culture proceeded overnight, and cells were washed once in PBS before cell lysis 
and determination of Luciferase activity as described above.
2.21.3. Cell culture supernatants
The assay was performed by plating stably transfected mink lung epithelial cells 
(tMLEC) at a density of 1.6 x 104 cells/well in DMEM/10% FCS in a 96-well tissue 
culture plate. After allowing cells to adhere for 3 hours the medium was aspirated and 
cells were washed in serum-free medium. 100pl recombinant porcine TGF-Pt 
standards (0.1-1ng/ml in the same culture medium as the samples) or samples 
(undiluted medium taken from pHALFs stimulated with or without FXa for 24 hours) 
were added in duplicate to the plated tMLEC. The plate was then incubated for 14 
hours at 37°C/5% C02. Following incubation, media were aspirated and cells were 
washed in PBS. Subsequently 10Optl of luciferase reporter gene assay lysis buffer 
(Roche, UK) was added to each well, and the plate agitated for 25 minutes. 20pl of 
each lysate was then transferred into the corresponding well of a 96-well opaque white 
optiplate (Nunc, UK). The luciferase substrate (Promega, UK), was automatically 
added and a luminescence reading obtained by the Tropix TR717 Microplate 
Luminometer (Applied Biosystems, UK).
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2.22. Methylene blue proliferation study
2.22.1. Principle of the assay
An assay based on the uptake and release of methylene blue was used to investigate 
fibroblast proliferation. Methylene blue possesses a positive charge at pH 8.5, and thus 
binds electrostatically to negatively charged groups, including nucleic acids with 
phosphate moieties and negatively charged amino acids/proteins within the cell layer. 
The dye can be eluted from the cell layer by lowering the pH to below 2 with 
hydrochloric acid. This results in the protonation of acidic groups and liberation of 
methylene blue into the eluent. Methylene blue forms dimers in aqueous solution at low 
pH and does not obey Beer-Lambert’s Law. This is suppressed by using a hydrochloric 
acid/ethanol eluent, resulting in a single absorbance peak at 650nm.
2.22.2. Cell culture conditions
All proliferation experiments were performed on pHALFs in sub-confluent culture in the 
absence of serum. Cells were brought into suspension as described in Section 2.18. 
and seeded into 96-well plates at a concentration of 5x 103 cells in 200 pi DMEM. To 
avoid edge effects, cell were only seeded into the central 10x6 wells of the 96-well 
plates. The outer wells were filled with 200pl DMEM only. Cells were allowed to attach 
to the plate over a period of 24 hours after which medium was removed by gentle 
aspiration and replaced with fresh serum-free medium for a further 24 hours. 
Subsequently cells were exposed to FXa (25nM) alone or to FXa previously pre­
incubated with ZK 807834 for 1 hour in serum-free DMEM (n=6 for each dose for all 
experiments). The cells were incubated at 37 °C for 48 hours. In order to determine the 
absorbance of cultures at the onset of each experiment (to absorbance), a plate 
containing cells plated as described above and left to incubate for the initial 24 hours 
only, was processed as described in the following paragraph, Section 2.22.3.
2.22.3. Methylene Blue Assay Procedure
At the end of the incubation period, the culture medium was removed by blotting the 
plate over absorbent paper and gentle dipping the plate in a beaker of PBS to wash. 
The plate was reblotted and the cell layer fixed by addition of 10Opil formal saline (10% 
v/v formalin in 0.15M NaCI) overnight. The plate was wrapped in foil to avoid 
evaporation of fixative during this period. Formal saline was then flicked off, the plate 
blotted dry and 10Opil freshly filtered methylene blue (1% w/v in 0.01 M borate buffer, pH
8.5) was added for 30 minutes. Excess dye was flicked off the plate and the cell layer 
washed by serially dipping the plate in 4 reservoirs containing 0.01 M borate buffer (pH
8.5). After the last rinse, the plate was blotted dry and bound dye was eluted from the
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cell layer by addition of 100pl acidified alcohol (0.1 M HCL in 50% ethanol). The plate 
was gently shaken and absorbance for each well measured at 650nm on a platereader 
(Titertek Multiscan MCC/340 Mk II, Flow Laboratories, UK). The platereader was 
blanked on the first column of wells containing the elution solvent only and results were 
expressed as fold increase in absorbance/well.
2.23. Statistical analysis and expression of data
All data in figures are presented as mean fold increase ± standard deviation unless 
indicated otherwise. Statistical comparison was performed between two treatment 
groups by student’s t test, and between multiple treatment groups by one way analysis 
of variance (ANOVA) with Student-Newman-Keuls post-hoc testing, using Sigmastat 
software (SYSTAT Software Inc, IL, USA). A p value of less than 0.05 was considered 
significant and individual p values for all figures are shown in the relevant figure 
legends unless value is <0.001.
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Chapter 3: Results
Overview
The experimental results of this thesis have been divided into three sections. The first 
section establishes the local production of FX/FXa in the normal and fibrotic mouse 
and human lung. The second section examines the effect of FXa on fibroblast to 
myofibroblast differentiation. The third and final section examines the effect of the 
direct FXa inhibitor ZK 807834 on FXa-induced fibroblast function in vitro and in the 
bleomycin mouse model of lung injury and fibrosis.
3.1. Local generation of coagulation zymogen FX in the lung
3.1.1. Introduction
It is generally held that coagulation proteinases such as FX are synthesised in the liver 
and circulate in the blood as inactive zymogens. In a recent study performed in our 
laboratory by Drs Scotton and Lee global expression profiling was used during the 
fibroproliferative response to bleomycin injury in mice to gain novel insights into the 
mechanism by which the coagulation pathway drives the fibrotic response to lung 
injury. This study revealed the regulation of 399 non-redundant genes 14 days after 
bleomycin challenge in C57BI/6J mice. Many of the regulated genes had previously 
been identified from microarray analysis of the bleomycin model (Lemay and Haston, 
2005;Haston et al, 2005), including collagen I, fibronectin, MMP-12 and PDGF. 
Surprisingly however, the most highly enriched cluster also contained the gene for the 
zymogen FX, suggesting that FX is generated locally in the injured lung.
3.1.2. FX gene expression in bleomycin-induced lung injury and fibrosis
To provide a quantitative and accurate method of validation of the microarray data 
obtained by Drs Scotton and Lee and to confirm reproducibility of these initial results, 
FX expression was evaluated in the bleomycin model of lung injury and fibrosis by 
real-time RT-PCR. Bleomycin was administered by oropharyngeal instillation at a 
dose of 2mg/kg. This route of administration was chosen preferentially over 
intratracheal administration which was previously used for all microarray studies to 
provide a more uniform distribution of pathology within the murine lung (see 
Discussion Section 4.1.1.) Total cellular RNA was prepared from whole lung tissue 
extracted from mice at 7 and 14 days post-saline or bleomycin challenge. Relative 
abundance of FX mRNA was established following normalization for the 18S
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housekeeping gene. Relative quantitation was calculated according to the E'mcp 
method.
As demonstrated in Figure 3.1. (A) microarray analysis performed by Drs Scotton and 
Lee demonstrated a significant 1.61 ± 0.17 and 2.54 ± 0.73-fold increase in FX mRNA 
levels over saline control at 7 and 14 days respectively. Real time RT-PCR analysis 
confirmed that the gene for FX was expressed in the murine lung. FX mRNA levels 
were significantly increased at both 7 and 14 days post-bleomycin injury by 1.62 and 
3.57-fold respectively when compared to saline controls (Figure 3.1. (B)). These data 
show that the coagulation zymogen FX is expressed at the mRNA level in the murine 
lung and that mRNA levels are significantly increased in bleomycin-induced lung injury 
and fibrosis.
3.1.3. FX gene expression in pulmonary fibrosis induced by aerosolised 
bleomycin
In order to confirm the gene expression of coagulation zymogen FX in bleomycin- 
induced lung injury and fibrosis, FX mRNA levels were measured in lung tissue 
obtained from a mouse model of fibrosis induced by aerosolised bleomycin rather 
than by conventional intratracheal instillation. Animal experiments were performed in 
Dr Eickelberg’s laboratory in Giessen, Germany where mice of similar age to the host 
laboratories’ were orotracheally intubated and mechanically ventilated. Bleomycin (at 
a dose of 15mg/kg) or saline were administered as an aerosol via a microsprayer (see 
Methods Section 2.6.2.), Lungs were isolated at 7, 14 and 21 days post 
bleomycin/saline instillation and RNA was analysed from whole lung homogenates by 
real-time RT-PCR. Relative abundance of FX mRNA was established following 
normalization for HPRT housekeeping gene. Of note, all real time RT-PCR 
experiments performed in our laboratory analysed mRNA levels following 
normalisation to the 18s housekeeping gene. Although this gene proved to be very 
stable in our samples, this housekeeping gene was unstable in experiments 
performed in Professor Eickelberg’s laboratory, particularly in samples obtained by 
microdissection. These differences may be explained by the increased susceptibility 
to degradation of microdissected samples. The HPRT housekeeping gene was 
therefore chosen for experiments performed in Professor Eickelberg’s laboratory.
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Figure 3.1. FX gene expression in bleomycin-induced lung injury and fibrosis.
(A )  Figure shows normalized gene expression from microarray data for murine FX in lung 
homogenates 7 and 14 days after intratracheal saline or bleomycin. ( B )  Figure shows FX 
mRNA levels in mouse lungs assessed by quantitative real-time RT-PCR of whole lung 
homogenates, collected from mice 7 and 14 days post o.p. challenge with saline or bleomycin 
(2mg/kg). Data expressed as mean fold increase ± s.e.m relative to saline control at 7 days 
(n= 3 in saline group and n=5 in bleomycin group) *and **and****and*****p<0.001, ***p=0.014
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In accordance with the data obtained in our laboratory, FX mRNA was detected at 
baseline in all samples tested (Figure 3.2.). A significant 11.38±4.29-fold increase in 
the FX mRNA levels was observed at day 7 post-bleomycin injury and this increase 
was sustained at day 14 with a 4.59±0.47-fold increase over saline control.
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Figure 3.2. FX mRNA levels in whole lung homogenates at 7, 14 and 21 days post 
bleomycin- induced lung injury
Graph shows FX and FVII mRNA levels in mouse lungs assessed by quantitative real-time RT- 
PCR of whole lung homogenates, collected from mice 7 and 14 days post aerosolised 
challenge with aerosolised saline or bleomycin (15mg/kg). Data expressed as mean fold 
increase ± s.e.m relative to saline control (n= 3 per group) *p=0.05, **p=0.014
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3.1.4. FX expression in isolated alveolar epithelial cells post bleomycin-induced 
lung injury and fibrosis
To begin to identify the source of FX expression in the murine lung, alveolar epithelial 
cells and lung fibroblasts isolated from mice challenged with aerosolised bleomycin or 
saline, were analysed for FX gene expression by real-time RT-PCR. FX mRNA levels 
were measured for alveolar epithelial cells at the 14 day time point only, as these 
samples were very difficult to obtain. FX mRNA levels by fibroblasts were measured 
at 7, 14 and 21 days post-bleomycin challenge. All RNA samples used in this 
experiment were prepared by Dr Oliver Eickelberg and I performed all cDNA 
synthesis, primer optimization and real time-RT-PCR experiments in his laboratory. 
Samples were prepared from cells isolated from whole lung tissue by a dispase 
digestion technique (see Methods Section 2.14. and 2.15.). Relative abundance of 
FX mRNA was established following normalization for HPRT housekeeping gene.
As seen in Figure 3.3. there was a trend for an increase in FX gene expression in 
alveolar epithelial cells isolated from bleomycin versus saline-treated lungs, although 
it was not possible to establish statistical significance, as two replicates in each group 
had to be excluded reducing the total n number per group to 2 only. These were 
excluded on the basis of their melting curves which showed multiple peaks indicating 
the generation of non-specific product. In contrast, a significant 11.05±3.81-fold 
increase in FX mRNA levels was observed in fibroblasts 7 days post bleomycin injury 
compared to saline control and this increase was sustained until 21 days (however, it 
did not reach significance at both 14 and 21 day time points). These data support the 
notion that alveolar epithelial cells as well as fibroblasts represent a prominent source 
of FX production in bleomycin-induced lung injury and fibrosis.
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Figure 3.3. FX gene expression in isolated murine fibroblasts and alveolar epithelial 
cells post-bleomycin- induced lung injury and fibrosis
(A) Figure shows FX mRNA levels in alveolar epithelial cells isolated 14 days post aerosolised 
instillation of aerosolised saline or bleomycin as assessed by quantitative real-time RT-PCR 
(n=2 per group). (B) Figure shows FX mRNA levels in isolated fibroblast 7, 14, and 21 days 
post bleomycin and saline challenge. FX mRNA was significantly increased at 7 days with a
11.05-fold increase observed. p=0.0058
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3.1.5. Immunohlstochemlcal localization of FX/FXa protein in bleomycin- 
induced lung injury and fibrosis
In order to determine where FX protein localizes in the normal and fibrotic lung, the 
antibody used for this study recognized both the zymogen and the activated form. 
FX/FXa protein was examined by immunohistochemistry in lung sections of mice 
challenged with bleomycin or saline by oropharyngeal instillation for 7 and 14 days.
For optimization of the primary antibody on lung tissue sections, a dilution series was 
constructed and lung tissue sections were incubated with a polyclonal, goat anti­
mouse FX/FXa primary antibody, overnight at 4°C, at varying concentrations 
(Appendix). Positive staining for FX/FXa was detected by incubating sections with an 
optimal concentration of the primary antibody (1:200), followed by a biotinylated rabbit 
anti-goat secondary antibody, a streptavidin/peroxidase complex and a solution of 
3,3’- diaminobenzidine (DAB), which generated a brown reaction product. Highly 
specific staining for FX/FXa was confirmed since control tissue sections incubated 
with serum only and with an isotype specific, non-immune primary antibody showed 
no detectable staining. In addition, the antibody specificity was confirmed by western 
blotting of whole lung and liver homogenates showing single bands at the correct 
molecular weights for the heavy chain of FX in both the pre-protein and processed 
conformations.
Figure 3.4. shows the immunohistochemical localization of FX/FXa in bleomycin- 
induced lung injury and fibrosis. Tissue sections from saline-treated animals had very 
weak brown staining, which was associated with bronchial epithelial cells. However, in 
the lungs of bleomycin-treated animals 7 and 14 days following instillation, there was 
intense and widespread brown staining, which was predominantly associated with 
bronchial and alveolar epithelial cells, but positive signals were also detected with 
macrophages and myofibroblasts within inflammatory and fibroproliferative foci.
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Figure 3.4. Immunohistochemical localization of FX/FXa in bleomycin-induced lung 
injury and fibrosis
Photomicrographs of representative histological sections showing FX/FXa immunoreactivity in 
mouse lungs 7 and 14 days post o.p. challenge with saline or bleomycin (n=4 per group). 
There was weak staining for FX/FXa in saline-treated animals at both 7 and 14 days which 
was restricted to bronchial epithelial cells ( B E C )  and macrophages ( M A C ) .  Immunostaining 
was visibly increased in bleomycin-instilled mice at both time points and localised mainly to 
alveolar ( A E C )  and bronchial epithelial cells as well as macrophages and myofibroblasts in 
fibrotic foci ( M F ) .  IgG isotype control section showed no apparent staining (insert shown in the 
top right hand corner of the 7 days bleomycin section), Specific staining is depicted in brown; 
nuclei are stained blue with haematoxylin. Scale bars, 100pm.
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3.1.6. BALF FXa levels In bleomycin-induced lung injury and fibrosis
To examine if local procoagulant activity in the alveolar space was increased following 
bleomycin challenge, FXa activity was assessed in mouse BALF samples using a 
commercially available chromogenic assay. These experiments were performed 6 
days post-bleomycin challenge to assess FXa activity at a time point preceding the 
evolution of the fibrotic phase.
Following collection at 6 days post oropharyngeal instillation of saline or bleomycin, 
unconcentrated BALF samples were centrifuged and light absorbance in the 
supernatant was serially measured using a spectrophotometer at 405nM over one 
hour and the rate of thrombin generation calculated. Figure 3.5. confirms that BALF 
FXa activity was significantly increased in mice treated with bleomycin compared to 
saline-treated control animals (150 ± 26.7 fold). These data show that FXa activity is 
increased in BALF in bleomycin-induced lung injury and fibrosis.
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Figure 3.5. FXa levels in BALF following bleomycin instillation
This Figure shows the effect of oropharyngeal bleomycin on BALF FXa levels after 6 days. 
FXa activity was determined by chromogenic assay in BALF samples taken at day 6 post 
intratracheal challenge with 2mg/kg bleomycin or saline. FXa activity increased 150-fold over 
saline control. Data expressed as mean fold increase ± s.d. (n=6 mice per group per group, 
**p=0.0023).
Bleomycin
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3.1.7. The zymogen FX Is expressed in the human lung and is upregulated in IFF
Having demonstrated that coagulation FX is expressed locally in the murine lung and 
is upregulated following bleomycin-induced lung injury and fibrosis, the following set of 
experiments aimed at examining whether these findings could be translated to human 
fibrotic lung disease. For these studies mRNA samples extracted from human lung 
tissue were provided by Dr Oliver Eikelberg, Giessen and all experiments were 
performed by me in his laboratory.
In the first set of experiments FX mRNA levels were measured by real time RT-PCR 
in samples taken from total RNA extracted from lung biopsy specimens of patients 
with UIP or control donor lungs by real-time RT-PCR (Figure 3.6.) In all samples 
tested, FX was clearly detectable but there was no apparent difference between 
control donor lung and fibrotic lung samples. This is in contrast to the mouse lungs 
were FX mRNA levels were significantly increased in whole lung homogenates (see 
Figure 3.1. (B)).
In order to analyze FX gene expression in specific cell populations, subsequent 
experiments assessed FX expression at the mRNA level in samples obtained from 
microdissected alveolar septae of patients with UIP compared with the corresponding 
areas from control lung tissue, whereby alveolar septae are thought to predominantly 
represent the alveolar epithelium (see Methods Section 2.13.). In contrast to data 
obtained from total lung biopsy material, there was a marked 5.78 ± 1.44-fold increase 
in FX mRNA levels for samples obtained from microdissected alveolar septae of 
patients with UIP compared with the corresponding areas from control lung tissue 
(Figure 3.7.). However, analysis of fibroblasts isolated by trypsin digest from the 
same patient material showed no significant increase in FX expression in UIP versus 
donor material, although all fibroblast samples had detectable FX mRNA (Figure
3.8.).
These data show that FX is expressed in the human lung and its expression is 
increased in alveolar epithelial cells from patients with UIP compared with epithelial 
cells taken from donor lung. Furthermore human lung fibroblasts also express FX at 
baseline however these do not increase FX gene expression in fibrotic lung disease.
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Figure 3.6. FX mRNA levels in total human fibrotic and donor lung specimens
FX expression at the mRNA level as analyzed by quantitative real time RT-PCR. No significant 
change in FX expression was observed. Data expressed as mean fold increase ± s.e.m 
relative to donor lung in four patients per group.
Donor lung IPF lung
Figure 3.7. FX expression in microdissected alveolar septae from human IPF and donor 
lungs
This figure shows FX expression at the mRNA level as analyzed by quantitative real time RT- 
PCR. FX expression is increased 5.78 ± 1.44-fold in IPF patients compared to control lung. 
Data expressed as mean fold increase ± s.e.m relative to donor lung in four patients per group, 
**p=0.005
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Figure 3.8. FX expression in fibroblasts isolated from human donor and fibrotic lung 
specimens
FX expression at the mRNA level as analysed by quantitative real time RT-PCR. No significant 
change in FX expression was observed. Data expressed as mean fold increase ± s.e.m 
relative to donor lung in four patients per group.
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3.1.8. Immunohlstochemlcal localization of FX/FXa In IPF
Having confirmed the expression of FX at the mRNA level in the human lung, 
experiments were performed in order to determine the immunohistochemical 
localisation of FX and its active form FXa in human donor and fibrotic lung tissues. To 
this end, human tissue sections taken from 6 donor and 6 IPF lungs were provided by 
Dr Toby Maher in the host laboratory. Optimisation of the anti-FX/FXa antibody was 
performed as previously described in Results Section 3.1.5.
Figure 3.9. (A, C, D) shows photomicrographs of representative histological sections 
demonstrating immunohistochemical localisation of FX/FXa in human control donor 
and IPF patients. Control donor lung tissues (n=6) had very weak brown staining, 
which was occasionally associated with resident macrophages (Figure 3.9. (A)). 
However, in the lungs of 7 patients with IPF there was intense and widespread brown 
staining confirming strong upregulation of FX/FXa in IPF lungs, which was associated 
with the bronchial and alveolar epithelium and also with infiltrating macrophages and 
myofibroblasts within fibrotic foci (Figure 3.9. (B and C)). Highly specific staining for 
FX/FXa was confirmed since control tissue sections incubated with serum only and 
with an isotype specific, non-immune primary antibody showed no detectable staining 
(D).
This immunostaining pattern was confirmed in human tissue microarrays (TMAs) 
taken from a second cohort of IPF and control lung biopsy samples provided by Dr 
Naftali Kaminski (Pittsburgh cohort, n=18; Figure 3.10.). TMA are small needle 
biopsies which allow for detection of 200 or more consecutive section from the same 
biopsy. The TMAs provided by Dr Kaminski contained 18 small biopsy samples each 
taken from a different patient with the clinical diagnosis of UIP which were all placed 
on a single microslide for simultaneous analysis for FX protein expression (see 
Methods Section 2.12.3.). Weak brown staining was again mainly associated with 
resident macrophages in TMA control donor lung tissues (Figure 3.10. (A)). Strong 
staining for FX/FXa was localised to the bronchial and alveolar epithelium together 
with macrophages and fibroblasts within fibrotic foci in IPF lung tissue (Figure 3.19. 
(B-D).
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Figure 3.9. Immunohistochemical localization of FX/FXa in human IPF
Photomicrographs of representative histological sections showing FX/FXa immunolocalisation 
in normal human and IPF lung biopsy specimens (Brompton cohort, n=7 in fibrotic lung, n=6 in 
control group). Specific staining is depicted in brown; nuclei are stained blue with 
haematoxylin. ( A )  Weak staining was observed in normal control biopsy tissue which mainly 
localized to alveolar macrophages ( M A C ) .  (B  a n d  C )  There was marked increase in staining in 
fibrotic biopsy specimens (two representative sections shown here) which mainly localized to 
alveolar epithelial cells ( A E C )  but also macrophages and myofibroblasts ( M F )  in fibrotic foci. 
( D )  IgG isotype control section showed no apparent staining. Scale bars, 100pm.
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Figure 3.10. Im m unohistochem ical localization o f FX/FXa in human UIP tissue 
microarrays
Photomicrographs of representative histological sections showing FX/FXa immunolocalisation 
in normal human and UIP tissue microarrays (Pittsburgh cohort, n=12 in fibrotic group, N=3 in 
control group). Specific staining is depicted in brown; nuclei are stained blue with 
haematoxylin. ( A )  Weak staining was observed in normal control biopsy tissue which mainly 
localized to alveolar macrophages (M A C ) .  (B ,  C  a n d  D )  There was marked increase in 
staining in fibrotic biopsy specimens (representative sections shown here) which mainly 
localized to alveolar epithelial cells ( A E C )  but also macrophages ( M A C )  and myofibroblasts 
( M F )  in fibrotic foci. IgG isotype control shown in F ig u r e  3 .9 .  ( D ) .  Scale bars 100pm.
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3.1.9. FX expression in human alveolar and bronchial epithelial cells in vitro
In the liver, newly synthesised single-chain precursor FX undergoes post-translational 
modification, including cleavage and y-carboxylation which are essential to ensure 
optimal activation of the zymogen which circulates as a mature two-chain 
protein(Furie and Furie, 1988;Wallin and Turner, 1990;Stanton and Wallin, 1992) (see 
Introduction Section 1.8.1.). To investigate if cultured alveolar and bronchial 
epithelial cells were capable of producing the mature form of FX, FX mRNA levels 
were measured from cultured alveolar and bronchial epithelial cells by real-time RT- 
PCR and protein derived from these cell lines was compared to that obtained from 
liver hepatocytes by western blotting.
As seen in Figure 3.11. (A), analysis of RNA extracted from type II alveolar epithelial 
cells (A549) and bronchial epithelial cells (BEAS-2Bs) confirmed FX expression in 
both cell lines at the mRNA level. FX protein from A549 and BEAS-2Bs migrated in 3 
bands with apparent molecular weights of 74, 70 and 42kD, corresponding to the two 
single chain precursors and the heavy chain of the mature protein, respectively (Furie 
and Furie, 1988) (Figure 3.11. (B)). FX band pattern observed by western blotting 
was consistent with the posttranslational processing observed for hepatocytes 
(Stanton and Wallin, 1992) which are classically viewed as the main cellular source of 
this zymogen. These data support the notion that alveolar and bronchial epithelial 
cells produce FX and have the capacity to induce correct processing of the mature FX 
zymogen.
3.1.10. Bleomycin induces FX expression in alveolar epithelial cells
A series of in vitro studies were undertaken in an attempt to identify potential 
mediators of FX expression in alveolar epithelial cells. To this end the human lung 
epithelial cell line A549 was grown to 80% confluency in 6-well plates and after 18 
hour starvation it was exposed to a variety of different stimuli over time. FX mRNA 
levels were analysed by real time RT-PCR. Initial experiments examined the effect of 
TGF-p and TNF-a on FX expression by A549. Increased levels of both cytokines have 
been measured in both animal models of pulmonary fibrosis as well as in human 
fibrotic lung disease and have been implicated in the pathogenesis and progression of 
pulmonary fibrosis (see Introduction Section 1.3.).
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Figure 3.11. FX  expression at the mRNA and protein level in human lung epithelial cells 
in vitro
(A) Quantitative expression of FX in A549 and BEAS2B at the mRNA level. (B) FX protein 
expression of HepG2, A549 and BEAS2B by western blotting. Results are representative of 
three separate experiments.
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Cells were exposed to a single dose of TGF-p (2ng/ml), TNF-a (1ng/ml) in serum-free 
conditions and FX mRNA levels were measured from 3 hours onwards. These 
concentrations were chosen based on those described previously for TGF-p-and TNF- 
a-induced stimulatory effects on alveolar epithelial cells (Willis et al, 2005). Table 3.1. 
is a summary of the effects of TNF-a and TGF-p on a-SMA expression. None of these 
stimuli produced any significant difference in FX mRNA expression at any given time 
point.
The effect of bleomycin on FX expression in alveolar epithelial cells was also 
examined. A549 were stimulated with a single concentration of bleomycin (50U/ml) 
and FX mRNA levels were measured over time by real time RT-PCR. As seen in 
Figure 3.12. bleomycin stimulated a significant increase in FX mRNA levels that 
reached significance at 1 hour post stimulation and escalated over a 24 hour time 
period.
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Time(hours) Control TGF-P TNFa
3 1.02±0.27 2.11 ±0.09 1.43± 0.01
6 1.46± 0.17 1.71 ±0.21 1.63 ±0.52
16 2.94 ±0.16 1.93 ±0.16 1.24 ±0.74
Table 3.1. Effect of TGF-p and TNF-a-stimulation on FX mRNA levels in A549
FX mRNA levels as analyzed by quantitative real time RT-PCR. No significant increase in 
FX expression was observed at any time point. Data expressed as mean fold increase ± s.d, 
three replicates per group,
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Figure 3.12. Effect of bleomycin stimulation on FX mRNA levels in alveolar epithelial 
cells
Fold change (normalized for 18s) in FX mRNA levels was measured by real-time RT-PCR for 
A549 human alveolar type II cells after 18 hour serum starvation followed by incubation with 
50U/ml concentration of bleomycin for 1, 2, 4, 6 and 24 hours. Data represent mean fold change 
± standard deviation between the samples, n=3 for all samples, representative experiment of 
three replicates *p=0.004, **p=0.03.
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3.1.11. Summary
The results described in this section, examining the local production of FX/FXa in the 
murine and human lung showed:
• FX is expressed in the murine lung and is upregulated in bleomycin-treated 
mice compared to saline-treated controls
• FX/FXa protein was localized mainly to alveolar and bronchial epithelial cells 
but also to fibroblasts and alveolar macrophages in bleomycin-treated animals.
• Alveolar epithelial cells isolated from mouse lungs post-bleomycin injury show a 
trend for increased expression of FX compared to saline controls.
• Fibroblasts isolated from mouse lungs post-bleomycin injury significantly 
upregulate FX expression at the mRNA level compared to saline control.
• BALF FXa levels were elevated in bleomycin treated mice compared to saline 
treated controls.
• Laser-capture microdissection of human alveolar septae but not whole lung 
homogenates demonstrated marked upregulation of FX gene expression in IPF 
patients compared with control lung. However, fibroblasts isolated from human 
donor and IPF lung showed no increase in FX expression at the mRNA level.
• FX/FXa protein localisation showed consistent immunoreactivity of FX/FXa 
associated with the bronchial and alveolar epithelium, macrophages and fibrotic 
foci, in biopsy tissue samples from 18 patients with UIP which were derived 
from independent cohorts in the USA and the UK.
• Alveolar and bronchial epithelial cells in culture express FX at the mRNA and at 
the protein level. FX protein produced by these cells appears to undergo 
equivalent processing to that of hepatocytes.
• Bleomycin stimulates an increase in FX gene expression in alveolar epithelial 
cell in vitro.
In summary, the results presented in this thesis show that FX is expressed and 
upregulated in bleomycin-induced lung injury and fibrosis and IPF, supporting the 
notion of local production of the coagulation system components in fibrotic lung 
disease. Furthermore, this thesis identified the alveolar epithelium as a major source 
of FX expression within the fibrotic lung and further supports the notion that alveolar 
epithelial cells may produce the mature form of the zymogen.
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3.2. The role of FXa in fibroblast to myofibroblast differentiation
3.2.1. Introduction
There is strong evidence that the differentiation of fibroblasts into myofibroblasts plays 
a central role in the pathogenesis of pulmonary fibrosis, as these cells are highly 
synthetic in terms of the production of extracellular matrix proteins and appear to be 
resistant to apoptosis (reviewed in (Phan, 2002)). In the previous results section, the 
observation was made that fibroblasts/myofibroblasts within fibrotic foci stain positively 
for FX/FXa by immunohistochemistry in the bleomycin model of lung injury and fibrosis 
as well as in human fibrotic samples. This led to the hypothesis that fibroblasts are 
major target cells for FXa in fibrotic lung disease. The following section examines this 
hypothesis by evaluating the effect of FXa on fibroblast to myofibroblast differentiation 
in vitro.
Myofibroblast differentiation was studied in vitro using primary human adult lung 
fibroblasts (pHALFs) previously isolated in the host laboratory from lung explants (for a 
more detailed description see Methods Section 2.15.). These cells were chosen since 
they provide the closest representation of human biology, compared to ordinary 
immortalized cell lines. In addition, they have been well characterized in our laboratory 
and have previously been used to establish the effects of thrombin and TGF-p 
stimulation on fibroblast function (Chambers et al, 2003). Myofibroblast differentiation 
was assessed by determining de novo expression of a-SMA, the cytoskeletal protein 
recognized as the most significant marker of the myofibroblast phenotype (Chaponnier 
and Gabbiani, 2004).
3.2.2. Effect of FXa on primary adult human lung fibroblast to myofibroblast 
differentiation
To initially determine the effect of FXa on myofibroblast differentiation, a detailed dose- 
response experiment was performed. Cells were grown to 80% confluency and 
exposed to FXa at a range of concentrations (100pM-50nM) in serum-free DMEM. This 
range of concentrations was chosen based on previous studies conducted in our 
laboratory (Blanc-Brude et al, 1999). a-SMA protein levels in whole cell layer extracts 
were measured by western blotting and the intensity of the bands was analyzed by 
densitometry (relative to the intensity of the bands for total ERK2 used as loading 
control).
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Figure 3.13. shows a representative experiment for the effect of FXa on fibroblast a- 
SMA expression. The anti-a-SMA antibody recognized a faint 42-kDa band in 
unstimulated pHALFs. The intensity of this band was highly increased in cells exposed 
to FXa. Densitometric analysis of the protein bands revealed that FXa increased 
fibroblast a-SMA protein levels in a concentration-dependent fashion between 10nM 
and 50nM. At 10nM FXa stimulated a-SMA protein level by 29.88 ± 5.6 -fold relative to 
DMEM control and this response was maximal at 25nM as a-SMA protein levels 
increased by 57.53 ± 6.15-fold over media control. At 50 nM, which was the highest 
concentration measured no further increase in a-SMA protein levels could be observed 
(51.76 ± 12.61-fold). These data show that FXa is a potent stimulus for fibroblast a- 
SMA expression.
Based on these results, a dose of 10nM of FXa was chosen for all subsequent 
experiments. This concentration falls below the physiological concentration of its 
precursor (140nM; (Laurent and Shapiro, 2007)) and is similar to concentrations of FXa 
previously described to induce stimulatory effects in fibroblast-, smooth muscle cell-and 
endothelial cell proliferation studies (Blanc-Brude et al, 2005;Herbert et al, 
1998;Nicholson et al, 1996).This concentration is also most likely to mediate a 
substantial increase in a-SMA expression with the least off-target effects, which are 
commonly observed at high concentrations of coagulation proteinases in general 
(Chambers and Laurent, 2002).
3.2.3. Kinetics of myofibroblast differentiation induced by FXa
The kinetics of the FXa-induced a-SMA expression were subsequently determined. 
Cells were exposed to a single dose of FXa (10nM) in serum-free conditions and a- 
SMA protein levels were measured by western blotting from 24hours up to 48hours.
As shown in Figure 3.14., the response was not immediate, with the earliest detectable 
increase in a-SMA protein levels observed at 36hours (3.74± 1.19-fold). Control 
fibroblasts treated with DMEM only, showed no significant increase in a-SMA protein 
levels over time. At 48hours, which was the last time point measured, the response 
was maximal compared to previous time-points with an observed increase of 9.45± 
0.31-fold over medium control cells. Similar kinetics in a-SMA expression were 
observed in three separate experiments that were performed. These data show that the 
effect of FXa on a-SMA expression is time-dependent. Given that 36hours was the first 
time point at which a significant effect was observed, all subsequent experiments
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assessing FXa-induced a-SMA protein levels were performed at this time point. In 
addition, pHALFs were used at passage 4 to 8  only based on the observation that fold 
increase in a-SMA expression in response to FXa rapidly decreased with an increase 
in passage number (passage 4, 29.88- fold and passage 8 , 2.91-fold, see Figure 
3.15.).
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Figure 3.13. FXa induces fibroblast a-SMA expression in a concentration-dependent 
manner.
(A) Figure shows the effect of varying concentrations of FXa on a-SMA protein levels. a-SMA 
protein was detected using an anti-a-SMA antibody and blots were then stripped and reprobed 
with total ERK2 as the protein loading control. (B) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. 
Representative experiment of two performed with three replicates for each value expressed in 
fold increase over control ± s.d. * and ** and ***p<0.001
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Figure 3.14. FXa induces fibroblast to myofibroblast differentiation in a time-dependent 
manner.
Figure shows the effect of time on FXa-induced a-SMA protein levels. (A) pHALFs were 
exposed to a single dose of FXa (10nM) and a-SMA protein levels were detected using an anti- 
a-SMA antibody and blots were then stripped and reprobed with total ERK2 as the protein 
loading control. (B) The relative increase in a-SMA protein levels normalised to total ERK2 
protein levels was determined by semi-quantitative densitometry. Representative experiment of 
three separate experiments performed with three replicates for each value, data expressed as 
mean fold change relative to control ± s.d. *p=0.013, **p<0.001
117
Chapter 3 Results
30-|
20 -
15-
Q .
P5 P6 P7 P8 P9P4
pHALF passage number
Figure 3.15. Effect of pHALF passage number on FXa-induced a-SMA expression.
Figure shows the effect of a single dose of FXa (1 0 nM) on a-SMA protein levels at 36hours in 
pHALFs with varying passage numbers. The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. Data 
expressed as fold increase over media control, one replicate for each value.
3.2.4. Effect of FXa on foetal human and mouse lung fibroblast to myofibroblast 
differentiation
To confirm that the effects of FXa on fibroblast to myofibroblast differentiation were not 
unique to pHALFs, the ability of FXa to induce a-SMA expression was confirmed in 
other cell types, including a human foetal lung fibroblast cell line (HFL-1) and murine 
lung fibroblasts (MLFs). HFL-1 and MLFs were grown in identical conditions to pHALFs 
and exposed to FXa (10nM) for 36hours.
Figure 3.16. shows that FXa is a potent inducer of a-SMA expression in both HFL-1 
and MLFs, with observed increases of 5.33 fold ±2.16 and 2.76 fold ± 0.15 in a-SMA 
protein levels over media control respectively. These data further confirm that FXa is a 
potent inducer of the a-SMA expression in mouse and human lung fibroblasts.
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Figure 3.16. FXa induces a-SMA expression in human foetal-and mouse lung fibroblasts
Figure shows the effect of FXa on a-SMA protein levels in mouse lung fibroblast (A) and human 
foetal (B) cell lines. (A (i) and B (ii)) Cells were exposed to a single dose of FXa (10nM) and a- 
SMA protein levels were detected using an anti-a-SMA antibody and blots were stripped and 
reprobed with total ERK2 as the protein loading control. (B (i)) Lines indicate that protein bands 
were not positioned directly adjacent to each other on the blot. The relative increase in a-SMA 
protein levels normalised to total ERK2 protein levels was determined by quantitative 
densitometry (A (ii) and B (ii)). Representative experiment for three separate experiments 
performed. All data represented as mean fold increase over media control ± s.d. ** and
*p<0.001
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3.2.5. FXa and Thrombin have similar stimulatory effects on myofibroblast 
differentiation
It has previously been shown that thrombin is a potent mediator of myofibroblast 
differentiation (Bogatkevich et al, 2001). In order to determine if the induction in a-SMA 
protein level by FXa is comparable to that induced by thrombin, the effects of thrombin 
and FXa were assessed at equimolar concentrations, likely to be physiologically 
relevant for both proteinases (10nM FXa and 10nM thrombin) (Laurent and Shapiro, 
2007).
Figure 3.17. shows that FXa and thrombin stimulated an increase in a-SMA protein 
levels by 4.11 fold ± 0.63 and by 3.83 fold ± 0.8 above baseline respectively. There 
was no significant difference in the magnitude of response obtained for both 
proteinases. Therefore, at equimolar concentrations, FXa and thrombin have similar 
stimulatory effects on myofibroblast differentiation.
3.2.6. Effects of FXa on primary human adult lung fibroblast a-SMA mRNA levels
To investigate if FXa-induced a-SMA protein induction was regulated at a 
transcriptional level, the effect of FXa on fibroblast a-SMA mRNA levels was assessed. 
pHALFs were grown to 80% confluency in 6 -well plates and a time-response 
experiment was performed in serum-free conditions with a single dose of FXa (10nM). 
mRNA levels were measured by real time RT-PCR of total cellular RNA.
As demonstrated in Figure 3.18., FXa caused a significant increase in a-SMA mRNA 
levels from 24 hours onwards, with an observed 2.74 ± 0.17-fold increase over DMEM 
control. This delayed increase in a-SMA mRNA levels was reminiscent of the increase 
in FXa-induced a-SMA expression at the protein level (see Figure 3.1.4.). The 
response was maximal compared to other time points measured at 36 hours and 
showed a 3.82 ± 0.47-fold increase in the a-SMA mRNA levels compared to control. 
Fibroblasts treated with DMEM alone showed no significant difference in a-SMA mRNA 
levels over time, suggesting that the increase is specific to FXa stimulation. These 
findings were confirmed in three separate experiments performed. These data 
therefore show that FXa transcriptionally regulates a-SMA expression.
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Figure 3.17. FXa and thrombin have similar effects on a-SMA expression
Figure shows the effect of thrombin and FXa on a-SMA protein levels. (A) pHALFs were 
exposed to FXa and thrombin at equimolar concentrations (10nM) and a-SMA protein was 
detected using an anti-a-SMA antibody and blots were then stripped and reprobed with total 
ERK2 as protein loading control. (B) The relative increase in a-SMA protein levels normalised to 
total ERK2 protein levels was determined by semi-quantitative densitometry. Representative 
experiment of three experiments performed with three replicates for each value expressed in 
fold increase above media control ± s.d. *p=0.0016 **p=0.0048
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Figure 3.18. Effect of FXa stimulation on a-SMA gene expression in pHALFs.
Figure shows the effect of FXa (10nM) stimulation on a-SMA mRNA levels in pHALFs over time, 
up to 36hours. a-SMA mRNA levels were determined by real time RT-PCR. Representative 
experiment of three separate experiments performed with three replicates per value. mRNA 
levels expressed as fold increase relative to their respective time-point matched control ± s.d, 
media controls replaced by a single dotted line for the sake of simplicity.
*and **p<0 .0 0 1
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3.2.7. Effect of FXa on a-SMA fibre formation on human adult lung fibroblasts
a-SMA is a mechanosensitive protein that in response to mechanical stress assembles 
into stress fibres which are characteristic of the myofibroblast phenotype (see 
Introduction Section 1.5.). To determine whether FXa induced the assembly of a- 
SMA stress fibres, a-SMA protein was visualized by immunocytochemical analysis. 
pHALFs were grown to subconfluence in chamber slides, quiesced for 24 hours and 
exposed to FXa and DMEM for 36 hours prior to methanol fixation. Cells were 
subsequently incubated with a primary anti-a-SMA antibody or non-specific IgG isotype 
control antibody and a secondary fluorescein isothiocyanate-conjugated antibody and 
visualised by immunocytofluorescent microscopy.
Figure 3.19. shows representative images of the effect of FXa stimulation on a-SMA 
fibre formation. In accordance with data obtained by western blotting, pHALFs 
expressed low levels of a-SMA in serum-free conditions which did not appear to 
assemble into stress fibres. After exposure to FXa for 36hours, fluorescence for a-SMA 
was highly increased and was visible as an extensive network of brightly stained fibres 
which assembled into stress fibres resembling the stress fibres which are characteristic 
of the myofibroblast phenotype. This phenotype persisted up to 96 hours which was the 
last time point investigated (Figure 3.20.).
Stress fibre assembly induced by FXa was also confirmed in a second fibroblast line- 
HFL-1 (Figure. 3.21.). Compared to pHALFs, HFL-1 showed an increased baseline 
expression in a-SMA protein, which was not assembled into stress fibres. 36 hours 
post stimulation with FXa (10nM) positive staining was markedly increased and a-SMA 
positive fibres formed with a morphology very reminiscent of that observed for pHALFs. 
Thrombin-induced a-SMA fibre formation after 36 hours was used as a positive control 
and showed a very similar staining pattern.
These results show that FXa is able to induce the assembly of stress fibres in human 
adult as well as foetal lung fibroblasts, which are characteristic of the myofibroblast 
morphology. Stress fibre assembly is generally thought to directly correlate with the 
contractile ability of granulation myofibroblasts (Hinz et al, 2001). These data therefore 
support the notion that FXa mediates the induction of contractile myofibroblast.
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Figure 3.19. Effect o f FXa on a-SMA fibre assembly in pHALFs at 36 hours
FXa induces the assembly of a-SMA positive stress fibres in pHALFs characteristic of the 
myofibroblast phenotype. Cells were grown on chamber slides and exposed to DMEM or FXa 
for 36hours. Cells were incubated with and anti-a-SMA antibody and fibres were visualized by 
immunocytofluorescent microscopy. a-SMA staining is shown in green, nuclei staining with 
propidium-iodide in red. Isotype control (ISO) showed no staining. Representative images of 
three separate experiments performed. Scale bar 40pm
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Figure 3.20. Effect o f FXa on a-SMA fibre formation in pHALFs at 96 hours
FXa induces the assembly of a-SMA positive stress fibres characteristic of the myofibroblast 
morphology which persists up to 96hours. Cells were grown on chamber slides and exposed to 
DMEM or FXa for 96hours. Cells were incubated with and anti-a-SMA antibody and fibres were 
visualized by immunocytofluorescent microscopy. a-SMA staining is shown in green, nuclei 
staining with propidium-iodide in red. Isotype control as shown in F ig u r e  3 .1 9 .  Representative 
images of three separate experiments performed. Scale bars 40pm
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Figure 3.21. Effect o f FXa and thrombin on a-SMA fibre formation in HFL-1 at 36 hours
FXa induces the assembly of a-SMA positive stress fibres characteristic of the myofibroblast 
morphology and very reminiscent of stress fibres induced by thrombin stimulation. Cells were 
grown on chamber slides and exposed to DMEM or FXa for 36hours. Cells were incubated with 
and anti-a-SMA antibody and fibres were visualized by immunocytofluorescent microscopy, a- 
SMA staining is shown in green, nuclei staining with propidium-iodide in red. Isotype control 
(ISO) showed no staining. Representative images of three separate experiments performed. 
Scale bars 40pm.
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3.2.8. Summary
The results described in this section examining the effect of FXa on myofibroblast 
differentiation showed:
• FXa induces a-SMA protein levels in a concentration-and time-dependant 
manner in primary human lung fibroblasts.
• FXa induces a-SMA protein levels in fetal human and mouse lung fibroblast cell 
lines.
• FXa regulates a-SMA expression in primary human lung fibroblasts at the 
transcriptional level.
• FXa induces the assembly of a-SMA-positive stress fibres characteristic of the 
myofibroblast morphology.
In summary, the results in this thesis show that FXa is a potent inducer of myofibroblast 
differentiation programme in human and mouse lung fibroblasts.
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3.3 The role of PA R i in FXa-induced myofibroblast differentiation
3.3.1. Introduction
Coagulation proteinases such as FXa are known to exert their cellular effects via the 
proteolytic activation of PARs and FXa can signal via PARi or PAR2, or both receptors, 
depending on cell type and co-factor expression (Blanc-Brude et al, 2005;Ruf et al, 
2003). The broad ranges of cellular effects induced by PAR signalling are enabled by 
the ability of PARs to couple to several different heterotrimeric G proteins, including 
Gaq, GOj and GCI12/13. To begin to understand the mechanism of action of FXa in the 
stimulation of myofibroblast differentiation, the following experiments assessed the role 
of thrombin and FXa catalytic site in a-SMA expression and explored the contribution of 
PAR1 and PAR2 signalling and differential G protein coupling in this system.
3.3.2. FXa-induced myofibroblast differentiation is independent of thrombin 
activity
To rule out the possibility that the effect of FXa on a-SMA expression was mediated via 
the local generation of thrombin, or contamination of the FXa preparation, FXa-induced 
a-SMA induction was investigated in the presence of the highly selective thrombin 
inhibitor, hirudin. FXa (10nM) and thrombin (positive control; 10nM) were preincubated 
with hirudin in molar excess (2 0 0 nM) in serum-free DMEM for 60 minutes at 37 °C prior 
to the addition to cell cultures. Preincubation time and concentration of hirudin were 
chosen according to previous work in our laboratory (Blanc-Brude et al, 2005). Control 
DMEM without inhibitor was incubated under the same conditions.
Figure 3.22. shows a representative experiment for the effect of hirudin on fibroblast a- 
SMA protein levels in response to FXa and thrombin stimulation. Both FXa and 
thrombin significantly stimulated a-SMA protein levels, as assessed at 36hours, by 
20.41 ±1.09 fold and 16.55±1.5 fold respectively. Hirudin had a small, albeit significant, 
effect on FXa-induced a-SMA induction (approximately 20% inhibition, 16.55 ± 1.5), but 
it inhibited over 95% of a-SMA expression stimulated by thrombin (2.52 ± 0.33). This 
suggests that thrombin exerts only a minor effect on FXa-induced a-SMA expression.
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Figure 3.22. The effect o f hirudin on FXa-induced a-SMA expression in pHALFs
Hirudin (200nM) inhibited over 95% of a-SMA protein levels in response to thrombin (10nM) but 
only exerted a small (albeit significant) effect on FXa induced a-SMA protein levels. Hirudin did 
not affect baseline a-SMA protein levels. a-SMA protein was detected using an anti-a-SMA 
antibody and blots were then stripped and reprobed with total ERK2 as protein loading control. 
(A) The effect of hirudin on FXa-induced a-SMA protein levels. (B) The effect of hirudin on 
thrombin-induced a-SMA protein levels. (C) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. The 
same control samples were used within the same experiment to allow for normalisation between 
blots. Data presented as mean fold increase ± s.d and representative of three separate 
experiments performed with three replicates per group.* and **and ***’****p<0.001.
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3.3.3. The Effect of antistasin on FXa-induced myofibroblast differentiation
To explore the role of the FXa catalytic site in the induction a-SMA expression, FXa 
was rendered proteolytically-inactive by complexing it with the potent and highly 
selective FXa inhibitor, antistasin (ASN). ASN is a specific natural inhibitor of FXa 
enzymatic activity, isolated from the leech Haementeria offinalis. Short synthetic 
peptides mimicking the core inhibitory region of ASN, including ASN D-Arg32-Pro38 
(ASN core peptide), have been shown to be active and abolish the catalytic activity of 
FXa selectively (Ohta et al, 1994). ASN core peptide inhibits FXa by binding to its’ 
catalytic site with great affinity, but in a reversible fashion. FXa and control medium 
only were preincubated with ASN core peptide (1pM) in serum-free DMEM for 120 
minutes at 37 °C prior to the addition to cell cultures. Preincubation time and 
concentration for ASN core peptide was chosen based on previous experiments 
performed in our laboratory (Blanc-Brude et al, 2005).
Figure 3.23. shows that, as expected, proteolytically active FXa induced a significant 
increase in a-SMA protein levels at 36hours (22.35 fold ± 1.15) which was completely 
inhibited by the ASN core peptide (about 96% inhibition). ASN core peptide alone had 
no effect on baseline a-SMA protein. Due to financial constraints this experiment was 
carried out only twice, however further evidence for the involvement of the FXa 
catalytic site in the response leading to a-SMA protein induction is shown in studies 
using the ZK 807834 inhibitor (see Results Section 3.5.2.). This study demonstrates 
that the FXa catalytic site is necessary for FXa stimulatory effects on a-SMA 
expression.
3.3.4. Confirmation of PAR1 and PAR2 expression at the mRNA level in lung 
fibroblasts
FXa is known to signal via PAR! or PAR2 (see Introduction Section 1.9.). To begin to 
examine the potential PAR receptor subtypes involved in mediating FXa-induced 
stimulatory effects on a-SMA expression, the relative expression of both receptors was 
assessed in pHALFs. PAR! and PAR2 expression was analysed in whole cell lysates 
by RT-PCR; RNA isolated from HFL-1 and MLFs cell lines was analysed in parallel.
Figure 3.24. demonstrates that both receptor subtypes were expressed by pHALFs. As 
expected, HFL-1 also expressed both subtypes whilst mouse lung fibroblasts only 
showed a positive signal for PAR!.
130
Chapter 3 Results
a-SMA
ERK total
Control ASN FXa FXa+ASN
B
2  25 -
!  °  20 
o  o
•- iQ) . >
o «
CL P
 15 -
2 : <D
co 2  A 0 
S .E
o
10 -
5 -
0
ASN
FXa
i
+  -  +  
+ +
Figure 3.23. The effect o f antistasin core peptide on FXa-induced a-SMA protein 
induction.
FXa and control medium were preincubated with ASN core peptide (1|iM) in serum-free DMEM 
for 120 minutes at 37 °C prior to addition to cell cultures. (A) The effect of ASN core peptide on 
FXa-induced a-SMA protein levels. a-SMA protein was detected using an anti-a-SMA antibody 
and blots were then stripped and reprobed with total ERK2 as protein loading control. ASN core 
peptide did not affect baseline a-SMA protein. (B) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. Data 
presented as mean fold increase ± s.d and representative of three separate experiments 
performed with three replicates per group.*' **p<0.001
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Figure 3.24. Expression o f PAR1 and PAR2 in pHALFs, HFL-1 and MLFs
Figure shows the expression of PARi and PAR2 as analysed by RT-PCR in whole cell 
lysates. pHALFs and HFL-1 show expression for both PARt and PAR2 whereas MLFs only 
express the PARi receptor subtype. This image is representative of three replicates performed 
in this experiment.
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3.3.5. PARi but not PAR2 activation is sufficient for fibroblast to myofibroblast 
differentiation.
Having demonstrated that pHALFs express both PAFL and PAR2 at the mRNA level, 
the next set of experiments examined whether activation of PARi or PAR2 or both was 
necessary and/or sufficient for the induction of a-SMA expression in pHALFs. Selective 
PARi and PAR2 activation was achieved by stimulating pHALFs with synthetic 
activating peptides TFLLRn-NH2 and SLIGKV-NH2 corresponding to the tethered ligand 
sequence of PAR! and its it’s and of PAR2 respectively. FTLLRN-NH2 was used as a 
scrambled peptide control.
As shown in Figure 3.25., TFLLR-NH2 significantly increased a-SMA protein levels at a 
standard dose of 200pM (2.38 fold ± 0.29) but was less efficient when compared to the 
level of induction seen following stimulation with FXa in previous experiments. Further 
detailed dose response experiments with TFLLR-NH2 showed no further increase in a- 
SMA expression suggesting that maximal stimulatory capacity for TFLLR-NH2 on a- 
SMA expression had been achieved (data not shown). In contrast, the scrambled PAR! 
control peptide FTLLR-NH2 exerted no effect on a-SMA expression, nor did the PAR2 
activating peptide SLIGKV-NH2.
Induction of a-SMA expression by PARi activating peptides was also confirmed in 
MLFs; SLIGKV-NH2 was not used since these cells lack PAR2 expression (Figure 
3.26.). TFLLR-NH2 induced a 5.33 fold ± 2.16 increase in a-SMA protein levels 
(compared to FXa which stimulated a-SMA by 6.19 fold ± 1.98); FTLLR-NH2 had no 
effect. These data show that PARl5 but not PAR2 activation, is sufficient for a-SMA 
induction.
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Figure 3.25. The effect o f TFLLR-NH2, SUGKV-NH2 and FTLLR-NH2 on FXa-induced a- 
SMA protein induction in pHALFs.
(A) The synthetic PARt (TFLLR-NH2, 200pM)-and PAR2 (SLIGKV-NH2, 200pM) activating 
peptides reveal that PAR! activation is sufficient for the induction of a-SMA and that PAR2 
activation does not induce a-SMA expression. a-SMA protein was detected using an anti-a- 
SMA antibody and blots were then stripped and reprobed with total ERK2 as protein loading 
control. (B) The relative increase in a-SMA protein levels normalised to total ERK2 protein 
levels was determined by semi-quantitative densitometry. Data representative of three separate 
experiments performed with three replicates in each group. **p=0.0002
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Figure 3.26. The effect o f TFLLR-NH2 and FTLLR-NH2 on FXa-induced a-SMA protein  
induction in MLFs
(A) The effect of synthetic peptide agonists for PARt (TFLLR-NH2, 200pM) and its scrambled 
peptide control FTLLR-NH2 (200pM) on a-SMA protein levels in MLFs. a-SMA protein was 
detected using an anti-a-SMA antibody and blots were then stripped and reprobed with total 
ERK2 as protein loading control. Line indicates that protein bands were not positioned directly 
adjacent to each other on the blot. (B) The relative increase in a-SMA protein levels normalised 
to total ERK2 protein levels was determined by semi-quantitative densitometry. Data 
representative of three separate experiments performed with three replicates in each group.
*p<0.001
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3.3.6. PARi activation is necessary for FXa-induced myofibroblast differentiation
To examine whether PAF^ was necessary for FXa-induced a-SMA expression, primary 
mouse lung fibroblasts were isolated by explant technique from PARrdeficient-mice 
and stimulated with FXa (1 0 nM) and the positive control TGF-p (2ng/ml) under identical 
conditions as previously used for MLF (see Results Section 3.2.4). Figure 3.27. shows 
that FXa had no stimulatory effect on a-SMA protein level in PARt-deficient fibroblasts. 
However TGF-p stimulation also failed to induce an increase. It was further noted that 
baseline expression of a-SMA was markedly higher compared to that observed for 
fibroblasts in previous experiments, suggesting that PARrdeficient fibroblasts were 
already expressing a maximum level of a-SMA and could therefore not be used for the 
purpose of this experiment.
In order to answer the question of whether the FXa-mediated increase in a-SMA 
expression was PARt dependent, the influence of the selective and potent inhibitor of 
PAR^ RWJ-58259, was therefore investigated. This compound is a highly selective 
small antagonist of PAR! that binds to the extracellular domain of the receptor, thereby 
inhibiting the binding of the tethered ligand or activation peptide to the second 
extracellular loop of the receptor (Damiano et al, 2003).Pre-incubation of pHALFs with 
RWJ-58259 for 30 minutes prior to stimulation with FXa attenuated the FXa-mediated 
increase in a-SMA protein levels in a concentration-dependent manner from 3pM 
onwards (about 61% inhibition; Figure 3.28.) At the highest concentration of RWJ- 
58259 (10pM) the increase in a-SMA protein levels was blocked by about 94%. This 
compound had no effect on basal a-SMA protein. These data confirm that FXa exerts 
its stimulatory effect on a-SMA expression via a PARi-dependent mechanism.
a-SMA
ERK total
DMEM FXa TGF-p
Figure 3.27. Effect o f FXa and TGF-p on PARr deficient m ouse lung fibroblasts. Lung 
fibroblasts were isolated from PARi deficient mice prior to stimulation with FXa (10nM) or TGF-p 
(2ng/ml). FXa and TGF-p had no effect on a-SMA protein levels. a-SMA protein was detected 
using an anti-a-SMA antibody and blots were then stripped and reprobed with total ERK2 as 
protein loading control. Data representative of three separate experiments performed.
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Figure 3.28. The effect o f the highly selective PAR1 antagonist, RW J-58259 on FXa- 
induced a-SMA expression.
(A) RWJ-58259 did not affect baseline a-SMA protein levels at any concentration. (B) RWJ- 
58259 attenuated FXa-induced a-SMA protein levels in a concentration-dependent manner, a- 
SMA was detected using an anti-a-SMA antibody and blots were then stripped and reprobed 
with total ERK2 as protein loading control. (C) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry, a- 
SMA protein levels were detected using an anti-a-SMA antibody and blots were reprobed with 
total ERK2 for protein loading control. The same control samples were used within the same 
experiment to allow for normalisation between blots. All data is representative of three separate 
experiments with three replicates in each experimental group expressed as mean fold increase 
± s.d, ‘and “ ‘and *“ *p<0.001, “ p=0.029.
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3.3.7. Effect of pertussis toxin (PTX) and the PARr Gccq inhibitor (Q94) on FXa- 
induced a-SMA expression
PARi is promiscuous in its ability to couple to multiple members of the G protein family, 
including Gotq, Gctj and Ga12/13. Different agonists of PARi have recently been shown to 
selectively activate different G-protein pathways (and therefore induce differential 
downstream cellular effects), by their ability to alter receptor/G protein binding 
(McLaughlin et al, 2005b). The following set of experiments therefore aimed to 
investigate which G protein units are involved in FXa-mediated a-SMA protein 
induction. To evaluate whether FXa-induced a-SMA protein levels were dependent on 
PARt coupling to GOj, pHALFs were pre-incubated with PTX (100 ng/ml) for 3 hours 
prior to exposure to FXa. Preincubation time and concentration of PTX were based on 
previous experiments performed in our laboratory (Blanc-Brude et al, 2005). As 
expected, FXa alone significantly increased a-SMA protein levels (6.99 fold ± 1.48). 
PTX exerted no inhibitory effect on the induction of a-SMA protein levels (Figure 3.29.) 
suggesting that PARrmediated a-SMA expression is independent of PARi coupling to 
Gai and its associated downstream signalling pathways.
To assess the role of Gaq signalling, a-SMA protein levels in response to FXa 
stimulation were measured in Gaq/n-deficient mouse lung fibroblasts (Gotq/n -/-) (see 
Methods Section 2.4.). Gaq/n-/- were grown in identical conditions to pHALFs and 
exposed to FXa (1 0 nM) or 10% FCS (positive control) for 36 hours. As seen in Figure 
3.30. FXa failed to induce a-SMA protein levels, however 10% FCS used as a positive 
control induced a 3-fold increase indicating that the lack of induction seen with FXa 
stimulation was not due to an inability of these cells to up regulate a-SMA per se. 
Unfortunately, it was not possible to obtain corresponding WT mouse lung fibroblasts 
from litter mates to exclude the possibility that fibroblasts isolated from this mouse 
strain are unable to respond to FXa in general. A pharmacological approach was 
therefore used to evaluate the potential involvement of Gaq. This question was 
addressed using the novel inhibitor Q94 which selectively blocks the PARi interaction 
with Gaq (Caden Biosciences). Pre-incubation of pHALFs with Q94 for 3 hours prior to 
stimulation with FXa (10nM) blocked the induction of a-SMA protein levels in a 
concentration-dependent manner from 0.1 pM onwards (about 20% inhibition, Figure 
3.31). This compound had no effect on basal a-SMA protein. These data suggest that 
FXa-mediated a-SMA expression via PARi is independent of receptor coupling to Gaj 
and dependent on receptor coupling to Gaq.
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Figure 3.29. Effect o f P TX  on FXa-induced a-SMA expression.
Incubation of pHALFs with PTX (100ng/ml) blocked FXa-induced a-SMA protein levels in a 
concentration dependent manner. (A) a-SMA protein levels were detected using an anti-a-SMA 
antibody and blots were then stripped and reprobed with total ERK2 as protein loading control. 
PTX did not affect baseline a-SMA protein (B) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. All 
data is representative of three separate experiments with three replicates in each experimental 
group expressed as mean fold increase ± s.d, *p= 0.0023, **p<0.001
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Figure 3.30. Effect o f FXa stim ulation on a-SM A protein induction in Gaq/11-deficient 
mouse lung fibroblasts.
(A) a-SMA protein levels were detected using an anti-a-SMA antibody and blots were then 
stripped and reprobed with total ERK2 as protein loading control. PTX did not affect baseline a- 
SMA protein (B) The relative increase in a-SMA protein levels normalised to total ERK2 protein 
levels was determined by semi-quantitative densitometry. All data expressed as mean fold 
increase ± s.d, *p<0 . 0 0 1
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Figure 3.31. Effect o f the selective Gaq antagonist Q94 on FXa-induced a-SMA induction
(A) Q94 did not affect baseline a-SMA protein levels at any concentration. (B) Q94 attenuated 
FXa-induced a-SMA protein levels in a concentration-dependent manner. a-SMA was detected 
using an anti-a-SMA antibody and blots were then stripped and reprobed with total ERK2 as 
protein loading control. (C) The relative increase in a-SMA protein levels normalised to total 
ERK2 protein levels was determined by semi-quantitative densitometry. Q94 blocked up to 95% 
of FXa induced a-SMA protein levels at its highest concentration. The same control samples 
were used within the same experiment to allow for normalisation between blots. All data is 
representative of three separate experiments with three replicates in each experimental group 
expressed.*and**and***and****p<0 .0 0 1 .
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3.3.8. Summary
The results described in this section examining the mechanisms of action of FXa in the 
stimulation of myofibroblast differentiation showed:
• FXa induces a-SMA expression mostly independently of thrombin activity.
• The FXa catalytic site is necessary for FXa-induced a-SMA protein induction.
• PARt but not PAR2 activation is necessary and sufficient for the induction of a- 
SMA protein by FXa.
• FXa-mediated a-SMA protein induction via PAR! is independent of receptor 
coupling to Get), and dependent on coupling to Gaq.
These studies show that PARi is the major signaling receptor involved in mediating 
FXa-induced fibroblast to myofibroblast differentiation and this effect is dependent 
on PARt coupling to Gaq.
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3.4. The role o f  TG F-p in FXa-induced myofibroblast differentiation
3.4.1. Introduction
Previous time-course experiments revealed that a-SMA induction at both the mRNA 
and protein level was a delayed response to FXa raising the possibility that FXa exerts 
its effects via the autocrine production and/or activation of a secondary mediator. TGF- 
(3 is one of the most potent known inducers of the myofibroblast differentiation 
programme and signals in fibroblasts via the activation of the activin-like kinase 5 (ALK- 
5) TGF-p type 1 receptor, which triggers the SMAD signalling pathway by 
phosphorylating SMAD-2 and- 3. Thrombin has previously been shown to increase 
expression and/or release of TGF-p from vascular smooth muscle cells (Bachhuber et 
al, 1997), and kidney mesangial and epithelial cells (Yamabe et al, 1997;Tsunoda et al, 
2001;Shirato et a l, 2003). The following section therefore explored the hypothesis that 
FXa is mediating its effects on a-SMA expression via a TGF-p-dependent mechanism.
3.4.2. FXa does n o t regulate TGF-p mRNA levels
Following cellular synthesis, TGF-p is released as biologically inactive latent-TGF-p, 
which comprises a  complex of a latency-associated peptide (LAP) and a 25kDa mature 
TGF-p dimer (see Introduction Section 1.6.2.). There is compelling evidence that TGF- 
p bioavailability is  regulated at the production level of the cytokine and/or at the level of 
activation of its latent form To examine if FXa influenced TGF-p production, the effect 
of FXa on TGF-Pi gene expression in pHALFs was assessed by real-time RT-PCR. 
pHALFs were grown to sub-confluency in 6 -well plates and stimulated with FXa (10nM) 
over time up to 2 4  hours (the time point at which the first significant increase in a-SMA 
mRNA levels can  be observed) in identical conditions to those used for a-SMA 
stimulation.
As seen in F igure  3.32. FXa caused no apparent change in TGF-p mRNA levels at any 
time point tested, suggesting that FXa does not regulate TGF-p production at the 
transcriptional level.
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3.4.3. TFLLR-NH2 induces activation of TGF-p
The next set of experiments determined whether FXa acts via activation of latent TGF- 
P rather than via a transcriptional mechanism. Active TGF-p levels were assessed 
using a bioassay based on a transformed Mink lung epithelial cell (tMLEC) and pHALF 
co-culture system where fibroblast-derived active TGF-p is detected as an increase in 
luciferase activity by tMLEC which express luciferase under the control of the TGF-p- 
responsive PAI-1 promoter (see Methods Section 2.21.).
In these experiments, it was not possible to test the effect of FXa on TGF-p activity. 
FXa induced a significant increase in luciferase activity at 10 and 25 nM concentration 
(1.22±0.06-and 1.57±0.11-fold, respectively), however the relative fold increase was 
not inhibited by the pan-specific TGF-p blocking antibody 1D11 (100ng, 1.14±0.1-and 
1.42±0.17-fold, respectively). To exclude the possibility that an antibody blocking 
strategy is not effective in this system, the effect of a small molecule inhibitor of the 
TGF-p type I receptor (ALK-5), SB431542 (Callahan et al, 2 0 0 2 ) was also examined. 
SB431542 similarly had no effect on FXa-induced increase in luciferase activity 
(1.22±0.11 -and 2.06±0.15-fold respectively), suggesting that FXa is influencing 
baseline luciferase activity in this assay (see Figure 3.33.). The experiments were 
therefore performed with the selective PARi agonist, TFLLR-NH2 and its scrambled 
peptide control FTLLR-NH2.
Luciferase activity was significantly increased in response to exogenous TFLLR-NH2 
used at a standard dose of 200pM compared with media control-treated cell cultures 
(1169 ± 68.67 versus 857 ± 98.6-fold increase, respectively Figure 3.34.). Moreover, 
this increase in luciferase activity was completely inhibited by the pan-specific TGF-p 
blocking antibody 1D11 (100pg/ml; 774.25 ± 107.72-fold increase), indicating that the 
increase in tMLEC luciferase activity was due to the presence of active TGF-p. As 
expected, FTLLR-NH2 had no stimulatory effect. Furthermore increased TGF-p activity 
was only observed when pHALFs were grown in co-culture with tMLEC rather than in a 
single culture system where tMLEC are stimulated with conditioned media taken from 
pHALFs (data not shown), that close cell contact between the two cell types (the 
effector and the reporter cell line) is essential.
3.4.4. FXa induces SMAD2/3 phosphorylation in pHALFs
To determine the time course of PARrmediated TGF-p activation, FXa stimulation of 
TGF-p-induced signalling pathways was assessed as a measure of TGF-p activity. 
Active TGF-p causes activation of ALK5 leading to phosphorylation of SMAD2/3 (see
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Introduction Section 1.6.1.)- The effect of FXa on SMAD2/3 phosphorylation in 
pHALFs was therefore examined. Cells were exposed to a single dose of FXa (10nM) 
in serum-free conditions and SMAD2/3 phosphorylation was determined from 1hour up 
to 24hours by western blotting.
As shown in Figure 3.35. (A), the anti-phospho SMAD2/3 antibody recognized a faint 
58-kDa band in unstimulated pHALFs. The intensity of this band was highly increased 
in cells exposed to FXa. Densitometric analysis revealed that FXa stimulated 
phosphorylation of SMAD2/3 from 6  hours onwards (5.9-fold at 6  hours; Figure 3.35. 
(B)). Control fibroblasts treated with DMEM only, showed no significant increase in a- 
SMA over time. The response was maximal at 12 hours with an observed increase of 
12.21-fold over medium control. Similar kinetics in phsphoSMAD2/3 protein levels were 
observed in six separate experiments that were performed with one replicate per 
experimental group. These experiments reveal that FXa increased SMAD2 
phosphorylation with the earliest detectable signal observed 6  hours following FXa 
stimulation
all ns
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■ FXa
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Figure 3.32. FXa does not stimulate TGF-p gene expression.
Figure shows the effect of FXa (10nM) stimulation on TGF-p mRNA levels in pHALFs over time, 
up to 36 hours. TG F-p  mRNA levels were determined by real- time RT-PCR. Representative 
figure of two separate experiments performed with three replicates in each experimental group. 
Data expressed as fold increase over media control ± s.d.
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Figure 3.33. FXa-induced luciferase activity is not blockable by 1D11 and SB431542
Graph showing the effect of FXa on luciferase activity measured using a tMLEC-fibroblast co­
culture system (1:1) where fibroblast-derived active TGF-p is detected as an increase in 
luciferase activity by tMLEC expressing luciferase under the control of the TGF-p-responsive 
PAI-1 promoter. FXa (10 and 25 nM) induced a significant increase in luciferase activity that 
was not blockable by the TGF-p blocking antibody 1 D11 (100pg/ml) nor by the ALK5 inhibitor 
SB431542 (10pM). Data expressed as fold increase over media control ± s.d. *and 
**and***and****p<0 .0 0 1
146
Chapter 3 Results
o
o3
10 800 - 
CD
f '  1000-
0
TFLLR
1D11
1200 -
1400-1
400 -
2 0 0 -
+ +
+ +
Figure 3.34. Effect of TFLLR-NH2 on TGF-p activity.
Graph showing the effect of TFLLR on luciferase activity measured using a tMLEC-fibroblast co­
culture system (1:1) where fibroblast-derived active TGF-p is detected as an increase in 
luciferase activity by tMLEC expressing luciferase under the control of the TGF-p-responsive 
PAI-1  promoter. TFLLR induced a significant increase in luciferase activity which was 
completely blocked by 1D11 (100|xg/ml). Data expressed as fold increase over media control ± 
s.d.*and **p<0 . 0 0 1
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Figure 3.35. Time course experim ent for phosphorylation o f SMAD 2/3 by FXa.
FXa increased SMAD2/3 phosphorylation with the earliest detectable signal observed 6  hours 
following FXa stimulation. (A) Phosphorylated SMAD2/3 was detected using an anti-phospho- 
SMAD2/3 antibody and blots were then stripped and reprobed with total SMAD as protein 
loading control. (B) The relative increase in phospho SMAD protein levels normalised to total 
SMAD protein levels was determined by semi-quantitative densitometry. All data are 
representative of six separate experiments with one replicate in each experimental group. Data 
expressed as fold increase over media control ± s.d.
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3.4.5. FXa stimulates thrombospondin-1 (TSP-1) expression at the mRNA an d  
protein level
The activation of TGF-p involves the conversion of the latent precursor to its 
biologically active form through interaction with the latency associate peptide (LAP) 
(see Introduction Section 1.6.3.). Several activation mechanisms have been described, 
including activation by integrin-dependent mechanisms as well as interaction of the 
LAP with TSP-1 . PARi activation is a strong inducer of TSP-1 expression in endothelial 
cells (Riewald and Ruf, 2005). To begin to examine if TSP-1 mediates activation of 
latent TGF-p by FXa, first the effect of FXa stimulation on TSP-1 expression in pHALFs 
was examined at the mRNA as well as at the protein level.
pHALFs were grown to sub-confluency in 6 -well plates and exposed to a single dose of 
FXa (1 0 nM) in serum-free conditions. TSP-1 mRNA levels were determined from 
3hours up to 48hours by real time RT-PCR. As shown in Figure 3.36., FXa stimulated 
fibroblast TSP-1 expression significantly from 3 hours onwards (3.74±1.19-fold). 
Control fibroblasts, treated with DMEM only, showed no significant increase in TSP - 1  
mRNA levels over time.
To determine the effect of FXa (10nm) on TSP-1 protein levels, pHALFs were exposed 
to a single dose of FXa in serum-free DMEM and TSP-1 protein in whole cell layer 
extracts was measured by western blotting, from 3 up to 24 hours. Figure 3.37. shows 
a representative experiment for the effect of FXa on fibroblast TSP-1 protein levels. 
The TSP-1 antibody recognized a faint 170-kDa band in unstimulated pHALFs. The 
intensity of this band was highly increased in cells exposed to FXa. Densitometric 
analysis of the protein bands revealed that FXa stimulated fibroblast TSP-1 protein 
levels significantly from 3hours onwards (5.93± 0.85-fold at 3 hours). Control fibroblasts 
treated with DMEM, showed no significant increase in TSP-1 protein over time. This 
time course was reminiscent of that observed for TSP-1 mRNA levels following FXa 
stimulation. These data show that FXa stimulates TSP-1 expression in pHALFs at both 
the mRNA and at the protein level.
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Figure 3.36. Effect of FXa stimulation on TSP-1 mRNA levels
Figure shows the effect of FXa (10nM) stimulation on TSP-1 mRNA levels in pHALFs over time, 
up to 48 hours. TSP-1 mRNA levels were determined by real- time RT-PCR. Representative 
figure of three separate experiments performed with three replicates in each experimental 
group. Data expressed as fold increase over media control ± s.d relative to time 0 
hours.*and**and***and****andf andtf p<0 .0 0 1
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Figure 3.37. Effect o f FXa on TSP-1 protein level in p H A L F s
FXa increased TSP-1 protein levels with the earliest detectable signal observed 3 hours 
following FXa stimulation. (A) TSP-1 protein was detected using an anti-TSP-1 antibody and 
blots were then stripped and reprobed with total ERK2 as protein loading control. (B) The 
relative increase in TSP-1 protein levels normalised to total ERK2 protein levels was determined 
by semi-quantitative densitometry. Representative experiment for three separate experiments 
performed. All data represented as mean fold increase over media control ± s.d relative to 
control at time 3 hours. *and **and ***p<0.001
151
Chapter 3 Results
3.4.6. PARi mediates TGF-p activation in a TSP-1-dependent manner
TSP-1 activates TGF-p by interacting with the LSKL region of LAP (reviewed in (Young 
and Murphy-Ullrich, 2004)). This interaction can be inhibited by synthetic peptides 
corresponding to the LSKL region of LAP (Ribeiro et al, 1999). To investigate the role 
of TSP-1 in mediating PAR!-dependent activation of TGF-p, the effect of LSKL 
peptides and the scrambled peptide control SLLK on TFLLR-NH2-mediated TGF-p 
activation was explored by using the tMLEC assay.
As seen in Figure 3.38. pre-incubation of pHALFs/tMLEC co-cultures with LSKL for 15 
minutes blocked the TFLLR-NH2 -induced increase in luciferase activity by 117%± 12.5. 
In contrast, the control peptide SLLK exerted no effect on TFLLR-NH2-induced TGF-p 
activation. This study demonstrates that TFLLR-NH2-mediated activation of TGF-p is 
TSP-1 dependent.
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Figure 3.38. Effect of TSP-1 blocking peptide on TFLLR-NH2-induced TGF-p activation.
Graph showing active TGF-p levels post PARi stimulation in the presence of LSKL and SLLK 
measured using a tMLEC-fibroblast co-culture system (1:1) where fibroblast-derived active 
TGF-p is detected as an increase in luciferase activity by tMLEC expressing luciferase under 
the control of the TGF-p-responsive PAI-1 promoter. *and **p<0.001
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3.4.7. FXa-induced a-SMA expression is dependent on TGF-p activity
To answer the question of whether FXa-stimulated a-SMA expression was dependent 
on TGF-p activity, the influence of two pharmacologically unrelated selective small 
molecule inhibitors of the TGF-p type 1 receptor kinase (ALK5) were investigated. Both 
compounds, SB431542 and SD-208 have previously been shown to inhibit TGF-p 
induced myofibroblast differentiation (Mori et al, 2004;Kapoun et al, 2006).
Pre-incubation of pHALFs with SB431542 and SD-208 for 30 minutes prior to 
stimulation with FXa reduced a-SMA protein levels in a concentration-dependent 
manner Figures 3.39. and 3.40.). At the highest concentrations of SB431542 (10|iM) 
and SD-208 (0.1 pM), a-SMA protein levels were blocked by about 95% and 99% 
respectively. At these concentrations, neither inhibitor influenced baseline expression 
of a-SMA but fully blocked a-SMA protein levels induced by 1ng/ml of exogenous TGF- 
p (Figures 3.41. and 3.42.). These data confirm that FXa exerts its stimulatory effect 
on a-SMA expression via a TGF-p-dependent mechanism.
3.4.8. PAR1} a-SMA and TSP-1 coiocalise in human fibrotic lesions
The data presented here support the conclusion that FXa is a potent inducer of 
fibroblast to myofibroblast differentiation via TSP-1-mediated activation of TGF-p. To 
further explore the possibility that this mechanism might be operative in human fibrotic 
lung disease, PARi, TSP-1 and a-SMA immunoreactivity was assessed in serial 
sections from human IPF lung tissue (Brompton cohort).
Figure 3.43. A-D shows that all three proteins were highly expressed within the fibrotic 
foci of these lung sections. PAFh and a-SMA were co-localised on numerous cells with 
a typical spindle-shaped myofibroblast appearance; whereas TSP-1 was localized to 
these cells as well as the matrix. The hyperplastic epithelium overlying fibrotic foci was 
completely negative for TSP-1.
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Figure 3.39. Effect o f inhibition o f ALK5 activity with SB431542 on FXa-induced a-SMA  
expression.
( A )  SB431542 did not affect baseline a-SMA protein levels at any concentration. ( B )  SB431542 
attenuated FXa-induced a-SMA protein levels in a concentration-dependent manner. a-SMA 
was detected using an anti-a-SMA antibody and blots were then stripped and reprobed with 
total ERK2 as protein loading control. (C) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. Q94 
blocked up to 95% of FXa induced a-SMA protein levels at its highest concentration. The same 
control samples were used within the same experiment to allow for normalisation between blots. 
Representative experiment for three separate experiments performed. All data represented as 
mean fold increase over media control ± s.d. *and **and ***p<0 .0 0 1
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Figure 3.40. Effect o f inhibition of ALK5 activity with SD-208 on FXa-induced a-SM A  
expression.
(A) SD-208 did not affect baseline a-SMA protein levels at any concentration. (B) SD-208 
attenuated FXa-induced a-SMA protein levels in a concentration-dependent manner. a-SMA 
was detected using an anti-a-SMA antibody and blots were then stripped and reprobed with 
total ERK2 as protein loading control. (C) The relative increase in a-SMA protein levels 
normalised to total ERK2 protein levels was determined by semi-quantitative densitometry. SD- 
208 blocked over 98% of FXa induced a-SMA protein levels at its highest concentration. The 
same control samples were used within the same experiment to allow for normalisation between 
blots. Representative experiment for three separate experiments performed. All data All data 
represented as mean fold increase over media control ± s.d. *p<0 .0 0 1
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Figure 3.41. Effect o f  inh ib ition  o f ALK5 activity with SB431542 on TGF-p-induced a-SMA  
expression.
(A) SB431542 attenuated TGF-p-induced a-SMA protein levels in a concentration-dependent 
manner. a-SMA was detected using an anti-a-SMA antibody and blots were then stripped and 
reprobed with total ERK2 as protein loading control. (B) The relative increase in a-SMA protein 
levels normalised to total ERK2 protein levels was determined by semi-quantitative 
densitometry. The effect of SB431542 on baseline a-SMA protein is shown in Figure 3.38 (A). 
The same control samples were used within the same experiment to allow for normalisation 
between blots. All data shown is representative of three separate experiments and shown as 
mean fold increase ± s.d., based on three replicates in each experimental group *and 
**and***p<0.001, ****p=0.021
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Figure 3.42. Effect o f inhibition of ALK5 activity with SD-208 on TGF-p-induced a-SMA  
expression.
(A) SD-208 attenuated TGF-p-induced a-SMA protein levels in a concentration-dependent 
manner. a-SMA was detected using an anti-a-SMA antibody and blots were then stripped and 
reprobed with total ERK2  as protein loading control. Lines indicate that protein bands were not 
positioned directly adjacent to each other on the blot. (B) The relative increase in a-SMA protein 
levels normalised to total ERK2 protein levels was determined by semi-quantitative 
densitometry. Graph showing effect of SD-208 on baseline a-SMA protein is shown in Figure 
3.5 (A). The same control samples were used within the same experiment to allow for 
normalisation between blots. All data shown is representative of three separate experiments 
and shown as mean fold increase ± s.d., based on three replicates in each experimental group 
*and **and***p<0.001
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Figure 3.43. Im m unohistochem icat localisation of PAR1t TSP-1 and a-SMA in IPF
Photomicrographs of representative 3pm serial histological sections showing immunoreactivity 
for PARt (A), TSP-1 (B), and a-SMA (C) in human IPF fibrotic foci. Spindle-shaped (myo) 
fibroblast-like cells co-localise for a-SMA, PAR, and TSP-1 (black arrows). IgG isotype control 
section showed no apparent staining (D). Scale bars, 100pm.
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3.4.9. Summary
The results described in this section examining the role of TGF-p in FXa-mediated 
myofibroblast differentiation showed:
• FXa stimulates TGF-p activity but does not regulate TGF-p production at least 
at the mRNA level.
• The PARi-activating peptide TFLLR-NH2 induces activation of latent TGF-p
• FXa stimulates TSP-1 expression at the mRNA and protein level
• PARr mediated activation of latent TGF-p is dependent on TSP-1
• FXa-induced a-SMA expression is dependent on TGF-p activity
• PARt, a-SMA and TSP-1 colocalise in human fibrotic lung tissue
In summary, these studies demonstrate that FXa is a potent inducer of the 
myofibroblast differentiation programme via the upregulation of TSP-1 and subsequent 
activation of latent TGF-p.
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3.5. Effect of the direct FXa inhibitor ZK 807834 on FXa-induced pro- 
fibrotic effects in vitro and in vivo
3.5.1. Introduction
The final aim of this study was to examine the potential contribution of FXa to the 
development of lung fibrosis by evaluating its profibrotic role in the bleomycin model of 
lung injury and fibrosis- a model that has previously been shown to be dependent on 
PAFh signalling by our host laboratory(Howell et al, 2005). To this end the effect of the 
direct FXa inhibitor, ZK 807834 was assessed in this animal model. This compound is 
a direct inhibitor of FXa and can inactivate both free FXa and FXa that is complexed 
with either TF/FVIIa, or FVa (the prothrombinase complex) (Phillips et al, 1998). These 
FXa conformations are relevant in the extravascular space, in particular the potent 
TF/FVIIa/FXa kinase signalling complex (Ruf et al, 2003). ZK807834 was therefore 
chosen to give the best possible chance of attenuating FXa activity in the bleomycin 
model of lung injury and fibrosis.
3.5.2. Effect of ZK 807834 on myofibroblast differentiation by FXa
The work in this thesis and previous work in our laboratory have demonstrated that 
FXa is a potent inducer of fibroblast to myofibroblast differentiation and proliferation 
(Blanc-Brude et al, 2005). In order to confirm the efficacy of ZK 807834 in blocking FXa 
signalling, the effect of this compound was initially evaluated against these FXa- 
induced fibroblast responses in vitro. Myofibroblast differentiation was measured by 
western blotting for a-SMA protein as described in Results Section 3.2.. Fibroblast 
proliferation was measured using the methylene blue assay, a spectrophotometric 
assay based on uptake and subsequent elusion of the dye methylene blue, according 
to the method described by (Oliver et al, 1989) (see Methods Section 2.22.).
Figure 3.44. shows a representative experiment for the effect of ZK 807834 on FXa- 
induced a-SMA expression. Prior to addition to cell cultures, ZK 807834 was 
preincubated at a range of concentrations (10nM-1pM) with a single dose of FXa 
(10nM) in serum- free DMEM for 60 minutes at 37 °C. To examine the effects of FXa 
alone, the protease was similarly preincubated in serum-free DMEM supplemented 
with equal concentrations of the ZK 807834 diluent at equal pH. In the experiment 
presented, exposure of pHALFs to FXa for 36hours in serum-free conditions induced a- 
SMA protein levels by 4.73-fold ± 0.87 relative to media control cells.
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Figure 3.44. Effect o f Z K  807834 on FXa-induced a-SMA expression
(A) ZK 807834 had no effect on baseline a-SMA protein levels. (B) ZK 807834 attenuated FXa- 
induced a-SMA protein levels in a concentration-dependent manner. a-SMA protein was 
detected using an anti-a-SMA antibody and blots were then stripped and reprobed with total 
ERK2 as protein loading control. (C) The relative increase in a-SMA protein levels normalised to 
total ERK2 protein levels was determined by semi-quantitative densitometry. The same control 
samples were used within the same experiment to allow for normalisation between blots. All 
data shown is representative of three separate experiments and shown as mean fold increase ± 
s.d., based on three replicates in each experimental group, *and **p<0 .0 0 1  ,***p=0 . 0 1 1
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This response was inhibited by ZK 807834 in a concentration-dependent manner from 
equimolar concentrations onwards and was completely blocked when ZK 807834 was 
added in 10-fold excess (10pM). ZK 807834 had no effect on basal fibroblast a-SMA 
protein levels up to its highest concentration.
Figure 3.45. shows a representative experiment for the effect of ZK 807834 on pHALF 
proliferation in response to FXa as measured by the methylene blue colorimetric assay. 
FXa induced fibroblast proliferation by 1.52±0.04-fold relative to media control cells, in 
serum-free conditions as assessed after 48 hours. FXa-induced proliferation was 
inhibited by ZK 807834 in a concentration-dependent manner from equimolar 
concentrations onwards (10 nM) and was completely blocked when ZK 807834 was 
added in 10-fold excess (1.52±0.04-versus 0.99±0.02-fold respectively). In addition, ZK 
807834 had no effect on basal fibroblast proliferation at any concentration.
These in vitro studies demonstrate that ZK 807834 blocks FXa-induced a-SMA 
expression and proliferation in fibroblasts, confirming earlier reports that this compound 
is capable of inhibiting FXa signalling (McLean et al, 2001).
FXa - -
ZK 807834(nM) 0 0.01 0.3 1
Figure 3.45. Effect of ZK 807834 on FXa-induced fibroblast proliferation in vitro
Figure shows the effect of the selective FXa inhibitor ZK 807834 on FXa-induced fibroblast 
proliferation as measured using the methylene blue colorimetric assay. All data shown is 
representative of three separate experiments and expressed as mean fold increase ± s.d., 
based on six replicates in each experimental group‘and “ and ***p<0 .0 0 0 1
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3.5.3. Effect of ZK 807834 on bleomycin-induced lung injury and fibrosis
Having confirmed the efficacy of ZK 807834 in blocking FXa-mediated fibroblast 
responses in vitro, the effect of this compound was evaluated in the bleomycin model 
of lung injury and fibrosis. Given the chronic nature of FXa generation following 
bleomycin administration, a daily dosing regime was chosen based on the 
pharmacokinetic data provided by Berlex, indicating that a circulating concentration of 
ZK 807834 above 2pM was sufficient to double the prothrombin time in C57BI/6J mice. 
Twenty-four hours post-bleomycin, administration of ZK 807834 (50mg/kg in acidified 
saline) or vehicle was started, by intraperitoneal injection twice a day in the first week 
and once a day in the second week until the end of the experiment.
Figure 3.46. shows the effect of intraperitoneal ZK 807834 on mouse body weight 
following administration of bleomycin or saline over a 14 day period. All animals given 
bleomycin showed a characteristic decrease in body weight compared to control 
animals treated with saline from days 5 onwards. In addition, animals in the saline/ZK 
807834 group had a significant decrease in body weight compared to mice in the 
saline/vehicle group at days 8  to 11. In terms of animal survival, three mice in the 
saline/ZK807834 group (originally n=6 ) and three mice in the bleomycin/ZK807834 
group (originally n=9) were sacrificed due to intraperitoneal hemorrhage. This, 
however, was thought to arise from the tissue damage caused by the administration of 
multiple intraperitoneal injections.
Figure 3.47. shows that daily i.p. injection of mice with this compound from 24hrs 
following bleomycin injury, led to a significant attenuation in lung collagen accumulation 
at 14 days. Total lung collagen was increased by 60% in bleomycin-injured mice 
compared with saline-instilled control animals. This increase was significantly reduced 
to only 27% in bleomycin-injured mice given ZK 807834. These data confirm the 
importance of FXa in driving the fibrotic response in this mouse model.
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Figure 3.46. E ffect o f ZK 807834 on mouse body weight in bleomycin-induced lung injury 
and fibrosis
Figure shows the effect of ZK 807834 (50mg/kg) on mouse body weight following a single 
instillation of bleomycin (1  mg/kg body weight) by oropharyngeal administration, or saline. 
Results are expressed as mean change in body weight as a percentage of the starting weight,
*p<0 .0 0 1 .
i.p. ZK 807834 
or Vehicle once daily
i.p. ZK 807834 
or Vehicle twice daily
-■-Saline vehicle 
Saline ZK 807834 
-x-Bleo vehicle 
-*~Bleo ZK 807834
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Figure 3.47. Effect o f ZK 807834 on lung collagen accumulation in bleomycin-induced 
lung injury and fibrosis
Figure shows the effect of daily i.p injections of ZK 807834 on lung collagen accumulation 14 
days following a single oropharyngeal instillation of bleomycin (1 mg/kg). Lung collagen was 
measured by reverse phase HPLC quantitation of lung hydroxyproline in acid hydrolysates of 
pulverized lung. Total amount of collagen in each lung was calculated assuming that lung 
collagen contains 12 .2%  w/w hydroxyproline (see Method Section 2.9.) Data represent the 
mean ± s.e.m of values obtained in groups of six (saline vehicle and bleomycin ZK 807834), 
three (saline ZK 807834) or seven (bleomycin vehicle) mice. *p=0.021,**p<0.001
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3.5.4. Effect of oropharyngeal instillation of ZK 807834 in bleomycin-induced 
lung injury and fibrosis
In order to assess the effect of localised inhibition of FXa on bleomycin-induced lung 
injury and fibrosis a site-targeted route of administration in the form of oropharyngeal 
instillations of ZK 807834 was chosen. It was felt that this route of administration would 
allow targeting of extravascular FXa activity whilst minimising systemic effects of 
anticoagulation.
Twenty-four hours post-bleomycin (single dose 1 mg/kg), administration of ZK 807834 
(50mg/kg in acidified saline, at the same dose that significantly attenuated lung 
collagen accumulation with multiple i.p. injections) or vehicle was started, by once daily 
oropharyngeal instillation in 50pl of acidified saline at pH 5.
Figure 3.48. shows representative images of histological sections of mice lungs treated 
with or without ZK 807834 taken from animals. About 70% of animals in the ZK 
807834/bleomycin and ZK 807834/saline group died of extensive intrapulmonary 
haemorrhage (B and D). As a result, in the next set of experiments, a 5-fold lower 
concentration of ZK 807834 was administered (10mg/kg) by daily oropharyngeal 
instillation. Figure 3.49. shows the effect on lung collagen accumulation at 14 days. ZK 
807834 administered oropharyngeally failed to attenuate the increase in total lung 
collagen, suggesting that this dose of anticoagulation may not have been sufficiently 
high to block FXa signalling.
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Figure 3.48. The effect of oropharyngeal instillation of ZK  807834 on lung histopathology 
in bleom ycin-induced lung injury and fibrosis
Representative images showing histological sections of lung tissue taken from mice challenged 
with bleomycin or saline and treated daily ZK 807834 or vehicle, stained with haematoxylin and 
eosin to assess histopathological changes. Lung architecture was normal in mice challenged 
with saline. Extensive patchy fibrotic foci were detected in the lungs of mice challenge with 
bleomycin at 14 days. Extensive haemorrhagic lesions (black arrows) were observed in the 
lungs of mice treated with ZK 807834 both in saline and bleomycin group. Histopathological 
pattern was assessed by three independent reviewers (n= 3 mice in ZK 807834 and saline 
group, n=3 mice in ZK 807834 and bleomycin group, n= 6  in saline and vehicle and bleomycin 
and vehicle group). Scale bars 100pm.
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Figure 3.49. Effect of administration of ZK 807834 by oropharyngeal instillation in 
bleomycin-induced lung injury and fibrosis
Figure shows the effect of daily oropharyngeal instillation of ZK 807834 (10mg/kg) on lung 
collagen accumulation 14 days following a single oropharyngeal instillation of bleomycin 
(1 mg/kg). Lung collagen was measured by reverse phase HPLC quantitation of lung 
hydroxyproline in acid hydrolysates of pulverized lung. Total amount of collagen in each lung 
was calculated assuming that lung collagen contains 12.2% w/w hydroxyproline (see Methods 
Section 2.9.) Data represent the mean ± s.e.m of values obtained in six mice per group.
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3.5.5. Summary
The results described in this chapter examine the effect of ZK 807834 on bleomycin- 
induced lung injury and fibrosis
- The direct FXa inhibitor ZK 807834 significantly blocks FXa-induced fibroblast 
to myofibroblast differentiation and proliferation in a concentration-dependent 
manner.
Intraperitoneal injection of the direct FXa inhibitor ZK 807834 significantly 
attenuated lung collagen accumulation in bleomycin-induced lung injury and 
fibrosis, at 14 days.
- Oropharyngeal administration of the direct FXa inhibitor ZK 807834, caused 
extensive hemorrhagic lesions in bleomycin-induced lung injury and fibrosis, at 
14 days.
- Oropharyngeal administration of the direct FXa inhibitor ZK 807834, 
administered at a 5-fold lower dose had no effect on lung collagen accumulation 
in the bleomycin-induced lung injury and fibrosis, at 14 days.
169
Chapter 4 Discussion
Chapter 4: Discussion
Overview
Differentiation of fibroblasts into highly synthetic and contractile, a-SMA expressing 
myofibroblasts plays a central role in the fibrotic response to lung injury. A number of 
human fibroproliferative disorders, including IPF are associated with uncontrolled 
activation of the coagulation cascade, with extravascular expression of TF leading to 
the activation of coagulation proteinases including FVII, FX and prothrombin 
(Hernandez Rodriguez et al, 1995;ldell, 2003;Gunther et al, 2003). Coagulation 
proteinases induce multiple pro-inflammatory and pro-fibrotic cellular effects via the 
activation of their major signalling receptors the PARs, including PAR!. In vivo PAR! 
deficient- mice are partially protected from acute inflammation and subsequent chronic 
fibrosis following bleomycin-induced lung injury (Howell et al, 2005).
Until recently, coagulation zymogens were thought to be mainly derived from the 
circulation and locally activated in response to tissue injury. However, global 
expression profiling studies performed in our laboratory revealed that the zymogen FX 
is locally upregulated in the murine lung in response to bleomycin-induced lung injury 
suggesting that this proteinase may play a central role in promoting fibrogenesis. This 
thesis therefore examined the hypothesis that FX/FXa is locally expressed in the 
fibrotic lung and contributes to the development of pulmonary fibrosis by 
influencing fibroblast function.
To address this hypothesis, the initial experiments of this thesis employed real time RT- 
PCR analysis and immunohistochemistry to examine FX gene and protein expression 
in the bleomycin model of lung injury and fibrosis. These studies confirmed that FX is 
locally upregulated following experimentally-induced lung injury. In terms of human 
disease relevance, this finding was confirmed by laser-capture microdissection of 
alveolar septae and immunohistochemistry of lung biopsy material from patients with 
IPF across three separate patient cohorts. These studies further identified the alveolar 
and bronchial epithelium as a prominent cellular source of FX in the fibrotic lung. In 
addition, this thesis reports for the first time that FXa is a potent inducer of the 
myofibroblast differentiation programme. PARi was identified as the major FXa 
signalling receptor involved in mediating this response via the transcriptional 
upregulation of the matricellular protein thrombospondin-1 (TSP-1) and the subsequent 
activation of the potent pro-fibrotic mediator, TGF-pi. Finally, the role of FXa in the 
development of lung fibrosis in vivo was examined using a direct inhibitor of FXa in the
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bleomycin model of lung injury and fibrosis, ZK 807834. These studies show that lung 
fibrosis in mice treated daily with this inhibitor from 24 hours after the initial insult was 
significantly reduced.
In summary, these data support the notion that FXa, a central proteinase of the 
coagulation pathway, is locally produced in the injured lung and represents a novel 
pathogenic factor that drives the fibrotic response to lung injury. The following sections 
will discuss these findings and their implications in more detail.
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4.1. Local FX generation in the lung
4.1.1. FX is expressed locally in the lung and is upregulated in fibrosis
The observation that the gene encoding FX is expressed and upregulated in the injured 
lung was initially made by Drs Scotton and Lee by microarray analysis of lung RNA 
from bleomycin-injured mice. Although this was not the first study to publish 
transcriptional profiling data in this model, the data produced was extensive in that the 
Affymetrix genechips contained probe sets representing approximately 14000 genes. 
As expected, for the fibrotic phase of the response to bleomycin, the upregulation of 
genes encoding proteins such as collagen I, III, IV and fibronectin was identified. Gene 
ontology data mining classified these genes into gene families which are implicated in 
fibrosis, such as “mesenchymal cell differentiation” and found that in the group of 
genes classified as genes involved in the ‘wound healing response’, FX was one of the 
most highly upregulated genes post-bleomycin injury.
Microarray analysis has revolutionized the field of molecular biology, allowing for the 
detection of the expression pattern of thousands of genes and their interactions 
simultaneously. However, this novel technology is a large-scale approach which 
therefore requires quantitative and qualitative validation. In addition, due to financial 
limitations, microarray studies are often performed with a limited number of replicates, 
such as in our study which examined 3 mice per experimental group only. The initial 
experiments of this thesis therefore employed quantitative real-time RT-PCR to 
investigate the reproducibility of the results obtained by microarray analysis. To this 
end, FX gene expression of whole lung homogenates was measured in two mouse 
models of bleomycin-induced lung injury and fibrosis. The first was induced by 
oropharyngeal (OP) bleomycin instillation whereas the second was induced by 
aerosolised administration (AS) of bleomycin (see Methods Section 2.6.) for more 
detailed description of the individual models). These methods of administration were 
preferentially chosen over the traditional method of intratracheal (IT) challenge of 
bleomycin which was used for all microarray studies. Whilst all models appear to have 
identical increases in total lung collagen 14 days post-bleomycin challenge, the 
distribution of fibrotic foci as observed histologically is different in the OP and AS 
models compared to the IT model. Localised lesions which do not appear to extend into 
the distal parenchyma can be observed following IT instillation; in contrast, OP and AS 
instillation results in a more diffuse pathology with multiple fibrotic foci distributed 
throughout the lung parenchyma, reminiscent of human fibrotic lung disease. In 
addition, these models were found to be more practical and less distressing to the mice
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because they do not require deep anaesthesia and surgery compared to the traditional 
route of administration.
The studies performed in our and Dr Eickelberg’s laboratories confirmed that FX was 
expressed in the murine lung at the mRNA level and was highly upregulated in 
response to bleomycin injury. Subsequent immunohistochemical analysis of tissue 
sections demonstrated strong immunoreactivity for FX/FXa associated with the 
bronchial and alveolar epithelium, as well as macrophages and spindle-shaped 
(myo)fibroblasts within fibrotic foci. In terms of the potential relevance of these findings 
to human fibrotic lung disease, FX was also expressed in lung biopsy transplant tissue 
from patients with pulmonary fibrosis by real time RT-PCR. Analysis of FX mRNA 
levels in total lung homogenates did not reveal upregulation of FX mRNA levels in 
human fibrotic lung tissue. However, laser-capture microdissection of alveolar septae 
demonstrated marked upregulation of FX mRNA levels in IPF patients compared with 
control lung. Immunohistochemical analysis of FX/FXa protein localisation further 
showed consistent immunoreactivity of FX/FXa associated with the bronchial and 
alveolar epithelium, macrophages and fibrotic foci, in biopsy tissue samples from 18 
patients with UIP which were derived from independent cohorts in the USA and the UK. 
In summary, these results provide compelling evidence that the zymogen FX is made 
locally in the fibrotic lung.
Until recently, it was generally held that coagulation zymogens are largely synthesised 
in the liver (Greenberg et al, 1995;Hung and High, 1996). Although FX expression at 
the mRNA level has been reported in other tissues (Wilcox et al, 2003), the expression 
levels are very low compared with those in the liver. In contrast, several in vitro studies 
suggest that coagulation zymogen FVII may be synthesised extrahepatically. For 
example, FVII expression has been documented in monocytes/ macrophages isolated 
from patient lungs with interstitial lung disease (Chapman, Jr. et al, 1985) and following 
LPS stimulation (Tsao et al, 1984). Similarly, ovarian cancer cells are also capable of 
synthesising FVII in vitro (Koizume et al, 2006). in vivo, FVII mRNA has been detected 
in human smooth muscle cells and macrophages in atherosclerotic lesions by in situ 
hybridisation (Wilcox et al, 2003). In contrast, evidence for an extrahepatic source of 
FX is inconclusive. A recent study published during the course of this PhD suggested 
that infiltrating macrophages may express FX in an experimental model of asthma 
(Shinagawa et al, 2007). However, this study showed that local resident lung cells did 
not synthesise the zymogen. The work presented in this thesis is therefore the first to 
report that FX is synthesised locally in the murine and human lung and that its
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expression is increased in experimental and human fibrotic lung disease. This finding 
supports the notion that in pathological states, other organs besides the liver are 
capable of expressing coagulation zymogens such as FX.
4.1.2. Alveolar epithelial cells produce FX
Having made the observation that FX expression was increased in the fibrotic lung, 
studies were undertaken to identify the cellular source responsible for the synthesis of 
this zymogen. Initial observations by immunohistochemistry of tissue sections taken 
from saline and bleomycin-treated mouse lungs showed a much localised staining 
pattern of FX/FXa which was mainly associated with bronchial epithelial cells in saline- 
treated animals and with the bronchial and alveolar epithelium, as well as 
macrophages and myofibroblasts within fibrotic foci in bleomycin-injured lungs. This 
immunohistochemical pattern was found to be identical for biopsy tissue samples from 
patients with UIP which were derived from independent cohorts in the USA (n=18) and 
the UK (n=6 ). Although these immunohistochemical studies did not necessarily reveal 
which cells are responsible for the production of FX, but rather where it might be 
accumulating, the staining pattern was particularly cell-associated in alveolar epithelial 
cells overlying fibrotic regions, suggesting that these cells may represent a local source 
of FX production.
To answer this question more precisely, a recently developed laser-capture 
microdissection technique was applied to human donor and IPF lung tissue, in order to 
specifically sample the alveolar epithelial cell population (alveolar septae) from the 
alveolar compartment. Subsequent real-time RT-PCR was used for quantitative 
analysis of gene expression. Compared with other methods of gene expression 
analysis such as in situ hybridisation, this method allows quantification of mRNA 
changes in a sensitive and reliable manner (Fink et al, 1998;Fink et al, 2000b;Fink et 
al, 2000a). Prior to laser-capture microdissection, alveolar epithelial cells were 
identified by cell-specific immunostaining allowing for a more precise identification of 
type II alveolar epithelial cells compared to conventional identification by morphological 
inspection only (Fink et al, 2000a;Fink et al, 2000b). These studies revealed that FX 
gene expression was highly upregulated (5-fold induction) in alveolar septae from 
patients with IPF compared to donor lung. Further in vitro analysis of FX expression 
confirmed these observations, as alveolar and bronchial epithelial cell lines in culture 
expressed FX at the mRNA and at the protein levels. These data suggest that alveolar 
epithelial cells represent a prominent source of FX expression/production in human 
fibrotic lung disease. These studies lend further support to the notion that alveolar
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epithelial cells may represent a prominent source of pro-inflammatory and pro-fibrotic 
mediators and thus play a key role in driving the fibrotic response to lung injury (Kasper 
and Haroske, 1996;Selman and Pardo, 2006).
Of interest, the upregulation in FX expression was not detectable using mRNA derived 
from total lung homogenates of the same donor and IPF lungs as used for laser 
capture microdissection studies. This result contrasts the findings obtained in the 
murine model of lung injury and fibrosis where a significant increase in FX expression 
was observed in whole lung homogenates. The difference in these findings may be 
explained by the difference in stages of disease pathology between both murine and 
human samples and by the heterogeneity of the human samples. In contrast to the 
murine samples which were all collected at single time points and from a genetically 
identical group of mice, human samples are much more varied, both in terms of the 
timing of the biopsy and the mixed genetic background of the patient groups so that a 
larger number of patient samples may be needed. Furthermore, the signal for FX 
expression may be diluted out by sampling total lung tissue so that the signal to noise 
ratio is too low when sampling total lung homogenates. In contrast, a statistically robust 
increase in FX gene expression was clearly discernable for IPF patients (n=5) when 
sampling the lung epithelium by laser-capture microdissection.
Analysis of fibroblasts isolated and then cultured from mouse lungs post-bleomycin 
injury showed a significant upregulation in FX mRNA levels compared to fibroblasts 
grown from saline-treated lungs. Although this finding was not replicated in human 
cultured fibroblasts, as mentioned above, samples used in this study only provide a 
single snapshot of the whole disease process in a heterogeneous group of patients at 
various stages of disease, so that an increase in FX gene expression may have been 
missed. Evidence that fibroblasts represent another prominent source of FX was 
provided by immunohistochemical studies which showed that myo(fibroblasts) in 
fibrotic foci stained positively for FX/FXa in human fibrotic lung samples. Further 
studies are clearly needed, possibly involving microdissected fibroblast samples as 
these will be more representative of the cell gene expression pattern in vivo than cells 
isolated from tissue and subsequently cultured in vitro and may thus have altered their 
expression pattern in culture. The observations that fibroblasts may synthesise FX are 
particularly interesting in light of the important role fibroblasts play as effector cells of 
coagulation signalling (Chambers et al, 1998;Chambers et al, 2000), which may thus 
represent an autocrine loop for FXa-driven effects.
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4.1.3. The lung is capable of generating the mature form of FX
To investigate if cultured alveolar epithelial cells are capable of producing the mature 
form of FX, this thesis compared FX protein derived from alveolar epithelial cells to that 
produced by hepatocytes by western blotting. In hepatocytes, the newly synthesised 
single-chain FX precursor translocates to the endoplasmic reticulum as a pre-pro­
protein, where the prepeptide signal is cleaved by a signal peptidase (Wallin and 
Turner, 1990). The remaining propeptide directs subsequent y-carboxylation by the 
vitamin K-dependant y-carboxylase which converts 1 0 - 1 2  glutamic acid residues in the 
N-terminus part of the protein into y-carboxyglutamic acid (Gla) residues, an essential 
modification to ensure optimal activation of the zymogen once secreted (Furie and 
Furie, 1988). Finally, the single chain protein is cleaved into a double chain by an as 
yet unknown mechanism (Stanton and Wallin, 1992); Consistent with this mode of 
synthesis, the protein produced by these epithelial cell lines migrated as three bands of 
74, 70 and 42 kDa, corresponding to the two single chain precursors and the heavy 
chain of the mature protein, respectively and in an identical fashion to that observed for 
the hepatocyte cell line HepG2 (Furie and Furie, 1988). In addition, the band pattern on 
western blotting of alveolar epithelial cells was consistent with the posttranslational 
processing observed for hepatocytes (Stanton and Wallin, 1992), which are classically 
viewed as the main cellular source of this zymogen. Interestingly, genechip studies 
performed in our laboratory further revealed that the enzymes y-carboxylase (essential 
for y-carboxylation of the zymogen) (Furie and Furie, 1988) and Vitamin K epoxide 
reductase (essential for the reduction of Vitamin K after it has been oxidized in the 
carboxylation of glutamic acid (Rost et al, 2004)) are expressed in the lung (data 
generated by Dr Scotton). Taken together, these data led to the conclusion that the 
lung epithelium has the capacity to synthesize the mature two-chain FX zymogen and 
represents an important cellular source of this zymogen in the fibrotic lung.
4.1.4. Potential mechanisms leading to increased expression of FX in pulmonary 
fibrosis
To begin to unravel the possible mechanisms that mediate local FX expression in the 
injured lung, initial in vitro experiments were performed to explore the influence of 
different stimuli on FX expression by alveolar epithelial cells. These experiments were 
performed on the epithelial cell line A549, which despite its pathological origin 
expresses all of the important markers of this cell type and is widely accepted and used 
as a model cell to study alveolar epithelial cell biology (Lieber et al, 1976). Initial 
experiments tested the effect of TGF-p! and TNF-a on FX expression. Both cytokines 
have been implicated in the development and progression of pulmonary fibrosis (see
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Introduction Section 1.3.) and have previously been shown to upregulate TF 
expression by fibroblasts and epithelial cells (Idell et al, 1994). However, no stimulus- 
dependent variation in FX mRNA expression was observed with these mediators. In 
contrast, in vitro stimulation of A549 cells with bleomycin increased FX mRNA levels in 
a time-dependent manner at concentrations of the compound that have previously 
been shown to induce the release of pro-inflammatory mediators including CCL-2 by 
these cells (Sato et al, 1999). Bleomycin is a highly toxic molecule which is widely used 
to induce pulmonary fibrosis in rodents (reviewed in (Chua et al, 2005)) but also causes 
pulmonary fibrosis in patients receiving bleomycin as a chemotherapeutic agent for 
certain neoplasms (Carver et al, 2007). The exact mechanism by which bleomycin 
influences cell function and often causes cell death remains unclear however it has 
been proposed that the production of reactive oxygen species (ROS) by way of a 
ferrous ion-molecular oxygen-mediated mechanism which may directly lead to DNA 
strand break may play a role (Manoury et al, 2005). There is increasing evidence that 
oxidative stress, defined as an imbalance between oxidants and antioxidants may 
contribute to the progression of fibrotic lung disease (Lenz et al, 1996;Rottoli et al, 
2005). For example, patients with IPF have been shown to have a redox imbalance 
with higher levels of oxidants (such as carbonylated proteins) and extracellular 
glutathione deficiency (Lenz et al, 1996;Behr et al, 2002). Reactive oxygen species are 
often secreted by inflammatory cells and fibroblasts and are thought to directly 
contribute to the pathogenesis of pulmonary fibrosis by mediating epithelial cell injury 
(Behr et al, 2 0 0 2 ;Lenz et al, 2004). Increased levels of ROS correlate with the degree 
of epithelial cell injury and importantly a recent trial examining the effect of the 
antioxidant A/-acetylcysteine showed a beneficial effect in slowing the progression of 
this disease (Kinnula et al, 2005). ROS mediated stress on alveolar epithelial cells may 
therefore represent a potential mechanism by which FX expression is induced in the 
fibrotic lung.
4.1.5. Activation of FX in the extravascular space
The work presented in this thesis supports the view that locally produced FX may be 
activated locally in the extravascular space. Activation of the zymogen FX can be 
catalysed by either FIXa/FVIIIa or by TF/FVIIa enzyme-cofactor complexes which both 
generate the identical FXa product, although it is generally believed that the TF/FVIIa 
complex plays a major role in the activation of FXa in the extravascular space, leading 
to the initiation of the extrinsic coagulation pathway (reviewed in (Idell, 2003), also see 
Introduction Section 1.7.1). Previous studies have shown that TF is constitutively 
expressed by alveolar macrophages, epithelial cells and fibroblasts in the normal
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murine lung (Olman et al, 1995). Importantly, these cells upregulate the expression of 
TF following tissue injury and inflammation and both fibroblasts and macrophages 
express higher levels of TF in developing fibroproliferative lesions of mouse lungs 
challenged with bleomycin (Olman et al, 1995). In terms of human fibrotic lung disease, 
TF is expressed by epithelial cells overlying fibrotic foci and to some extent by alveolar 
macrophages, in close association with fibrin deposits in the lungs of patients with IPF 
and systemic sclerosis (Imokawa et al, 1997) and in pulmonary fibrosis associated with 
chronic lung disease of prematurity (Dik et al, 2003b). Similarly, alveolar macrophages 
from patients with fibrotic lung disease have been shown to express FVIl in vitro 
(Chapman, Jr. et al, 1985). In studies presented in this thesis FX/FXa protein was 
immunolocalised to the bronchial and alveolar epithelium, fibroblasts and macrophages 
suggesting that FX localises to cells which express TF/FVII where FX is likely to be 
subsequently activated by the tenase complex.
Further evidence that locally generated FX is converted to FXa can be inferred from the 
timing for the increase in FX/FXa staining in the lungs of mice challenged with 
bleomycin. Bleomycin-induced lung injury is associated with epithelial and importantly 
endothelial damage causing an increase in endothelial permeability and vascular leak 
of plasma proteins into the alveolar space. This process is thought to peak early in the 
bleomycin model when inflammation is present (Howell et al, 2001). Whilst FX/FXa 
immunostaining was detected 7 days post-bleomycin challenge, the signal was 
dramatically increased in the later stages (14 days post-bleomycin instillation). 
Although, this does not exclude that FX may be leaking into the lung parenchyma as a 
result of microvascular leak, it is likely that local production of FX may play a major 
contributing role in the signal observed at 14 days. Furthermore, increased FXa activity 
was measured in the BALF obtained from mice challenged with bleomycin compared to 
saline-instilled animals. BALF is thought to predominantly sample the alveolar 
epithelium, thus suggesting that alveolar epithelial cell-derived FX may contribute to 
this pool of FX thus providing the extravascular substrate for the tenase complex, 
leading to local generation of FXa.
The significance of vascular leak in the pathogenesis of human fibrotic lung disease, in 
particular in IPF, is less well understood. Although excessive and disregulated 
procoagulant-and antifibrinolytic activity has been documented in patients with IPF 
(Martinez et al, 2005;Gunther et al, 2000;Perez et al, 1993) accumulation of fibrin, often 
visible as hyaline membranes in ALI, is less well documented in these patients (verbal 
communication by Dr A.G. Nicholson, NHLI, London). Fibrin deposition requires the
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presence of vascular-derived thrombin and fibrinogen implying that vascular leak is not 
an ongoing feature in stable IPF. Hyaline membranes are however a well-recognised 
feature of ALI/ARDS which is characterised by initial widespread lung injury resulting in 
diffuse alveolar damage with leakage of protein rich fluids from capillaries into the 
alveolar space (reviewed in (Ware et al, 2006)). Whilst IPF is characterised by a stable 
decline in respiratory failure some patients with IPF undergo acute deteriorations in 
respiratory function, known as acute exacerbations which are pathologically and 
clinically very reminiscent of ARDS (Collard et al, 2007). It has therefore been recently 
proposed that vascular leak and fibrin deposition may be major features of acute 
exacerbations in IPF patients contributing to the worsening in pathology (Collard et al, 
2007). Locally produced FX/FXa may therefore contribute to the increase in 
procoagulant activity in IPF. Once activated FXa, or indeed, the TF/FVIIa/FXa complex 
is then capable of activating PARi or PAR2, leading to a number of downstream cellular 
effects which will be discussed in the subsequent section.
4.2. The role of FXa in fibroblast to myofibroblast differentiation
4.2.1. FXa induces the differentiation of lung fibroblasts to myofibroblasts
There is compelling evidence that the primary effector cell in fibrosis is the 
myofibroblast-a contractile and highly synthetic, spindle-shaped cell, characterised by 
the de novo expression of a-SMA positive stress fibres. Myofibroblasts are a major 
source of excessive production of collagen and other ECM proteins. Several studies 
have demonstrated that the myofibroblast population is increased in the lungs of 
patients with pulmonary fibrosis and that the number of myofibroblasts correlates with 
disease severity (Zhang et al, 1996;Kapanci et al, 1995). Identifying mediators and 
interfering with pathways that lead to the expansion of the myofibroblast population 
within the IPF lung has thus been a major focus of research within this area (reviewed 
in (Scotton C.J. and Chambers, 2007)).
The work presented in this thesis examined the role of FXa in myofibroblast 
differentiation in vitro by assessing the effect of FXa on a-SMA mRNA and protein 
levels. Using primary fibroblasts derived from human lung explants, this study reports 
for the first time that activation of lung fibroblasts by FXa promotes their differentiation 
into a-SMA positive myofibroblasts. Furthermore, this study provides compelling 
evidence that FXa induces myofibroblast differentiation via the activation of PARi and 
the upregulation of the matricellular protein TSP-1 and subsequent activation TGF-D,. 
Although FXa can signal via PARi or PAR2 (or both) depending on cell type and co­
179
Chapter 4 Discussion
factor expression (Blanc-Brude et al, 2005;Riewald and Ruf, 2001), the data presented 
here adds further evidence that in terms of fibroblast function, PARi plays a dominant 
role. Importantly, PARr deficient mice are significantly protected from bleomycin- 
induced fibrosis (Howell et al, 2005). Although previous work in the host laboratory 
suggested that thrombin might be the major physiological activator of PARi in the 
context of lung fibrosis (Howell et al, 2002), the data presented here raise the likelihood 
that locally-produced and activated FX is equally a credible physiological activator of 
PAR! in this disease setting.
The effects of FXa on myofibroblast differentiation were found to be both concentration- 
and time-dependent and independent of changes in fibroblast cell number. The 
stimulatory effects of FXa were first observed at concentrations of 10 nM with maximal 
stimulatory effects obtained between 25 and 50nM. These concentrations are similar to 
the range of concentrations of FXa previously described to mediate lung fibroblast 
proliferation and procollagen production (Blanc-Brude et al, 2005) as well as mediating 
the mitogenic effect of FXa on smooth muscle cells-and endothelial cells (Herbert et al, 
1998;Nicholson et al, 1996). Upregulation of a-SMA by FXa was not observed until 36 
hours at the protein level which was preceded by an increase in a-SMA mRNA levels at 
24 hours. These findings are consistent with similar kinetics previously observed for 
thrombin in mediating the differentiation of lung fibroblasts to myofibroblasts which was 
observed from 24 hours onwards (Bogatkevich et al, 2001). Furthermore, the 
magnitude of the response obtained with FXa stimulation was very similar to that 
obtained for thrombin at equimolar concentrations of both proteinases (work presented 
here), suggesting that FXa is as efficient at stimulating myofibroblast differentiation as 
thrombin.
During the course of the work performed for this thesis, a report was published 
suggesting that stimulation of lung fibroblasts with high doses of thrombin up to 100 nM 
induces a-SMA expression in lung fibroblasts within 2 hours of stimulation (Zhang et al, 
2005). The mechanism of induction appears to be different to that reported in this 
thesis and by (Bogatkevich et al, 2001). The authors propose that high concentrations 
of thrombin regulate a-SMA expression at a posttranscriptional-rather than at a 
transcriptional level via the cold shock domain protein YB-1, a known repressor of a- 
SMA transcription but which also binds mRNA and thus regulates the translational 
efficiency of a-SMA (Zhang et al, 2005). Although the authors did not analyse the 
signalling receptor involved, high levels of thrombin such as 100 nM are known to 
activate other PARs (e.g. PAR4) and also act via non receptor mechanisms (reviewed
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in (Coughlin, 1999)). The mechanism proposed in this thesis and by (Bogatkevich et al, 
2001) suggest that transcriptional regulation of a-SMA is mediated via the activation of 
PARi which would explain the difference in observed mechanisms. It is also worth 
mentioning that this is a very high concentration of thrombin and whether such 
concentrations can be generated in extravascular compartments remains an 
unresolved issue.
The stimulatory effects of FXa on myofibroblast differentiation in primary adult human 
lung fibroblasts was confirmed in other fibroblast lines, including human fatal and 
mouse lung fibroblasts, indicating that the effects of FXa on myofibroblast 
differentiation are not restricted to primary adult human lung fibroblasts (pHALFs). In all 
experiments performed in this thesis, FXa consistently stimulated a-SMA expression, 
however, the basal expression rates of pHALFs and their responsiveness to this 
proteinase varied between experiments with responses ranging from as high as 40-fold 
to as low as 3-fold at an optimised concentration of FXa of 10nM. This difference in 
responsiveness did not seem to be related to differences in cell number but rather 
appeared to be dependent on the different stages of passage of cells with older cells 
gradually losing their responsiveness. Although great care was taken to keep cell 
culture conditions as constant as possible, variability in cell responsiveness is a 
problem in particular when working with primary cells as these are not immortalised 
and undergo rapid cell senescence in culture with increasing passage number.
Apart from their pivotal role in ECM deposition, myofibroblasts also acquire a 
contractile phenotype. This is particularly apparent during the process of wound 
healing, where myofibroblasts are responsible for the force generation resulting in 
wound contraction and connective tissue retraction (reviewed in (Desmouliere et al, 
2005), also see Introduction Section 1.5.2). Contraction of myofibroblasts and 
remodelling of connective tissue is thought to play a role in pulmonary fibrosis. 
Evidence for this is reflected in the pathological stiffness of lungs of patients with 
pulmonary fibrosis (reviewed in (King, Jr. et al, 2001)). Although the ability of the 
myofibroblasts to contract following FXa stimulation was not directly assessed during 
the course of this thesis, immunocytofluorescence studies were used to visualise the 
expression and assembly of a-SMA fibres, since these are directly linked to an 
increase in the contractile phenotype of the myofibroblast (Arora and McCulloch, 
1994;Hinz et al, 2001). Untreated fibroblasts revealed a low level of expression of a- 
SMA that did not appear to be polymerised. In contrast, a-SMA expression in cells 
stimulated by FXa assembled into an extensive network of stress fibres characteristic
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of the myofibroblast phenotype, supporting the notion that FXa induces the 
differentiation of fibroblast into contractile a-SMA positive myofibroblasts.
4.2.2. FXa exerts its stimulatory effects on myofibroblast differentiation via PAR1 
coupling to Gaq
FXa and other coagulation proteinases, such as thrombin, exert their cellular effects via 
the activation of PARs by limited proteolytic cleavage of the N-terminal extracellular 
domain thereby unmasking a tethered ligand (Camerer et al, 2002) which by binding to 
the second extracellular loop initiates downstream signalling events. FXa is known to 
activate PARi or PAR2, or both dependent on cell type and cofactor expression 
(reviewed in (Ruf et al, 2003)).
Experiments performed in this thesis to determine the mechanism by which FXa exerts 
its effects on a-SMA expression examined the receptor mechanism involved in some 
detail. First, experiments were performed to determine the effect of the specific 
thrombin inhibitor, hirudin, on FXa-induced myofibroblast differentiation. Hirudin only 
had a small, but significant inhibitory effect on a-SMA protein levels induced by FXa, 
indicating that FXa-induced myofibroblast differentiation occurs largely independent of 
thrombin signalling. The small stimulatory effect that appears to be thrombin mediated 
may be explained by activation of prothrombin by FXa due to prothrombin remaining 
either on the cell surface from the culture medium/serum or due to contamination of the 
FXa preparation. However, over 90% of FXa stimulatory activity could be blocked with 
the FXa inhibitor, antistasin suggesting that FXa exerts these effects via its proteolytic 
activity. I next examined the requirement for FXa catalytic activity using ASN, a specific 
natural inhibitor of FXa catalytic site isolated from leech Haementeria offinalis (Ohta et 
al, 1994). Short synthetic peptides mimicking the core inhibitory region of the molecule, 
including ASN D-Arg32-Pro38- (ASN core peptide), have been shown to be active and 
abolish the catalytic activity of FXa selectively (Ohta et al, 1994). These bind to the 
catalytic site of FXa in a reversible but highly specific fashion and compete with natural 
substrates. In addition, being derived from the naturally occurring molecule, ASN has 
the advantage of being active in complex physiological fluids. In the current study high 
molecular ratio of inhibitor/proteinase (16:1) was used to ensure efficient inhibition over 
the 36 hour incubation period of these myofibroblast differentiation experiments. These 
agonist/inhibitor ratios were based on previous work performed in our laboratory 
demonstrating that the effects of FXa on fibroblast proliferation and collagen production
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were abrogated at these concentrations of ASN (Blanc-Brude et al, 2001 ;Blanc-Brude 
et al, 2005).
Experiments performed to characterize the PAR involved in FXa-mediated 
myofibroblast differentiation assessed the effect of the highly selective peptide agonists 
TFLLR and SLIGKV on a-SMA expression. These agonists mimic the tethered ligand 
sequences of PAR! and PAR2 respectively and therefore allow selective activation of 
the receptor, independent of receptor cleavage. TFLLR selectively activates PAR! and 
unlike the commonly used peptide SFLLR, it does not cross-activate PAR2 in 
mesenchymal cells (Hollenberg et al, 1997). This is of particular importance given that 
the primary adult human lung fibroblasts used in this study were found to express 
PAR2. The work presented here shows that the synthetic activating peptide of PARi, 
TFLLRN was capable of mimicking the stimulatory effects of FXa whilst the PAR2 
activating peptide had no effect. The concentration of TFLLRN needed to stimulate a- 
SMA expression was at least three orders of magnitude higher than for FXa, however 
the maximum stimulation obtained was almost 50% lower when compared to FXa. 
Similar differences in potency and efficacy have been observed between coagulation 
proteinases and activating peptides for several other PARr mediated cellular effects 
(Chambers et al, 2000).There are several explanations that have been proposed to 
explain these differences. First, it is possible that following cleavage of PAR! by FXa 
the tethered ligand may adopt a more favourable position to ensure efficient activation 
of the receptor compared to free-floating activating peptide. Second, receptor cleavage 
per se may be necessary to ensure efficient activation. Third, it is possible that in 
addition to receptor cleavage, interactions of FXa with the receptor itself may be 
required. Forth, multiple rounds of receptor activation by FXa may be needed and 
peptides may only be short acting due to degradation over time. However the lack of an 
increased response with additional spiking of agonist throughout the time-course 
excludes a role for protein degradation.
Further indirect evidence for the importance of PARi was provided by studies showing 
that FXa significantly induced the expression of a-SMA in mouse lung fibroblasts, as 
these cells have been shown in this study and by others to only express PARi and not 
PAR2(Bachli et al, 2003). Finally, critical evidence confirming a central role for PARi in 
mediating FXa stimulatory effects on myofibroblast differentiation was obtained from 
studies utilising the potent and selective antagonist of PARi, RWJ-58259 (Damiano et 
al, 2003). This is a small indole-based compound which specifically inhibits the 
tethered ligand of PARi binding to its second extracellular loop, and thus prevents
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receptor activation. RWJ-58259 has been shown to block PARr mediated signalling 
events both in vitro and in vivo (Andrade-Gordon et al, 2001). This inhibitor completely 
abrogated FXa-induced myofibroblast differentiation at pM concentrations similar to the 
IC50 previously described to block thrombin-induced platelet responses in in vitro 
culture systems (Andrade-Gordon et al, 2001;Damiano et al, 2003). Taken together, 
these studies provide compelling evidence that PARi is the major signalling receptor 
involved in FXa-induced myofibroblast differentiation.
Previous studies in our laboratory have shown that in terms of fibrogenic effects, PARi 
is the major cell signalling receptor for FXa mediating fibroblast G-protein signalling, 
proliferation and extracellular matrix production (Blanc-Brude et al, 1999;Blanc-Brude 
et al, 2005). In heterologous transfection systems, Riewald and Ruf reported that FXa 
activates PARi and PAR2 (Riewald et al, 2 0 0 1 ). PAR! activation by FXa was greatly 
enhanced by cotransfection of tissue factor and the addition of FVIIa. This group also 
showed that FXa can stimulate gene expression in HeLa cells that express PARi and 
not PAR2. Consistent with these studies, the data presented here adds further 
evidence that in terms of fibroblast function, PAR! plays a dominant role. In contrast, 
current evidence suggests that PAR2 plays an important role in mediating the effects of 
FXa on cancer cell migration and endothelial cell function (Jiang et al, 2004;Feistritzer 
et al, 2005).
PARi mediates its pluripotent cellular effects by coupling to multiple G protein subunits 
including Gaq, Gai, and G a i^  (see Introduction Section 1.9.2.). Although many of the 
resultant biological consequences of PARi activation in fibroblasts are known, less is 
known about which G proteins mediate these events. Using the specific Gai inhibitor 
pertussis toxin and a novel PARi selective Gaq protein signalling antagonist, the work 
presented in this thesis shows that Gaq but not Ga* was necessary for PARi-mediated 
myofibroblast differentiation. Together with unpublished data from our laboratory 
examining PARi-activation induced CCL2 release in lung fibroblasts (Deng et al, 
unpublished data) this finding suggests that Gaq plays an important role in mediating 
the stimulatory effects of PARi on fibroblast function. Interestingly, a recent report has 
suggested that there may be important differences between thrombin and peptide 
agonists in terms of subsequent ability of PARi to activate different G-proteins 
(McLaughlin et al, 2005b). This may potentially further explain the differences in a-SMA 
expression observed between FXa and TFLLR stimulation. Furthermore, previous 
studies by the host laboratory examining the effect of FXa on fibroblast proliferation 
suggested that this effect is mainly Gaj mediated (Blanc-Brude et al, 2005). It is
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therefore tempting to speculate that FXa may induce different fibroblast responses by 
selectively recruiting different G proteins.
4.2.3. FXa induces myofibroblast differentiation via a TGF-p 1 -dependent 
mechanism in vitro
FXa elicits a number of its cellular responses, including pro-inflammatory and pro- 
fibrotic effects via the release of secondary mediators. For example FXa exerts its 
potent fibroblast mitogen effects via the autocrine release of PDGF (Blanc-Brude et al, 
2 0 0 1 ). Consistent with these observations, myofibroblast differentiation induced in 
response to FXa is a delayed response, raising the possibility that FXa exerts its 
effects via the autocrine production and/or activation of a secondary mediator (Cogan 
et al, 2002;Chambers et al, 2003;Subramanian et al, 2004). TGF-Pt is one of the major 
cytokines that has been implicated in myofibroblast differentiation and experiments 
performed during the course of this thesis provided strong evidence that FXa mediated 
fibroblast to myofibroblast differentiation is dependent on TGF-Pt activity.
The initial studies of this thesis assessed if FXa was capable of producing and/or 
activating TGF-p! in primary human lung fibroblasts. TGF-Pi is a potent cytokine which 
is secreted in an inactive from (reviewed in (Sheppard, 2001a) and activation of TGF-Pi 
is a major rate limiting step in the regulation of TGF-p! bioavailability (see Introduction 
Section 1.6.2.). Active TGF-fy was measured using a bioassay, based on mink lung 
epithelial cells stably transfected with truncated TGF-p!-responsive PAI-1 promoter 
fused to a luciferase reporter gene and capable of detecting concentrations of active 
TGF-p! as low as 0.2pM (Abe et al, 1994). In these experiments performed here, it was 
not possible to test the effect of FXa since FXa interfered with the bioassay; however 
activation of PARi with TFLLR was shown to induce the activation of TGF-p! in primary 
human lung fibroblasts. Further evidence for a role of FXa in mediating activation of 
TGF-pi was provided by studies assessing the effect of FXa stimulation on TGF-pr 
mediated signalling pathways in fibroblasts. TGF-p! induces cell signalling by binding to 
TGFpllR which causes the recruitment and activation of TGFpiR (ALK5) in fibroblasts 
and subsequently induces SMAD 2/3 phosphorylation (Franzen et al, 1993;ten et al, 
1993). Phosphorylated SMAD 2/3 then associates with SMAD 4, and translocates to 
the nucleus where this complex modulates the transcription of a large number of genes 
(Miyazono et al, 2000). SMAD signalling is generally held to be the major pathway 
activated in response to TGF-p and involved in mediating TGF-P’s profibrotic effects 
(Kapoun et al, 2006). The studies performed here demonstrate that stimulation of
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primary lung fibroblasts with FXa induced the phosphorylation of SMAD2/3 in a time- 
dependent manner and provide evidence that FXa mediates the activation of TGF-Pi in 
cultured lung fibroblast. Furthermore, there was no apparent change in TGF-Pi mRNA 
levels following FXa stimulation. Together these studies suggest that the activation of 
TGF-fy rather than production is the main mechanism by which FXa regulates the 
bioavailability of TGF-Pt in human lung fibroblasts.
Several activation mechanisms for TGF-p! have been described including that 
mediated by the potent extracellular matrix protein TSP-1 (reviewed in (Murphy-Ullrich 
and Poczatek, 2000), also see Introduction Section 1.6.3.). TSP-1 is known to activate 
latent TGF-Pi by binding to the LSKL region of the LAP thus inducing a conformational 
change in the LAP in such a way that LAP bound to TSP-1 is unable to confer latency 
to TGF-Pt (Schultz-Cherry and Murphy-Ullrich, 1993). In the work presented in this 
thesis, FXa was found to upregulate TSP-1 both at the mRNA and protein levels. The 
earliest increase in TSP-1 expression preceded FXa-induced SMAD2/3 
phosphorylation. Importantly, the blocking peptide LSKL, previously shown to prevent 
the activation of TGF-p! by TSP-1 in vitro and in vivo (Ribeiro et al, 1999;Kondou et al,
2003), completely blocked PARi-mediated TGF-Pi activation as measured by the Mink 
lung bioassay, indicating that TSP-1 is involved in mediating the activation of TGF-fr by 
FXa. Although, previous studies have shown that activation of PARi by thrombin 
increases TSP-1 mRNA levels in endothelial cells (McLaughlin et al, 2005a), this is the 
first study to directly link the upregulation of TSP-1 to the subsequent activation of 
latent TGF-Pi.
A direct role for TGF-Pi in FXa-induced myofibroblast differentiation was assessed by 
using two pharmacologically unrelated selective small molecule inhibitors of ALK-5, 
SB431542 (Callahan et al, 2002) and SD-208 (Uhl et al, 2004). SB431542 inhibits 
ALK5 and also two other types of type I receptors of the TGF-p superfamily, the activin 
type I receptor ALK4 and the nodal type I receptor ALK7 (Inman et al, 2002a). 
SB431542 has been shown to have selectivity for ALK receptor kinases in vitro (IC50 
~1 |a,M) and only weakly inhibits MAP kinase p38a with an IC5o of ~1 0 pM (Inman et al, 
2002a). However, previous studies have provided convincing evidence that p38 MAP 
kinase is not involved in TGF-Prmediated a-SMA expression in lung fibroblasts 
(Kapoun et al, 2006). SD-208 is a 2,4-disubstituted pteridine-derived, ATP-competitive 
inhibitor (IC50 of ~35 nM ) which is selective for TGF-pIR kinase by >100-fold compared 
with TGF-pRII kinase and at least 20-fold over a panel of related protein kinases such 
as c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, MAP kinase p38,
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and epidermal growth factor receptor kinase (Bonniaud et al, 2005). In vivo, oral 
administration of SD-208 has previously been shown to significantly inhibit the 
progression of fibrosis in a rat model of TGF-p!-mediated lung fibrosis (Bonniaud et al,
2005). In the present study, SB431542 and SD-208 completely blocked FXa-induced 
a-SMA expression at micromolar and nanomolar ranges respectively and also blocked 
TGF-Prmediated a-SMA expression at similar concentrations. These concentrations 
were chosen based on previous studies in the literature examining the effect of 
SB431542 on TGF-Prmediated fibroblast effects, including procollagen production and 
myofibroblast differentiation (Mori et al, 2004). Similar concentration were also used in 
studies blocking TGF-p1-induced PAI-1 protein levels with SD-208 in primary rat lung 
fibroblasts (Kapoun et al, 2006). In addition, both compounds inhibited a-SMA 
expression by approximately 50% at concentrations close to the IC50 previously 
reported for these compounds (Mori et al, 2004;Kapoun et al, 2006).
The proposed mechanism of FXa-mediated myofibroblast differentiation contrasts with 
that by which thrombin mediates myofibroblast differentiation. Bogatkevich and 
colleagues showed that thrombin mediated myofibroblast differentiation via the 
activation of PARi but in a TGF-pi-independent manner (Bogatkevich et al, 2001). The 
interesting difference between this previous report and the data presented here with 
FXa may have several explanations. First, the present study employed a small 
molecule antagonist approach to block TGF-Pi-induced signalling via ALK5 the 
efficiency of which may be greater compared to an antibody blocking strategy such as 
used in thrombin-induced myofibroblast differentiation studies. Further, TSP-1- 
mediated TGF-Pi activation by FXa was only detectable when lung fibroblasts were 
grown in co-culture with transformed mink lung cells, indicating that close cell contact 
between the two cell types (the effector and the reporter cell line) is essential. This 
observation is consistent with the TSP-1 mechanism of activation of TGF-p previously 
described which is thought to retain active TGF-Pi bound to the extracellular matrix, 
thus restricting TGF-p! signalling close to the site of activation (see Introduction 
Section 1.6.2.). The high affinity of TGF-P! for its receptor together with the lack of 
release of active TGF-pi into the culture medium may explain why antibody blockade 
may not be an efficient strategy to interfere with TGF-p! signalling in these in vitro 
studies. Second, although FXa and thrombin can both signal via PAR! in fibroblasts, 
there is increasing evidence that these proteinases do not always induce identical 
cellular responses. For example, our laboratory has previously reported that thrombin 
and FXa mediate distinct intracellular calcium transients in fibroblasts (Blanc-Brude et 
al, 2005). Thrombin and activated protein C (APC) which both signal via PARi in
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perturbed endothelial cells have also been reported to mediate distinct biological 
effects (Riewald and Ruf, 2005). As previously mentioned, different agonists of PARi 
have recently been shown to selectively activate different G-protein pathways by their 
ability to alter receptor/G protein binding (McLaughlin et al, 2005b). Taken together, 
these data support the concept that FXa-triggered signalling via PARi may be distinct 
from thrombin signalling and this may explain why these proteinases mediate distinct 
cellular responses.
4.2.4. In vivo evidence for FXa-induced myofibroblast differentiation via a TGF-p 
and TSP-1-dependent mechanism
Having provided convincing evidence that FXa mediates fibroblast to myofibroblast 
differentiation via the activation of PARi and subsequent TSP-1-mediated activation of 
latent TGF-p, further studies were performed to assess the potential relevance of this 
mechanism in vivo. To this end PARi, TSP-1 and a-SMA immunoreactivity was 
analysed in serial sections from human fibrotic and donor lung samples. The work 
presented in this thesis provides further evidence that the FXa-mediated mechanism of 
TGF-Pi activation via TSP-1 might be operative in human fibrotic lung disease as PARi, 
TSP-1 and a-SMA were found to be co-expressed by myofibroblasts within fibrotic foci 
in IPF lung sections. It is worth pointing out that this mechanism of TGF-Pi activation is 
likely to be highly specific to fibroblasts within these regions as there was no TSP-1 
staining on hyperplastic epithelial cells within the same tissue samples. There is further 
good evidence that the avp6  integrin mechanism is the major activation mechanism 
involved in TGF-|3i activation by epithelial cells (Munger et al, 1999) so that the 
absence of TSP-1 in these regions is consistent with this alternative mode of TGF-Pi 
activation. During the course of this thesis, our laboratory working in collaboration with 
Dr. Jenkins showed that PARi ligation on epithelial cells can lead to the activation of 
TGF-Pi via an avp6  integrin-dependent mechanism (Jenkins et al, 2000), so that PAR! 
activation on several cell types may play a pivotal role in driving the fibrotic response to 
lung injury by activating TGF-p!.
4.3. Role of FXa in bleomycin-induced lung injury and fibrosis
4.3.1. ZK 807834
In order to determine if FXa was causally involved in the development of pulmonary 
fibrosis in vivo, FXa inhibition studies were performed in the bleomycin model of lung 
injury and fibrosis. To this end a suitable pharmacological tool had to be identified. A 
number of direct FXa inhibitors have recently been developed as a novel strategy to
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target specific components to the coagulation cascade to provide safer anticoagulants. 
There are two main strategies for inhibiting FXa that are currently being pursued 
clinically: direct inhibitors and indirect inhibitors which rely on antithrombin as a cofactor 
(Karnicki et al, 2004). ZK 807834 is a direct inhibitor of FXa and can inactivate both 
free FXa and FXa that is complexed with either TF/FVIIa, or FVa (the prothrombinase 
complex) (Light and Guilford, 2001). This is in contrast to indirect FXa inhibitors, such 
as fondaparinux or enoxaparin, which are unable to inactivate FXa which is part of a 
complex, as these indirect inhibitors act by bridging antithrombin to FXa which has no 
inhibitory effects on the complex (Bauer et al, 2002). ZK 807834 was therefore chosen 
to evaluate the effect of attenuating FXa activity in the bleomycin model of lung injury 
and fibrosis, since this compound will block FXa directly in the multiple conformations 
that may be particularly relevant in the extravascular space, such as the potent 
TF/FVIIa/FXa signalling complex (reviewed in (Riewald and Ruf, 2 0 0 2 )J. Furthermore, 
ZK 807834 is highly selective for FXa (Ki = 0.11nM, compared with its Ki for thrombin 
of 2020 nM, (Light and Guilford, 2001)) and this selective nature was critical to ensure 
lack of inhibition of other proteinases such as thrombin which are known to influence 
the fibrotic response in this model (Howell et al, 2001). In addition, this compound has 
been shown to be effective in vivo and has anti-thrombotic activity in experimental 
models of venous and arterial thrombosis (Abendschein et al, 2000;Karnicki et al,
2004).
4.3.2. ZK 807834 blocks the pro-fibrotic effects of FXa in vitro
An important initial consideration was whether ZK 807834 would be capable of 
inhibiting FXa-induced cellular effects in the fibrotic lung and in particular fibroblast 
responses. Therefore the efficacy of ZK 807834 in blocking FXa-induced fibroblast 
proliferation and myofibroblast differentiation in vitro was initially assessed. In these 
experiments, ZK 807834 significantly inhibited FXa-induced fibroblast proliferation and 
myofibroblast differentiation in a concentration-dependent manner from equimolar 
concentrations of ZK 807834 onwards. The effects of ZK 807834 were comparable to 
those achieved with antistasin on myofibroblast differentiation in this thesis and to 
PPACK and rTAP on fibroblast proliferation used in previous studies in our laboratory 
(Blanc-Brude et al, 2005). In addition, at a concentration of 10nM, ZK 807834 inhibited 
FXa-induced a-SMA protein levels by about 50%. This is consistent with a previous in 
vitro study reporting ZK 807834 inhibition of FXa in clot-bound prothrombinase with an 
average IC50 of 1 0  nM (Post et al, 2 0 0 2 ).
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4.3.3. Effect of ZK 807834 on lung collagen accumulation in bleomycin-induced 
lung injury and fibrosis
For in vivo studies, mice were given either bleomycin (1 mg/kg) or saline by 
oropharyngeal administration followed by 50 mg/kg ZK 807834 or vehicle by 
intraperitoneal injection twice daily in the first week and then once a day in the second 
week until the end of the experiment. This dosing regime and route of administration 
were chosen based on the pharmacokinetic data provided by Berlex, indicating that a 
circulating concentration of ZK 807834 above 2pM was sufficient to double the 
prothrombin time in C57BI/6J mice. In addition, real-time RT-PCR and 
immunohistochemistry studies presented in this thesis suggested that FX/FXa is 
generated chronically after-bleomycin injury; so that continuous FXa inhibition would be 
necessary. ZK 807834 was administered 24 hours prior to mice receiving a single 
oropharyngeal dose of saline or bleomycin so that a steady-state concentration of the 
drug would have been established at the time of oropharyngeal challenge. The 
experimental end point was 14 days, a time point at which extensive fibrotic lesions 
and an approximate doubling in total lung collagen can be observed (unpublished data 
in our laboratory).
These experiments predictably proved to be very difficult due to bleeding 
complications. Analysis of the animal’s body weight, which is generally thought to be a 
good surrogate marker for the animal’s welfare, revealed that ZK 807834 was delivered 
at a dose that was well tolerated. However, several animals in the saline/ZK 807834 
and in the bleomycin/ZK 807834 group had to be sacrificed during the course of the 
experiment due to intraperitoneal haemorrhage thought to arise from the technical 
challenge of performing multiple intraperitoneal injections with an anticoagulant drug. 
This led to the decision to decrease the number of i.p injections to one per day only in 
the second week. This visibly reduced any haemorrhagic lesions close to the site of 
injection in the remaining animals. After 14 days, the effect of ZK 807834 on lung 
collagen accumulation in bleomycin-induced lung injury was evaluated. The data 
obtained showed that lung collagen accumulation at 14 days in mice treated with this 
compound was significantly attenuated. These observations provide strong-proof-of 
concept that FXa plays a significant role in the development of fibrosis in this model. 
During the course of these PhD studies, a study was published reporting that 
intratracheal gene delivery of TFPI, an endogenous inhibitor of TF/FVII and the ternary 
TF/FVIIa/FXa complex (Broze, Jr., 1995), also significantly attenuated lung collagen 
accumulation in the bleomycin model of lung injury and fibrosis in rats (Kijiyama et al,
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2006). However, the present study is the first to show a direct functional link between 
FXa activity and the development of pulmonary fibrosis.
The data presented here contrasts with a previous study which assessed the effect of 
the FXa inhibitor enoxaparin in the bleomycin model of lung injury and fibrosis and 
showed no effect on collagen accumulation (Laxer et al, 1999). The differences in the 
effect of enoxaparin and ZK 807834 on fibrogenesis may have several explanations. 
First, and probably most important, similarly to fondaparinux, enoxaparin blocks FXa 
indirectly by influencing the activity of antithrombin III. This raises questions as to 
whether FXa was not efficiently targeted in the enoxaparin study as antithrombin III has 
no inhibitory actions against complexed FXa (i.e. TF/FVIIa/FXa). When assembled into 
the ternary complex, TF/FVII/FXa, FXa is 5-times more efficient at activating PARi 
compared with free FXa (Riewald and Ruf, 2001). If FXa is predominantly present in 
the complexed form in the extravascular space, enoxaparin may not have effectively 
interfered with extravascular FXa activity. Second, the enoxaparin study evaluated 
collagen accumulation in mouse lungs by analysis of BALF and by histological, semi- 
quantitive image analysis of alveolar wall fraction and fibrosis fraction. The data 
presented here analysed total lung hydroxyproline content by the highly sensitive and 
quantitative HPLC method (Campa et al, 1990;Chambers et al, 1994). It is therefore 
possible that smaller differences in lung collagen accumulation may have been missed 
in the enoxaparin study.
4.3.4. Possible mechanisms by which FXa inhibition by ZK 807834 may have 
afforded protection in the bleomycin model of lung injury and fibrosis
There are several mechanisms by which FXa inhibition may afford protection in the 
bleomycin model of lung injury and fibrosis. First, it is tempting to speculate that the 
stimulatory effects of FXa on myofibroblast differentiation demonstrated in this thesis 
may be a major mechanism by which FXa drives the fibrotic response to bleomycin- 
induced lung injury. Immunohistochemical studies presented in this thesis showing 
colocalisation of PAR^ a-SMA and TSP-1 further lend some support to this notion in 
patients with IPF. Whilst this is an important question arising from the work in this 
thesis, due to time limitations there is currently no direct evidence to support this 
hypothesis. Second, the possibility that protection may have been partly influenced by 
an effect on inflammation cannot be ruled out at present. Inflammation plays an 
important role in driving the fibrotic response to lung injury and several studies have 
shown that blocking inflammation in the bleomycin model affords protection from 
subsequent lung collagen accumulation (Chen et al, 2006;Dik et al, 2003a).
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Importantly, previous work in our laboratory has shown that PAR!-deficiency is 
associated with an attenuated inflammatory response as measured by the reduction in 
pro-inflammatory cytokines and protein leak (Howell et al, 2005). In addition, FXa is a 
potent inducer of pro-inflammatory cytokines such as IL-1 in fibroblasts (Jones and 
Geczy, 1990), IL-2 by lymphocytes (Altieri and Stamnes, 1994), IL- 6  and IL- 8  in 
endothelial cells (Senden et al, 1998) and CCL2, IL-1 IL- 8  and IL- 6  in dermal 
fibroblasts (Bachli et al, 2003). Third, because of the central role of FXa in the 
coagulation cascade, direct FXa inhibition may also afford protection in this model by 
interfering with thrombin generation and thrombin-dependent procoagulant, as well as 
PARi-mediated pro-fibrotic signalling. Several studies to date have shown that a 
reduction in thrombin generation leads to a substantial attenuation in the fibrotic 
response to lung injury (Howell et al, 2001;Yasui et al, 2001 ;Kijiyama et al, 2006). 
However, this study in combination with previous studies in our laboratory have clearly 
shown that FXa exerts its stimulatory effects on fibroblast to myofibroblast 
differentiation, proliferation and procollagen production independently of thrombin 
generation (Blanc-Brude et al, 2005). Thrombin levels in BALF have previously been 
reported to peak 6  days post-bleomycin injury (Howell et al, 2001). The work in this 
thesis shows for the first time that FX is locally expressed in the injured lung, and that 
its local production persists throughout the fibrotic phase of the bleomycin model of 
lung injury and fibrosis. This finding suggests that during the fibrotic phase of this 
model, FXa signalling may occur independently of thrombin generation, but further 
work is clearly needed to substantiate this claim. Fourth, a role for FXa procoagulant 
effects in this model cannot be excluded at present. Intra-alveolar accumulation of fibrin 
has been extensively documented in bleomycin-induced lung injury and fibrosis and in 
human studies of fibrotic lung disease (Idell et al, 1987;Chapman et al, 1986;lkeda et 
al, 1989;Kotani et al, 1995). Fibrin in combination with fibronectin is thought to 
influence the tissue repair/fibrotic response by providing a provisional matrix, on which 
fibroblasts can proliferate and produce collagen (Pohl et al, 1979). This matrix 
contributes to alveolar collapse and traction of remaining airspaces (honeycombing). 
Furthermore, it binds fibrogenic factors and cytokines which are released during 
fibrinolysis (Grainger et al, 1995). However, the question of whether fibrin deposition 
plays a role in the development of fibrosis remains at present controversial as two 
independent studies have shown that mice deficient in fibrinogen are not protected 
from bleomycin-induced lung injury and fibrosis (Ploplis et al, 2000) (Hattori et al,
2000). These studies have led to the suggestion that fibrin per se may not be required 
for the progression of fibrosis in this model.
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4.3.5. Problems encountered during the assessment of ZK 807834 In the 
bleomycin model of lung injury and fibrosis
In order to specifically block FXa activity in the extravascular space an attempt was 
made to administer ZK 807834 by oropharyngeal instillation. These experiments 
however were very unsuccessful with the majority of animals not surviving to the end of 
the study. Administration of the compound at a dose which attenuated collagen 
deposition when administered via multiple i.p. injections was associated with severe 
bleeding complications resulting in massive pulmonary haemorrhage and eventual 
death of animals. Interestingly, when the anticoagulant dose was reduced by five-fold, 
all mice survived the treatment and no apparent bleeding was observed on 
macroscopic inspection of the lungs. However, there was no significant effect on lung 
collagen accumulation in response to bleomycin indicating that this dosing regime may 
not have successfully blocked FXa signalling.
It is possible that the therapeutic window for FXa blockade is much narrower when 
targeted locally within the pulmonary compartment. In addition, although 
pharmacokinetic data was made available to us by Berlex for the administration of this 
compound via a parental route, this data was not available for oropharyngeal 
administration. It is therefore possible that the compound was not cleared efficiently 
within the pulmonary compartment and therefore accumulated. Furthermore, due to the 
low solubility of this compound, to achieve adequate concentrations of the inhibitor, it 
had to be administered in large volumes of saline (50pl) on a daily basis. This was 
poorly tolerated by the animals, especially in the first week of administration when lung 
oedema is highest. In summary, oropharyngeal administration of ZK 807834 was 
associated with massive bleeding complications and future studies are needed to 
evaluate the pharmacokinetic properties of this compound for this route of 
administration.
4.4. Conclusions and implications
This thesis examined the hypothesis that FX/FXa is locally upregulated in the fibrotic 
lung and contributes to the development of pulmonary fibrosis by influencing fibroblast 
function via the activation of PARi. The work presented in this thesis reports the novel 
finding that FXa, a central proteinase of the coagulation cascade, is locally expressed 
and upregulated in experimentally-induced lung injury and in IPF. Furthermore this 
thesis reports that FXa is a potent mediator of the myofibroblast differentiation 
programme via the activation of PARi and subsequent TSP-1-mediated activation of
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latent TGFp. Finally, FXa blockade modulated the fibrotic response to experimentally- 
induced lung injury and fibrosis. These data provide a paradigm shift in our 
understanding of the origin of the procoagulant activity by providing an alternative 
mechanism for the generation of FXa via the local extravascular expression of the 
zymogen in the injured lung and further identifies FXa as a novel fibrogenic factor in the 
pathogenesis of pulmonary fibrosis (Figure 4.1.).
4.4.1. A novel origin for procoagulant activity in the lung
The findings presented in this thesis provide broad-reaching implications to our current 
understanding of the generation of procoagulant activity in fibrotic lung disease. 
Importantly, they challenge the long-held perception of the origin of increased 
procoagulant activity in fibrotic lung disease, and shift the focus from the circulation as 
a major source of this activity to coagulation factors that are locally produced within the 
injured lung. This thesis focused on FX, however there is increasing evidence that 
other coagulation proteinases may be locally produced in the lung. Preliminary data in 
our laboratory suggest that FVII is locally produced in experimentally-induced lung 
injury and fibrosis (verbal communication by Dr Scotton) and a recent report indicates 
that FXII may be synthesized by alveolar epithelial cells in the lungs of patients with 
fibrotic lung disease (Wygrecka et al, 2007a). This raises the tantalizing possibility that 
the lung is capable of inducing an extravascular coagulation system in response to 
injury.
The lung has developed a complex set of strategies to limit injury and promote repair 
whereby the coagulation system in concert with the inflammatory system play major 
roles. Both systems are inextricably linked and are thus not only activated 
simultaneously but control each other. For example excessive activation of the 
coagulation cascade often follows systemic inflammatory states and some components 
of the coagulation cascade are always activated in patients with septic shock (reviewed 
in (Riewald and Ruf, 2002)). It is thus tempting to speculate that a local inducible 
coagulation system has evolved in parallel with the inflammatory system to work in 
concert providing homeostatic balance in the extravascular space.
4.4.2. FXa is a novel pathogenic factor in fibrotic lung disease
Much of the work in the field of coagulation thus far has provided compelling evidence 
for a central role for thrombin in the development of pulmonary fibrosis (Howell et al,
2001). A role for coagulation proteinases upstream of thrombin such as FXa has long 
been suspected, however this is the first study to suggest a direct functional link
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between FXa and the development of pulmonary fibrosis. The work presented in this 
study together with previous work in our laboratory provides further compelling 
evidence that PARi is the major signalling receptor by which this proteinase exerts its 
pro-fibrotic effects on fibroblasts. Further studies are needed to confirm the relative in 
vivo importance of PARi signalling by FXa, however recent reports in our laboratory 
have shown that PARi-deficient mice are significantly protected from bleomycin- 
induced fibrosis (Howell et al, 2005). It has previously been proposed that thrombin 
might be the major physiological activator of PARi in this model based on the evidence 
that direct thrombin inhibition is also protective (Howell et al, 2001), however the data 
presented here raise the possibility that circulation-derived/and or locally-produced 
FX/FXa in concert with TF and FVII could generate sufficient extravascular FXa to be a 
credible physiological activator of this receptor in the context of fibrotic lung disease.
4.4.3. Possible therapeutic implication for antifibrotic compounds
There is overwhelming evidence that the coagulation cascade plays a central role in 
driving the pro-inflammatory and pro-fibrotic effects in response to experimental lung 
injury. Some evidence that targeting the coagulation cascade in human fibrotic lung 
disease may be beneficial has recently been provided by a small non-blinded, 
randomized trial of 56 patients with IPF given prednisolone alone or prednisolone plus 
anticoagulation (oral warfarin for outpatients or low molecular weight heparin for 
hospitalized patients)(Kubo et al, 2005). The investigators report a significant increase 
in survival in the anticoagulant group, with 63% survival at 3 years in the anticoagulant 
group versus 35% in the non-anticoagulant group. Both patient groups had a similar 
incidence of acute exacerbations, but mortality associated with acute exacerbation was 
lower in the anticoagulant group (18% versus 71%). Despite some methodological 
caveats (e.g. possible selection bias towards advanced disease, concerns regarding 
patient randomization etc.), this remains one of the most significant beneficial 
outcomes on survival in an IPF clinical study suggesting that disordered coagulation 
may be an important component of acute exacerbations in IPF(Collard et al, 2007).
The work presented in this thesis has provides proof-of-principle that targeting FXa 
may be therapeutically beneficial in fibrotic lung disease. From a clinical perspective it 
is now increasingly recognised that therapeutic approaches based on selective 
inhibitors of specific coagulation factors, such as FXa rather than traditional, multi­
targeted anticoagulants, such as warfarin and unfractionated heparin, are likely 
associated with a wider therapeutic window and therefore more effective, safer and 
easier to use (Bauer, 2006a;Bauer, 2006b).
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Figure 4.1. Proposed m echanism  underlying the contribution o f FX  to lung fibrosis
Following lung injury, both locally produced as well as circulation-derived FX contributes to the 
increase in FXa activity in the fibrotic lung. FXa induces its profibrotic effects via the activation 
of PAR, and subsequent differentiation of fibroblasts into the myofibroblast phenotype. This is 
dependent on the transcriptional induction of TSP-1 leading to the activation of the major 
profibrotic cytokine TGF-P! in a TSP-1-dependent manner.
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The recombinant hirudins, which target thrombin, were the first anticoagulants to be 
developed that target a specific coagulation factor. However, direct thrombin inhibitors 
have a narrow therapeutic index (Bauer, 2006b). Accordingly, selective inhibition of 
coagulation factors located further upstream in the coagulation pathway might be safer 
with respect to bleeding risks. Selective FXa inhibitors are felt to be effective at 
blocking coagulation since FXa is positioned at the start of the common pathway of the 
extrinsic and intrinsic coagulation systems. Furthermore, as the levels of serine 
proteinases are amplified at each step of the coagulation cascade, anticoagulants 
which target coagulation factors located higher up in the cascade, such as FXa, might 
be more effective than those directly targeting thrombin. In addition, alveolar epithelial 
cell-derived FXa may be of particular interest as an inhalation route would deliver the 
drug more directly to the epithelium and would further avoid potential bleeding 
complications. Currently a phase I clinical trial is underway in Germany to assess the 
effects of inhaled low molecular weight heparins in patients with IPF(Andreas Gunther, 
University of Giessen, Germany), which will no doubt be informative.
Finally, PARi is emerging as a critical receptor in the context of fibrotic lung conditions. 
This thesis and previous work in our laboratory demonstrates a major role for PAR! in 
mediating the cellular effects of FXa and thrombin on fibroblast to myofibroblast 
differentiation, proliferation and procollagen production (Chambers et al, 1998;Blanc- 
Brude et al, 2005;Bogatkevich et al, 2001). The finding that PARi knockout mice are 
protected from lung oedema, inflammatory cell recruitment and the development of 
fibrosis in the bleomycin model of lung injury and fibrosis, place this receptor central to 
the crosstalk between coagulation, inflammation and fibrosis in this model (Howell et al,
2005). Evidence that PARi may play a major role in the context of human fibrotic lung 
disease was provided by observations in our and other laboratories showing that this 
receptor is highly upregulated on fibroblasts and macrophages within fibrotic foci in the 
lungs of patients with IPF (Howell et al, 2001) and pulmonary fibrosis associated with 
systemic sclerosis (Bogatkevich et al, 2005).
Work performed in collaboration with our laboratory also demonstrated a link between 
PARi ligation on epithelial cells and the subsequent activation of the major profibrotic 
cytokine TGF-(3i via the av06 integrin (Jenkins et al, 2006) and data presented here 
show that in fibroblasts, PARi activation by FXa activates latent TGF-01  via the 
transcriptional upregulation of TSP-1. The important role of PARi in mediating TGF-|3i 
activation is of particular interest in terms of current drug targeting strategies in IPF. 
Given the important role of TGF-pi in regulating inflammation and acting as a tumour
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suppressor in certain contexts (see Introduction Section 1.6.1.). therapies aimed 
directly at TGF-Pi as a drug target may be complicated by undesirable side-effects. 
Thus, targeting pathways involved in the activation of TGF-Pi that are highly 
upregulated in fibrotic lung disease such as PARi, may allow for successful blockade of 
TGF-p! profibrotic effects without significant impediment on its other biological functions 
involving different latent TGF-Pi activation mechanisms.
The recent development of PARi receptor antagonists could thus be of considerable 
interest in this area. PAR! blocking strategies are now increasingly credible therapeutic 
agents as in April 2006, Schering-Plough announced fast-track designation for a PAR! 
antagonist (SCH530348), after successful phase II clinical drug development, for 
assessment in its ability to reduce cardiovascular morbidity and mortality in patients 
with acute coronary syndromes (Schering-Plough Corporation 04/19/2006).
The work presented in this thesis further demonstrates the effectiveness of blocking 
FXa-induced fibroblast to myofibroblast differentiation using a recently developed novel 
small molecule inhibitor, which blocks PARi at the intracellular interaction site with Gaq 
(Caden Biosciences) and therefore allows more selective targeting of some, but not all, 
PARi-mediated cellular responses. Such an antagonist approach may therefore hold 
promise for selectively interfering with deleterious FXa signalling in the context of 
fibrotic lung disease, whilst preserving other essential PARi-mediated cellular 
responses. In conclusion, the rationale for strategies aimed at blocking coagulation 
signalling is gaining strength and may provide new hope for the treatment of 
fibroproliferative lung disease.
4.5. Future Studies
This thesis has provided compelling evidence that the coagulation proteinase FXa and 
its major fibroblast signalling receptor, PARi, play important roles in the 
pathophysiology of pulmonary fibrosis. The discovery that the zymogen FX can be 
derived from a local tissue source rather than the circulation suggests that FXa may 
represent an important physiological activator of PARi in extravascular compartments 
and may signal in the absence of thrombin generation and vascular leak. Further 
studies are needed to determine the molecular mechanisms that regulate locally 
produced FX in the fibrotic lung and the relative role it plays in the development of 
pulmonary fibrosis versus FXa derived from the circulation:
198
Chapter 4 Discussion
a) The role of local FX in mediating the fibrotic response to bleomycin-induced 
lung injury
To address the relative contribution of locally-produced FX in the pathogenesis of 
pulmonary fibrosis studies could be performed examining the effect of local knockdown 
of existing FX by short-hairpin RNA (shRNA) against FX in the bleomycin model of lung 
injury and fibrosis. Recent success in knocking down genes using shRNA in other 
models (Siner et al, 2007) suggest that this approach might be fruitful. Furthermore, the 
effect of bleomycin administration could be assessed by the generation of tissue 
specific knock-out mice, which do not express FX in alveolar epithelial cells.
b) Mechanisms leading to increased expression of FX in the fibrotic lung
Experiments performed in this thesis examining the potential mediators involved in 
regulating FX expression in fibrotic lung disease suggest that bleomycin increases FX 
mRNA levels in alveolar epithelial cells. Given that bleomycin exerts many of its pro­
fibrotic effects via oxidative stress responses, further studies could be performed to 
examine the potential link between the generation of reactive oxygen species and the 
upregulation of FX mRNA levels. To this end alveolar epithelial cell lines and primary 
cells could be stimulated with a number of reagents, (e.g. hydrogen peroxide) that 
mimic oxidative stress environments and their effect on FX mRNA and protein levels 
could be measured. The antioxidant n-acetylcysteine has previously been shown to be 
beneficial in the bleomycin model of lung injury and fibrosis (Shahzeidi et al, 1991). To 
examine if oxidative stress mediates FX expression in vivo the effect of n- 
acetylcysteine on FX expression in this model could be assessed.
c) The role of FXa in mediating EMT and fibrocyte recruitment
The work presented in this thesis showed that FXa is a potent mediator of the 
myofibroblast differentiation programme. There is increasing evidence that a significant 
proportion of myofibroblasts can be produced from transdifferentiation of adjacent 
epithelial cells through a process known as epithelial-mesenchymal transdifferentiation 
(EMT) (see Introduction Section 1.5.3.). A role for thrombin in inducing EMT in alveolar 
epithelial cells was recently suggested (Ando et al, 2007) and plasmin promotes the 
transdifferentiation of murine tubular epithelial cells via activation of PAR! (Zhang et al,
2007). This has led to the hypothesis that FXa may play a role in mediating EMT. To 
address this hypothesis in vitro, experiments could assess the stimulatory effect of FXa 
on EMT in cultured alveolar epithelial cells.
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d) Differential downstream signalling effects of FXa and thrombin
The results in this thesis suggest that the coagulation proteinases thrombin and FXa 
induce differential downstream signalling events. Whilst this study has provided 
compelling evidence for a role of TGF-p1 in FXa-induced myofibroblast differentiation, 
previous reports by others suggest that thrombin mediates fibroblast function 
independently of TGF-(3i activation (Bogatkevich et al, 2001). This is in agreement with 
previous studies performed in our laboratory demonstrating that although FXa, similarly 
to thrombin is also able to activate PAF^ on lung fibroblasts, the calcium signals 
generated by thrombin-mediated PARi activation are different compared to FXa- 
induced activation of the receptor (Blanc-Brude et al, 2005). To further understand the 
potentially different roles of these proteinases in influencing fibroblast function, 
transcriptional profiling studies comparing the stimulatory effects of thrombin and FXa 
on fibroblast could be examined.
e) Mechanism of protection of FXa inhibition in bleomycin-induced lung injury 
and fibrosis
The work presented in this thesis demonstrated that mice treated with the selective 
FXa inhibitor, ZK 807834, were significantly protected form lung collagen accumulation 
at 14 days. To begin to elucidate the mechanisms by which FXa inhibition affords 
protection in this model the following experiments could be performed. First, the effect 
of FXa inhibition on lung inflammation could be assessed. To this end, levels of serum 
and BALF pro-inflammatory cytokines, which are known to be induced following FXa 
stimulation such as IL-1, IL- 6  and IL- 8  (see Introduction Section 1.8.3.), could be 
assayed. Second, the effect of ZK 807834 on pulmonary vascular permeability could 
be further evaluated by the technique of Evans blue extravasation. Third, the effect of 
FXa inhibition on fibroblast to myofibroblast differentiation could be assessed by 
measuring a-SMA mRNA and protein levels. Fourth, the relative contribution of each 
pathway to lung collagen accumulation could be assessed, by delivering ZK 807834 at 
different phases of the injury response following bleomycin instillation. Finally, to 
evaluate if FXa exerts its profibrotic effects via the activation of PARt in vivo, the effect 
of FXa inhibition by ZK 807834 in PARt null mice following bleomycin-induced lung 
injury could be assessed.
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